COMPOSITIONS AND METHODS FOR THE SUPPRESSION OF TARGET POLYNUCLEOTIDES FROM LEPIDOPTERA

Abstract
Methods and compositions are provided which employ a silencing element that, when ingested by a pest, such as a pest from the Lepidoptera order, they are capable of decreasing the expression of a target sequence in the pest. In specific embodiments, the decrease in expression of the target sequence controls the pest and thereby the methods and compositions are capable of limiting damage to a plant. The present invention provides target polynucleotides encoding polypeptides from specific protein families and various target polynucleotides set forth in SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 or active variants and fragments thereof, wherein a decrease in expression of one or more the sequences in the target pest controls the pest (i.e., has insecticidal activity). Further provided are silencing elements which when ingested by the pest decrease the level of the target polypeptide and thereby control the pest. In specific embodiment, the pest is Spodoptera frugiperda. Plants, plant part, bacteria and other host cells comprising the silencing elements or an active variant or fragment thereof of the invention are also provided.
Description
FIELD OF THE INVENTION

The present invention relates generally to methods of molecular biology and gene silencing to control pests.


REFERENCE TO A SEQUENCE LISTING SUBMITTED AS A TEXT FILE VIA EFS-WEB

The official copy of the sequence listing is submitted concurrently with the specification as a text file via EFS-Web, in compliance with the American Standard Code for Information Interchange (ASCII), with a file name of 366590seqlist.txt, a creation date of Jan. 9, 2009, and a size of 102 Kb. The sequence listing filed via EFS-Web is part of the specification and is hereby incorporated in its entirety by reference herein.


BACKGROUND OF THE INVENTION

Insect pests are a serious problem in agriculture. They destroy millions of acres of staple crops such as corn, soybeans, peas, and cotton. Yearly, these pests cause over $100 billion dollars in crop damage in the U.S. alone. In an ongoing seasonal battle, farmers must apply billions of gallons of synthetic pesticides to combat these pests. Other methods employed in the past delivered insecticidal activity by microorganisms or genes derived from microorganisms expressed in transgenic plants. For example, certain species of microorganisms of the genus Bacillus are known to possess pesticidal activity against a broad range of insect pests including Lepidoptera, Diptera, Coleoptera, Hemiptera, and others. In fact, microbial pesticides, particularly those obtained from Bacillus strains, have played an important role in agriculture as alternatives to chemical pest control. Agricultural scientists have developed crop plants with enhanced insect resistance by genetically engineering crop plants to produce insecticidal proteins from Bacillus. For example, corn and cotton plants genetically engineered to produce Cry toxins (see, e.g., Aronson (2002) Cell Mol. Life Sci. 59(3):417-425; Schnepf et al. (1998) Microbiol. Mol. Biol. Rev. 62(3):775-806) are now widely used in American agriculture and have provided the farmer with an alternative to traditional insect-control methods. However, these Bt insecticidal proteins only protect plants from a relatively narrow range of pests. Moreover, these modes of insecticidal activity provided varying levels of specificity and, in some cases, caused significant environmental consequences. Thus, there is an immediate need for alternative methods to control pests.


BRIEF SUMMARY OF THE INVENTION

Methods and compositions are provided which employ a silencing element that, when ingested by a pest, such as a pest from the Lepidoptera order, is capable of decreasing the expression of a target sequence in the pest. In specific embodiments, the decrease in expression of the target sequence controls the pest and thereby the methods and compositions are capable of limiting damage to a plant. The present invention provides various target polynucleotides encoding polypeptides from specific families as disclosed elsewhere herein and various target polynucleotides set forth in SEQ ID NOS:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 or active variants or fragments thereof, wherein a decrease in expression of one or more the sequences in the target pest controls the pest (i.e., has insecticidal activity). Further provided are silencing elements, which when ingested by the pest, decrease the level of expression of one or more of the target polynucleotides. In specific embodiments, the silencing element comprises at least 15, 20, or 22 consecutive nucleotides of any one of SEQ ID NO:1-50. In specific embodiments, the pest that is controlled is Spodoptera frugiperda. Plants, plant parts, plant cells, bacteria and other host cells comprising the silencing elements or an active variant or fragment thereof are also provided.


In another embodiment, a method for controlling a pest, such as a pest from the Lepidoptera order, is provided. The method comprises feeding to a pest a composition comprising a silencing element, wherein the silencing element, when ingested by the pest, reduces the level of a target sequence in the pest and thereby controls the pest. Further provided are methods to protect a plant from a pest. Such methods comprise introducing into the plant or plant part a silencing element of the invention. When the plant expressing the silencing element is ingested by the pest, the level of the target sequence is decreased and the pest is controlled.







DETAILED DESCRIPTION OF THE INVENTION

The present inventions now will be described more fully hereinafter with reference to the accompanying drawings, in which some, but not all embodiments of the inventions are shown. Indeed, these inventions may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will satisfy applicable legal requirements Like numbers refer to like elements throughout.


Many modifications and other embodiments of the inventions set forth herein will come to mind to one skilled in the art to which these inventions pertain having the benefit of the teachings presented in the foregoing descriptions and the associated drawings. Therefore, it is to be understood that the inventions are not to be limited to the specific embodiments disclosed and that modifications and other embodiments are intended to be included within the scope of the appended claims. Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation.


I. Overview

Methods and compositions are provided which employ a silencing element that, when ingested by a pest, such as a pest from the Lepidoptera order, is capable of decreasing the expression of a target sequence in the pest. In specific embodiments, the decrease in expression of the target sequence controls the pest and thereby the methods and compositions are capable of limiting damage to a plant or plant part. The present invention provides target polynucleotides which encode polypeptides from a variety of protein classes including, for example, a juvenile hormone polypeptide, a vacuolar polypeptide, a cadherin polypeptide, a cuticle polypeptide, a translation initiation factor, a SARI polypeptide, an elongation factor, a phosphooligosaccharide, a myosin polypeptide, a potassium channel amino acid transporter, a potassium inwardly rectifier polypeptide, an amino acid transporter, a tubulin polypeptide, a ubiquitin polypeptide, and small nuclear ribonucleoprotein. In other embodiments the target polynucleotides are set forth in SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 or active variants and fragments thereof. Silencing elements designed in view of these target polynucleotides are provided which, when ingested by the pest, decrease the expression of one or more of the target sequences and thereby controls the pest (i.e., has insecticidal activity). See, for example, SEQ ID NOS:51-465.


As used herein, by “controlling a pest” or “controls a pest” is intended any affect on a pest that results in limiting the damage that the pest causes. Controlling a pest includes, but is not limited to, killing the pest, inhibiting development of the pest, altering fertility or growth of the pest in such a manner that the pest provides less damage to the plant, decreasing the number of offspring produced, producing less fit pests, producing pests more susceptible to predator attack, or deterring the pests from eating the plant.


By “disease resistance” is intended that the plants avoid the disease symptoms that are the outcome of plant-pathogen interactions. That is, pathogens are prevented from causing plant diseases and the associated disease symptoms, or alternatively, the disease symptoms caused by the pathogen is minimized or lessened.


Reducing the level of expression of the target polynucleotide or the polypeptide encoded thereby, in the pest results in the suppression, control, and/or killing the invading pathogenic organism. Reducing the level of expression of the target sequence of the pest will reduce the disease symptoms resulting from pathogen challenge by at least about 2% to at least about 6%, at least about 5% to about 50%, at least about 10% to about 60%, at least about 30% to about 70%, at least about 40% to about 80%, or at least about 50% to about 90% or greater. Hence, the methods of the invention can be utilized to protect plants from disease, particularly those diseases that are caused by pests from the Lepidoptera order.


Assays that measure the control of a pest are commonly known in the art, as are methods to quantitate disease resistance in plants following pathogen infection. See, for example, U.S. Pat. No. 5,614,395, herein incorporated by reference. Such techniques include, measuring over time, the average lesion diameter, the pathogen biomass, and the overall percentage of decayed plant tissues. See, for example, Thomma et al. (1998) Plant Biology 95:15107-15111, herein incorporated by reference. See, also the examples below.


The invention is drawn to compositions and methods for protecting plants from a plant pest, such as pests from the Lepidoptera order or inducing resistance in a plant to a plant pest, such as pests from the Lepidoptera order. Caterpillars and related forms of lepidopteran insects comprise an important group of plant-feeding agricultural pests, especially during the larvae stage of growth. Feeding methods of Lepidoptera larvae typically include chewing plants or plant parts. As used herein, the term “Lepidoptera” is used to refer to any member of the Lepidoptera order. In particular embodiments, compositions and methods of the invention control Lepidoptera larvae (i.e. caterpillars). Accordingly, the compositions and methods are also useful in protecting plants against any Lepidoptera including, for example, Pieris rapae, Pectinophora gossypiella, Synanthedon exitiosa, Melittia cucurbitae, Cydia pomonella, Grapholita molesta, Ostrinia nubilalis, Plodia interpunctella, Galleria mellonella, Manduca sexta, Manduca quinquemaculata, Lymantria dispar, Euproctis chrysorrhoea, Trichoplusia ni, Mamestra brassicae, Agrotis ipsilon, Plutella xylostella, Anticarsia gemmatalis, Psuedoplusia includens, Epinotia aporema, Helicoverpa zea, Heliothis virescens, Heliothis armigera, Spodoptera exigua, Scirpophaga incertulus, Sesamia spp., Buseola fusca, Cnaphalocrocis medinalis, Chilo suppressalis, or Spodoptera littoralis. In particular embodiments, methods control Spodoptera frugiperda.


II. Target Sequences

As used herein, a “target sequence” or “target polynucleotide” comprises any sequence in the pest that one desires to reduce the level of expression. In specific embodiments, decreasing the level of the target sequence in the pest controls the pest. For instance, the target sequence can be essential for growth and development. While the target sequence can be expressed in any tissue of the pest, in specific embodiments of the invention, the sequences targeted for suppression in the pest are expressed in cells of the gut tissue of the pest, cells in the midgut of the pest, and cells lining the gut lumen or the midgut. Such target sequences can be involved in gut cell metabolism, growth or differentiation.


In one embodiment of the invention the target sequence comprises a polypeptide belonging to one or more classes of enzymes such as a juvenile hormone polypeptide, a vacuolar polypeptide, a cadherin polypeptide, a cuticle polypeptide, a translation initiation factor, a SARI polypeptide, an elongation factor, a phosphooligosaccharide, a myosin polypeptide, a potassium channel amino acid transporter, a potassium inwardly rectifier, an amino acid transporter, a tubulin polypeptide, a ubiquitin polypeptide, and a small nuclear ribonucleoprotein. Non-limiting examples of target sequences of the invention include a polynucleotide set forth in SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50. As exemplified elsewhere herein, decreasing the level of expression of these target sequence or members of the recited enzyme classes in Lepidoptera controls the pest.


III. Silencing Elements

By “silencing element” is intended a polynucleotide which when ingested by a pest, is capable of reducing or eliminating the level or expression of a target polynucleotide or the polypeptide encoded thereby. The silencing element employed can reduce or eliminate the expression level of the target sequence by influencing the level of the target RNA transcript or, alternatively, by influencing translation and thereby affecting the level of the encoded polypeptide. Methods to assay for functional silencing elements that are capable of reducing or eliminating the level of a sequence of interest are disclosed elsewhere herein. A single polynucleotide employed in the methods of the invention can comprises one or more silencing elements to the same or different target polynucleotides.


In specific embodiments, the target sequence is not a plant endogenous gene. In other embodiments, while the silencing element controls pests, preferably the silencing element has no effect on the normal plant or plant part.


As discussed in further detail below, silencing elements can include, but are not limited to, a sense suppression element, an antisense suppression element, a double stranded RNA, a miRNA, or a hairpin suppression element. Non-limiting examples of silencing elements that can be employed to decrease expression of these target Lepidoptera sequences comprise fragments and variants of the sense or antisense sequence or consists of the sense or antisense sequence of the sequence set forth in SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 102, 105, 108, 111, 114, 117, 120, 123, 126, 129, 132, 135, 138, 141, 144, 147, 150, 153, 156, 159, 162, 165, 168, 171, 174, 177, 180, 183, 186, 189, 192, 195, 198, 201, 204, 207, 210, 213, 216, 219, 222, 225, 228, 231, 234, 237, 240, 243, 246, 249, 252, 255, 258, 261, 264, 267, 270, 273, 276, 279, 282, 285, 288, 291, 294, 297, 300, 303, 306, 309, 312, 315, 318, 321, 324, 327, 330, 333, 336, 339, 342, 345, 348, 351, 354, 357, 360, 363, 366, 369, 372, 375, 378, 381, 384, 387, 390, 393, 396, 399, 402, 405, 408, 411, 415, 418, 421, 424, 427, 430, 433, 436, 439, 442, 457, 460, and/or 463 or a biologically active variant or fragment thereof. In specific embodiments, the silencing element comprises or consists of at least one of the sequences set forth in any one of SEQ ID NOS: 51-465. In further embodiments, the silencing elements can comprise at least one thymine residue at the 3′ end. This can aid in stabilization. Thus, the silencing elements can have at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more thymine residues at the 3′ end.


In further embodiments, the silencing element comprises SEQ ID NO: 52 and 53; 55 and 56; 58 and 59; 61 and 62; 64 and 65; 67 and 68; 70 and 71; 73 and 74; 76 and 77; 79 and 80; 82 and 83; 85 and 86; 88 and 89; 91 and 92; 94 and 95; 97 and 98; 100 and 101; 103 and 104; 106 and 107; 109 and 110; 112 and 113; 115 and 116; 118 and 119; 121 and 122; 124 and 125; 127 and 128; 130 and 131; 133 and 134; 136 and 137; 139 and 140; 142 and 143; 145 and 146; 148 and 149; 151 and 152; 154 and 155; 157 and 158; 160 and 161; 163 and 164; 166 and 167; 169 and 170; 172 and 173; 175 and 176; 178 and 179; 181 and 182; 184 and 185; 187 and 188; 190 and 191; 193 and 194; 196 and 197; 199 and 200; 202 and 203; 205 and 206; 208 and 209; 211 and 212; 214 and 215; 217 and 218; 220 and 221; 223 and 224; 226 and 227; 229 and 230; 232 and 233; 235 and 236; 238 and 239; 241 and 242; 244 and 245; 247 and 248; 250 and 251; 253 and 254; 256 and 257; 259 and 260; 262 and 263; 265 and 266; 268 and 269; 271 and 272; 274 and 275; 277 and 278; 280 and 281; 283 and 284; 286 and 287; 289 and 290; 292 and 293; 295 and 296; 298 and 299; 301 and 302; 304 and 305; 307 and 308; 310 and 311; 313 and 314; 316 and 317; 139 and 320; 322 and 323; 325 and 326; 328 and 329; 331 and 332; 334 and 335; 337 and 338; 340 and 341; 343 and 344; 346 and 347; 349 and 350; 352 and 353; 355 and 356; 358 and 359; 361 and 362; 364 and 365; 367 and 368; 370 and 371; 373 and 374; 376 and 377; 379 and 380; 382 and 383; 385 and 386; 388 and 389; 391 and 392; 394 and 395; 397 and 398; 400 and 401; 403 and 404; 406 and 407; 409 and 410; 412 and 413; 416 and 417; 419 and 420; 422 and 423; 425 and 426; 428 and 429; 431 and 432; 434 and 435; 437 and 438; 440 and 441; 443 and 444; 458 and 459; 461 and 462; and/or 464 and 465.


By “reduces” or “reducing” the expression level of a polynucleotide or a polypeptide encoded thereby is intended to mean, the polynucleotide or polypeptide level of the target sequence is statistically lower than the polynucleotide level or polypeptide level of the same target sequence in an appropriate control pest which is not exposed to (i.e., has not ingested) the silencing element. In particular embodiments of the invention, reducing the polynucleotide level and/or the polypeptide level of the target sequence in a pest according to the invention results in less than 95%, less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, or less than 5% of the polynucleotide level, or the level of the polypeptide encoded thereby, of the same target sequence in an appropriate control pest. Methods to assay for the level of the RNA transcript, the level of the encoded polypeptide, or the activity of the polynucleotide or polypeptide are discussed elsewhere herein.


i. Sense Suppression Elements


As used herein, a “sense suppression element” comprises a polynucleotide designed to express an RNA molecule corresponding to at least a part of a target messenger RNA in the “sense” orientation. Expression of the RNA molecule comprising the sense suppression element reduces or eliminates the level of the target polynucleotide or the polypeptide encoded thereby. The polynucleotide comprising the sense suppression element may correspond to all or part of the sequence of the target polynucleotide, all or part of the 5′ and/or 3′ untranslated region of the target polynucleotide, all or part of the coding sequence of the target polynucleotide, or all or part of both the coding sequence and the untranslated regions of the target polynucleotide.


Typically, a sense suppression element has substantial sequence identity to the target polynucleotide, typically greater than about 65% sequence identity, greater than about 85% sequence identity, about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity. See, U.S. Pat. Nos. 5,283,184 and 5,034,323; herein incorporated by reference. The sense suppression element can be any length so long as it allows for the suppression of the targeted sequence. The sense suppression element can be, for example, 15, 20, 22, 25, 30, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 900 or longer.


ii. Antisense Suppression Elements


As used herein, an “antisense suppression element” comprises a polynucleotide which is designed to express an RNA molecule complementary to all or part of a target messenger RNA. Expression of the antisense RNA suppression element reduces or eliminates the level of the target polynucleotide. The polynucleotide for use in antisense suppression may correspond to all or part of the complement of the sequence encoding the target polynucleotide, all or part of the complement of the 5′ and/or 3′ untranslated region of the target polynucleotide, all or part of the complement of the coding sequence of the target polynucleotide, or all or part of the complement of both the coding sequence and the untranslated regions of the target polynucleotide. In addition, the antisense suppression element may be fully complementary (i.e., 100% identical to the complement of the target sequence) or partially complementary (i.e., less than 100% identical to the complement of the target sequence) to the target polynucleotide. In specific embodiments, the antisense suppression element comprises at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence complementarity to the target polynucleotide. Antisense suppression may be used to inhibit the expression of multiple proteins in the same plant. See, for example, U.S. Pat. No. 5,942,657. Furthermore, the antisense suppression element can be complementary to a portion of the target polynucleotide. Generally, sequences of at least 15, 20, 22, 25, 50, 100, 200, 300, 400, 450 nucleotides or greater may be used. Methods for using antisense suppression to inhibit the expression of endogenous genes in plants are described, for example, in Liu et al (2002) Plant Physiol. 129:1732-1743 and U.S. Pat. Nos. 5,759,829 and 5,942,657, each of which is herein incorporated by reference.


iii. Double Stranded RNA Suppression Element


A “double stranded RNA silencing element” or “dsRNA” comprises at least one transcript that is capable of forming a dsRNA either before or after ingestion by a pest. Thus, a “dsRNA silencing element” includes a dsRNA, a transcript or polyribonucleotide capable of forming a dsRNA or more than one transcript or polyribonucleotide capable of forming a dsRNA. “Double stranded RNA” or “dsRNA” refers to a polyribonucleotide structure formed either by a single self-complementary RNA molecule or a polyribonucleotide structure formed by the expression of least two distinct RNA strands. The dsRNA molecule(s) employed in the methods and compositions of the invention mediate the reduction of expression of a target sequence, for example, by mediating RNA interference “RNAi” or gene silencing in a sequence-specific manner. In the context of the present invention, the dsRNA is capable of reducing or eliminating the level or expression of a target polynucleotide or the polypeptide encoded thereby in a pest.


The dsRNA can reduce or eliminate the expression level of the target sequence by influencing the level of the target RNA transcript, by influencing translation and thereby affecting the level of the encoded polypeptide, or by influencing expression at the pre-transcriptional level (i.e., via the modulation of chromatin structure, methylation pattern, etc., to alter gene expression). See, for example, Verdel et al. (2004) Science 303:672-676; Pal-Bhadra et al. (2004) Science 303:669-672; Allshire (2002) Science 297:1818-1819; Volpe et al. (2002) Science 297:1833-1837; Jenuwein (2002) Science 297:2215-2218; and Hall et al. (2002) Science 297:2232-2237. Methods to assay for functional iRNA that are capable of reducing or eliminating the level of a sequence of interest are disclosed elsewhere herein. Accordingly, as used herein, the term “dsRNA” is meant to encompass other terms used to describe nucleic acid molecules that are capable of mediating RNA interference or gene silencing, including, for example, short-interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), hairpin RNA, short hairpin RNA (shRNA), post-transcriptional gene silencing RNA (ptgsRNA), and others.


In specific embodiments, at least one strand of the duplex or double-stranded region of the dsRNA shares sufficient sequence identity or sequence complementarity to the target polynucleotide to allow for the dsRNA to reduce the level of expression of the target sequence. As used herein, the strand that is complementary to the target polynucleotide is the “antisense strand” and the strand homologous to the target polynucleotide is the “sense strand.”


In one embodiment, the dsRNA comprises a hairpin RNA. A hairpin RNA comprises an RNA molecule that is capable of folding back onto itself to form a double stranded structure. Multiple structures can be employed as hairpin elements. In specific embodiments, the dsRNA suppression element comprises a hairpin element which comprises in the following order, a first segment, a second segment, and a third segment, where the first and the third segment share sufficient complementarity to allow the transcribed RNA to form a double-stranded stem-loop structure.


The “second segment” of the hairpin comprises a “loop” or a “loop region.” These terms are used synonymously herein and are to be construed broadly to comprise any nucleotide sequence that confers enough flexibility to allow self-pairing to occur between complementary regions of a polynucleotide (i.e., segments 1 and 3 which form the stem of the hairpin). For example, in some embodiments, the loop region may be substantially single stranded and act as a spacer between the self-complementary regions of the hairpin stem-loop. In some embodiments, the loop region can comprise a random or nonsense nucleotide sequence and thus not share sequence identity to a target polynucleotide. In other embodiments, the loop region comprises a sense or an antisense RNA sequence or fragment thereof that shares identity to a target polynucleotide. See, for example, International Patent Publication No. WO 02/00904, herein incorporated by reference. In specific embodiments, the loop region can be optimized to be as short as possible while still providing enough intramolecular flexibility to allow the formation of the base-paired stem region. Accordingly, the loop sequence is generally less than 1000, 900, 800, 700, 600, 500, 400, 300, 200, 100, 50, 25, 20, 15, 10 nucleotides or less.


The “first” and the “third” segment of the hairpin RNA molecule comprise the base-paired stem of the hairpin structure. The first and the third segments are inverted repeats of one another and share sufficient complementarity to allow the formation of the base-paired stem region. In specific embodiments, the first and the third segments are fully complementary to one another. Alternatively, the first and the third segment may be partially complementary to each other so long as they are capable of hybridizing to one another to form a base-paired stem region. The amount of complementarity between the first and the third segment can be calculated as a percentage of the entire segment. Thus, the first and the third segment of the hairpin RNA generally share at least 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, up to and including 100% complementarity.


The first and the third segment are at least about 1000, 500, 400, 300, 200, 100, 50, 40, 30, 25, 22, 20, 15 or 10 nucleotides in length. In specific embodiments, the length of the first and/or the third segment is about 10-100 nucleotides, about 10 to about 75 nucleotides, about 10 to about 50 nucleotides, about 10 to about 40 nucleotides, about 10 to about 35 nucleotides, about 10 to about 30 nucleotides, about 10 to about 25 nucleotides, about 10 to about 20 nucleotides. In other embodiments, the length of the first and/or the third segment comprises at least 10-20 nucleotides, 20-35 nucleotides, 30-45 nucleotides, 40-50 nucleotides, 50-100 nucleotides, or 100-300 nucleotides. See, for example, International Publication No. WO 0200904. In specific embodiments, the first and the third segment comprise at least 20 nucleotides having at least 85% complementary to the first segment. In still other embodiments, the first and the third segments which form the stem-loop structure of the hairpin comprises 3′ or 5′ overhang regions having unpaired nucleotide residues.


In specific embodiments, the sequences used in the first, the second, and/or the third segments comprise domains that are designed to have sufficient sequence identity to a target polynucleotide of interest and thereby have the ability to decrease the level of expression of the target polynucleotide. The specificity of the inhibitory RNA transcripts is therefore generally conferred by these domains of the silencing element. Thus, in some embodiments of the invention, the first, second and/or third segment of the silencing element comprise a domain having at least 10, at least 15, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 40, at least 50, at least 100, at least 200, at least 300, at least 500, at least 1000, or more than 1000 nucleotides that share sufficient sequence identity to the target polynucleotide to allow for a decrease in expression levels of the target polynucleotide when expressed in an appropriate cell. In other embodiments, the domain is between about 15 to 50 nucleotides, about 20-35 nucleotides, about 25-50 nucleotides, about 20 to 75 nucleotides, about 40-90 nucleotides about 15-100 nucleotides.


In specific embodiments, the domain of the first, the second, and/or the third segment has 100% sequence identity to the target polynucleotide. In other embodiments, the domain of the first, the second and/or the third segment having homology to the target polypeptide have at least 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater sequence identity to a region of the target polynucleotide. The sequence identity of the domains of the first, the second and/or the third segments to the target polynucleotide need only be sufficient to decrease expression of the target polynucleotide of interest. See, for example, Chuang and Meyerowitz (2000) Proc. Natl. Acad. Sci. USA 97:4985-4990; Stoutjesdijk et al. (2002) Plant Physiol. 129:1723-1731; Waterhouse and Helliwell (2003) Nat. Rev. Genet. 4:29-38; Pandolfini et al. BMC Biotechnology 3:7, and U.S. Patent Publication No. 20030175965; each of which is herein incorporated by reference. A transient assay for the efficiency of hpRNA constructs to silence gene expression in vivo has been described by Panstruga et al. (2003) Mol. Biol. Rep. 30:135-140, herein incorporated by reference.


The amount of complementarity shared between the first, second, and/or third segment and the target polynucleotide or the amount of complementarity shared between the first segment and the third segment (i.e., the stem of the hairpin structure) may vary depending on the organism in which gene expression is to be controlled. Some organisms or cell types may require exact pairing or 100% identity, while other organisms or cell types may tolerate some mismatching. In some cells, for example, a single nucleotide mismatch in the targeting sequence abrogates the ability to suppress gene expression. In these cells, the suppression cassettes of the invention can be used to target the suppression of mutant genes, for example, oncogenes whose transcripts comprise point mutations and therefore they can be specifically targeted using the methods and compositions of the invention without altering the expression of the remaining wild-type allele.


Any region of the target polynucleotide can be used to design the domain of the silencing element that shares sufficient sequence identity to allow expression of the hairpin transcript to decrease the level of the target polynucleotide. For instance, the domain can be designed to share sequence identity to the 5′ untranslated region of the target polynucleotide(s), the 3′ untranslated region of the target polynucleotide(s), exonic regions of the target polynucleotide(s), intronic regions of the target polynucleotide(s), and any combination thereof. In specific embodiments a domain of the silencing element shares sufficient homology to at least about 15, 20, 22, 25 or 30 consecutive nucleotides from about nucleotides 1-50, 50-100, 100-150, 150-200, 200-250, 250-300, 300-350, 350-400, 400-450, 450-500, 550-600, 600-650, 650-700, 750-800, 850-900, 950-1000, 1000-1050, 1050-1100, 1100-1200, 1200-1300, 1300-1400, 1400-1500, 1500-1600, 1600-1700, 1700-1800, 1800-1900, 1900-2000 of the target sequence. In some instances to optimize the siRNA sequences employed in the hairpin, the synthetic oligodeoxyribonucleotide/RNAse H method can be used to determine sites on the target mRNA that are in a conformation that is susceptible to RNA silencing. See, for example, Vickers et al. (2003) J. Biol. Chem 278:7108-7118 and Yang et al. (2002) Proc. Natl. Acad. Sci. USA 99:9442-9447, herein incorporated by reference. These studies indicate that there is a significant correlation between the RNase-H-sensitive sites and sites that promote efficient siRNA-directed mRNA degradation.


The hairpin silencing element may also be designed such that the sense sequence or the antisense sequence do not correspond to a target polynucleotide. In this embodiment, the sense and antisense sequence flank a loop sequence that comprises a nucleotide sequence corresponding to all or part of the target polynucleotide. Thus, it is the loop region that determines the specificity of the RNA interference. See, for example, WO 02/00904, herein incorporated by reference.


In specific embodiments, the silencing element comprising the hairpin comprises sequences selected from the group consisting of SEQ ID NO: 52 and 53; 55 and 56; 58 and 59; 61 and 62; 64 and 65; 67 and 68; 70 and 71; 73 and 74; 76 and 77; 79 and 80; 82 and 83; 85 and 86; 88 and 89; 91 and 92; 94 and 95; 97 and 98; 100 and 101; 103 and 104; 106 and 107; 109 and 110; 112 and 113; 115 and 116; 118 and 119; 121 and 122; 124 and 125; 127 and 128; 130 and 131; 133 and 134; 136 and 137; 139 and 140; 142 and 143; 145 and 146; 148 and 149; 151 and 152; 154 and 155; 157 and 158; 160 and 161; 163 and 164; 166 and 167; 169 and 170; 172 and 173; 175 and 176; 178 and 179; 181 and 182; 184 and 185; 187 and 188; 190 and 191; 193 and 194; 196 and 197; 199 and 200; 202 and 203; 205 and 206; 208 and 209; 211 and 212; 214 and 215; 217 and 218; 220 and 221; 223 and 224; 226 and 227; 229 and 230; 232 and 233; 235 and 236; 238 and 239; 241 and 242; 244 and 245; 247 and 248; 250 and 251; 253 and 254; 256 and 257; 259 and 260; 262 and 263; 265 and 266; 268 and 269; 271 and 272; 274 and 275; 277 and 278; 280 and 281; 283 and 284; 286 and 287; 289 and 290; 292 and 293; 295 and 296; 298 and 299; 301 and 302; 304 and 305; 307 and 308; 310 and 311; 313 and 314; 316 and 317; 139 and 320; 322 and 323; 325 and 326; 328 and 329; 331 and 332; 334 and 335; 337 and 338; 340 and 341; 343 and 344; 346 and 347; 349 and 350; 352 and 353; 355 and 356; 358 and 359; 361 and 362; 364 and 365; 367 and 368; 370 and 371; 373 and 374; 376 and 377; 379 and 380; 382 and 383; 385 and 386; 388 and 389; 391 and 392; 394 and 395; 397 and 398; 400 and 401; 403 and 404; 406 and 407; 409 and 410; 412 and 413; 416 and 417; 419 and 420; 422 and 423; 425 and 426; 428 and 429; 431 and 432; 434 and 435; 437 and 438; 440 and 441; 443 and 444; 458 and 459; 461 and 462; and/or 464 and 465.


In addition, transcriptional gene silencing (TGS) may be accomplished through use of a hairpin suppression element where the inverted repeat of the hairpin shares sequence identity with the promoter region of a target polynucleotide to be silenced. See, for example, Aufsatz et al. (2002) PNAS 99 (Suppl. 4):16499-16506 and Mette et al. (2000) EMBO J 19(19):5194-5201.


In other embodiments, the dsRNA can comprise a small RNA (sRNA). sRNAs can comprise both micro RNA (miRNA) and short-interfering RNA (siRNA) (Meister and Tuschl (2004) Nature 431:343-349 and Bonetta et al. (2004) Nature Methods 1:79-86). miRNAs are regulatory agents comprising about 19 ribonucleotides which are highly efficient at inhibiting the expression of target polynucleotides. See, for example Javier et al. (2003) Nature 425: 257-263, herein incorporated by reference. For miRNA interference, the silencing element can be designed to express a dsRNA molecule that forms a hairpin structure containing a 19-nucleotide sequence that is complementary to the target polynucleotide of interest. The miRNA can be synthetically made, or transcribed as a longer RNA which is subsequently cleaved to produce the active miRNA. Specifically, the miRNA can comprise 19 nucleotides of the sequence having homology to a target polynucleotide in sense orientation and 19 nucleotides of a corresponding antisense sequence that is complementary to the sense sequence.


When expressing an miRNA, it is recognized that various forms of an miRNA can be transcribed including, for example, the primary transcript (termed the “pri-miRNA”) which is processed through various nucleolytic steps to a shorter precursor miRNA (termed the “pre-miRNA”); the pre-miRNA; or the final (mature) miRNA is present in a duplex, the two strands being referred to as the miRNA (the strand that will eventually basepair with the target) and miRNA*. The pre-miRNA is a substrate for a form of dicer that removes the miRNA/miRNA* duplex from the precursor, after which, similarly to siRNAs, the duplex can be taken into the RISC complex. It has been demonstrated that miRNAs can be transgenically expressed and be effective through expression of a precursor form, rather than the entire primary form (Parizotto et al. (2004) Genes & Development 18:2237-2242 and Guo et al. (2005) Plant Cell 17:1376-1386).


The methods and compositions of the invention employ silencing elements that when transcribed “form” a dsRNA molecule. Accordingly, the heterologous polynucleotide being expressed need not form the dsRNA by itself, but can interact with other sequences in the plant cell or in the pest gut after ingestion to allow the formation of the dsRNA. For example, a chimeric polynucleotide that can selectively silence the target polynucleotide can be generated by expressing a chimeric construct comprising the target sequence for a miRNA or siRNA to a sequence corresponding to all or part of the gene or genes to be silenced. In this embodiment, the dsRNA is “formed” when the target for the miRNA or siRNA interacts with the miRNA present in the cell. The resulting dsRNA can then reduce the level of expression of the gene or genes to be silenced. See, for example, U.S. Provisional Application No. 60/691,613, filed Jun. 17, 2005, entitled “Methods and Compositions for Gene Silencing, herein incorporated by reference. The construct can be designed to have a target for an endogenous miRNA or alternatively, a target for a heterologous and/or synthetic miRNA can be employed in the construct. If a heterologous and/or synthetic miRNA is employed, it can be introduced into the cell on the same nucleotide construct as the chimeric polynucleotide or on a separate construct. As discussed elsewhere herein, any method can be used to introduce the construct comprising the heterologous miRNA.


IV. Variants and Fragments

By “fragment” is intended a portion of the polynucleotide or a portion of the amino acid sequence and hence protein encoded thereby. Fragments of a polynucleotide may encode protein fragments that retain the biological activity of the native protein. Alternatively, fragments of a polynucleotide that are useful as a silencing element do not need to encode fragment proteins that retain biological activity. Thus, fragments of a nucleotide sequence may range from at least about 10, about 15, about 20 nucleotides, about 22 nucleotides, about 50 nucleotides, about 75 nucleotides, about 100 nucleotides, 200 nucleotides, 300 nucleotides, 400 nucleotides, 500 nucleotides, 600 nucleotides, 700 nucleotides and up to the full-length polynucleotide employed in the invention. Methods to assay for the activity of a desired silencing element or a suppressor enhancer element are described elsewhere herein.


“Variants” is intended to mean substantially similar sequences. For polynucleotides, a variant comprises a deletion and/or addition of one or more nucleotides at one or more internal sites within the native polynucleotide and/or a substitution of one or more nucleotides at one or more sites in the native polynucleotide. As used herein, a “native” polynucleotide or polypeptide comprises a naturally occurring nucleotide sequence or amino acid sequence, respectively. For polynucleotides, conservative variants include those sequences that, because of the degeneracy of the genetic code, encode the amino acid sequence of one of the polypeptides employed in the invention. Variant polynucleotides also include synthetically derived polynucleotide, such as those generated, for example, by using site-directed mutagenesis, but continue to retain the desired activity. Generally, variants of a particular polynucleotide of the invention (i.e., a silencing element) will have at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to that particular polynucleotide as determined by sequence alignment programs and parameters described elsewhere herein.


Variants of a particular polynucleotide of the invention (i.e., the reference polynucleotide) can also be evaluated by comparison of the percent sequence identity between the polypeptide encoded by a variant polynucleotide and the polypeptide encoded by the reference polynucleotide. Percent sequence identity between any two polypeptides can be calculated using sequence alignment programs and parameters described elsewhere herein. Where any given pair of polynucleotides employed in the invention is evaluated by comparison of the percent sequence identity shared by the two polypeptides they encode, the percent sequence identity between the two encoded polypeptides is at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity.


“Variant” protein is intended to mean a protein derived from the native protein by deletion or addition of one or more amino acids at one or more internal sites in the native protein and/or substitution of one or more amino acids at one or more sites in the native protein. Variant proteins encompassed by the present invention are biologically active, that is they continue to possess the desired biological activity of the native protein, as discussed elsewhere herein. Such variants may result from, for example, genetic polymorphism or from human manipulation. Biologically active variants of a native protein will have at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the amino acid sequence for the native protein as determined by sequence alignment programs and parameters described elsewhere herein. A biologically active variant of a protein of the invention may differ from that protein by as few as 1-15 amino acid residues, as few as 1-10, such as 6-10, as few as 5, as few as 4, 3, 2, or even 1 amino acid residue.


The following terms are used to describe the sequence relationships between two or more polynucleotides or polypeptides: (a) “reference sequence”, (b) “comparison window”, (c) “sequence identity”, and, (d) “percentage of sequence identity.”


(a) As used herein, “reference sequence” is a defined sequence used as a basis for sequence comparison. A reference sequence may be a subset or the entirety of a specified sequence; for example, as a segment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence.


(b) As used herein, “comparison window” makes reference to a contiguous and specified segment of a polynucleotide sequence, wherein the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two polynucleotides. Generally, the comparison window is at least 20 contiguous nucleotides in length, and optionally can be 30, 40, 50, 100, or longer. Those of skill in the art understand that to avoid a high similarity to a reference sequence due to inclusion of gaps in the polynucleotide sequence a gap penalty is typically introduced and is subtracted from the number of matches.


Unless otherwise stated, sequence identity/similarity values provided herein refer to the value obtained using GAP Version 10 using the following parameters: % identity and % similarity for a nucleotide sequence using GAP Weight of 50 and Length Weight of 3, and the nwsgapdna.cmp scoring matrix; % identity and % similarity for an amino acid sequence using GAP Weight of 8 and Length Weight of 2, and the BLOSUM62 scoring matrix; or any equivalent program thereof. By “equivalent program” is intended any sequence comparison program that, for any two sequences in question, generates an alignment having identical nucleotide or amino acid residue matches and an identical percent sequence identity when compared to the corresponding alignment generated by GAP Version 10.


(c) As used herein, “sequence identity” or “identity” in the context of two polynucleotides or polypeptide sequences makes reference to the residues in the two sequences that are the same when aligned for maximum correspondence over a specified comparison window. When percentage of sequence identity is used in reference to proteins it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. When sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Sequences that differ by such conservative substitutions are said to have “sequence similarity” or “similarity”. Means for making this adjustment are well known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated, e.g., as implemented in the program PC/GENE (Intelligenetics, Mountain View, Calif.).


(d) As used herein, “percentage of sequence identity” means the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison, and multiplying the result by 100 to yield the percentage of sequence identity.


V. DNA Constructs

The use of the term “polynucleotide” is not intended to limit the present invention to polynucleotides comprising DNA. Those of ordinary skill in the art will recognize that polynucleotides can comprise ribonucleotides and combinations of ribonucleotides and deoxyribonucleotides. Such deoxyribonucleotides and ribonucleotides include both naturally occurring molecules and synthetic analogues. The polynucleotides of the invention also encompass all forms of sequences including, but not limited to, single-stranded forms, double-stranded forms, hairpins, stem-and-loop structures, and the like.


The polynucleotide encoding the silencing element or in specific embodiments employed in the methods and compositions of the invention can be provided in expression cassettes for expression in a plant or organism of interest. It is recognized that multiple silencing elements including multiple identical silencing elements, multiple silencing elements targeting different regions of the target sequence, or multiple silencing elements from different target sequences can be used. In this embodiment, it is recognized that each silencing element can be contained in a single or separate cassette, DNA construct, or vector. As discussed, any means of providing the silencing element is contemplated. A plant or plant cell can be transformed with a single cassette comprising DNA encoding one or more silencing elements or separate cassettes comprising each silencing element can be used to transform a plant or plant cell or host cell. Likewise, a plant transformed with one component can be subsequently transformed with the second component. One or more silencing elements can also be brought together by sexual crossing. That is, a first plant comprising one component is crossed with a second plant comprising the second component. Progeny plants from the cross will comprise both components.


The expression cassette can include 5′ and 3′ regulatory sequences operably linked to the polynucleotide of the invention. “Operably linked” is intended to mean a functional linkage between two or more elements. For example, an operable linkage between a polynucleotide of the invention and a regulatory sequence (i.e., a promoter) is a functional link that allows for expression of the polynucleotide of the invention. Operably linked elements may be contiguous or non-contiguous. When used to refer to the joining of two protein coding regions, by operably linked is intended that the coding regions are in the same reading frame. The cassette may additionally contain at least one additional polynucleotide to be cotransformed into the organism. Alternatively, the additional polypeptide(s) can be provided on multiple expression cassettes. Expression cassettes can be provided with a plurality of restriction sites and/or recombination sites for insertion of the polynucleotide to be under the transcriptional regulation of the regulatory regions. The expression cassette may additionally contain selectable marker genes.


The expression cassette will include in the 5′-3′ direction of transcription, a transcriptional and translational initiation region (i.e., a promoter), a polynucleotide comprising the silencing element employed in the methods and compositions of the invention, and a transcriptional and translational termination region (i.e., termination region) functional in plants. The regulatory regions (i.e., promoters, transcriptional regulatory regions, and translational termination regions) and/or the polynucleotides employed in the invention may be native/analogous to the host cell or to each other. Alternatively, the regulatory regions and/or the polynucleotide employed in the invention may be heterologous to the host cell or to each other. As used herein, “heterologous” in reference to a sequence is a sequence that originates from a foreign species, or, if from the same species, is substantially modified from its native form in composition and/or genomic locus by deliberate human intervention. For example, a promoter operably linked to a heterologous polynucleotide is from a species different from the species from which the polynucleotide was derived, or, if from the same/analogous species, one or both are substantially modified from their original form and/or genomic locus, or the promoter is not the native promoter for the operably linked polynucleotide. As used herein, a chimeric gene comprises a coding sequence operably linked to a transcription initiation region that is heterologous to the coding sequence.


The termination region may be native with the transcriptional initiation region, may be native with the operably linked polynucleotide encoding the silencing element, may be native with the plant host, or may be derived from another source (i.e., foreign or heterologous) to the promoter, the polynucleotide comprising silencing element, the plant host, or any combination thereof. Convenient termination regions are available from the Ti-plasmid of A. tumefaciens, such as the octopine synthase and nopaline synthase termination regions. See also Guerineau et al. (1991) Mol. Gen. Genet. 262:141-144; Proudfoot (1991) Cell 64:671-674; Sanfacon et al. (1991) Genes Dev. 5:141-149; Mogen et al. (1990) Plant Cell 2:1261-1272; Munroe et al. (1990) Gene 91:151-158; Ballas et al. (1989) Nucleic Acids Res. 17:7891-7903; and Joshi et al. (1987) Nucleic Acids Res. 15:9627-9639.


Additional sequence modifications are known to enhance gene expression in a cellular host. These include elimination of sequences encoding spurious polyadenylation signals, exon-intron splice site signals, transposon-like repeats, and other such well-characterized sequences that may be deleterious to gene expression. The G-C content of the sequence may be adjusted to levels average for a given cellular host, as calculated by reference to known genes expressed in the host cell. When possible, the sequence is modified to avoid predicted hairpin secondary mRNA structures.


In preparing the expression cassette, the various DNA fragments may be manipulated, so as to provide for the DNA sequences in the proper orientation and, as appropriate, in the proper reading frame. Toward this end, adapters or linkers may be employed to join the DNA fragments or other manipulations may be involved to provide for convenient restriction sites, removal of superfluous DNA, removal of restriction sites, or the like. For this purpose, in vitro mutagenesis, primer repair, restriction, annealing, resubstitutions, e.g., transitions and transversions, may be involved.


A number of promoters can be used in the practice of the invention. The polynucleotide encoding the silencing element can be combined with constitutive, tissue-preferred, or other promoters for expression in plants.


Such constitutive promoters include, for example, the core promoter of the Rsyn7 promoter and other constitutive promoters disclosed in WO 99/43838 and U.S. Pat. No. 6,072,050; the core CaMV 35S promoter (Odell et al. (1985) Nature 313:810-812); rice actin (McElroy et al. (1990) Plant Cell 2:163-171); ubiquitin (Christensen et al. (1989) Plant Mol. Biol. 12:619-632 and Christensen et al. (1992) Plant Mol. Biol. 18:675-689); pEMU (Last et al. (1991) Theor. Appl. Genet. 81:581-588); MAS (Velten et al. (1984) EMBO J. 3:2723-2730); ALS promoter (U.S. Pat. No. 5,659,026), and the like. Other constitutive promoters include, for example, U.S. Pat. Nos. 5,608,149; 5,608,144; 5,604,121; 5,569,597; 5,466,785; 5,399,680; 5,268,463; 5,608,142; and 6,177,611.


An inducible promoter, for instance, a pathogen-inducible promoter could also be employed. Such promoters include those from pathogenesis-related proteins (PR proteins), which are induced following infection by a pathogen; e.g., PR proteins, SAR proteins, beta-1,3-glucanase, chitinase, etc. See, for example, Redolfi et al. (1983) Neth. J. Plant Pathol. 89:245-254; Uknes et al. (1992) Plant Cell 4:645-656; and Van Loon (1985) Plant Mol. Virol. 4:111-116. See also WO 99/43819, herein incorporated by reference.


Of interest are promoters that are expressed locally at or near the site of pathogen infection. See, for example, Marineau et al. (1987) Plant Mol. Biol. 9:335-342; Matton et al. (1989) Molecular Plant-Microbe Interactions 2:325-331; Somsisch et al. (1986) Proc. Natl. Acad. Sci. USA 83:2427-2430; Somsisch et al. (1988) Mol. Gen. Genet. 2:93-98; and Yang (1996) Proc. Natl. Acad. Sci. USA 93:14972-14977. See also, Chen et al. (1996) Plant J. 10:955-966; Zhang et al. (1994) Proc. Natl. Acad. Sci. USA 91:2507-2511; Warner et al. (1993) Plant J. 3:191-201; Siebertz et al. (1989) Plant Cell 1:961-968; U.S. Pat. No. 5,750,386 (nematode-inducible); and the references cited therein. Of particular interest is the inducible promoter for the maize PRms gene, whose expression is induced by the pathogen Fusarium moniliforme (see, for example, Cordero et al. (1992) Physiol. Mol. Plant Path. 41:189-200).


Additionally, as pathogens find entry into plants through wounds or insect damage, a wound-inducible promoter may be used in the constructions of the invention. Such wound-inducible promoters include potato proteinase inhibitor (pin II) gene (Ryan (1990) Ann. Rev. Phytopath. 28:425-449; Duan et al. (1996) Nature Biotechnology 14:494-498); wun1 and wun2, U.S. Pat. No. 5,428,148; win1 and win2 (Stanford et al. (1989) Mol. Gen. Genet. 215:200-208); systemin (McGurl et al. (1992) Science 225:1570-1573); WIP1 (Rohmeier et al. (1993) Plant Mol. Biol. 22:783-792; Eckelkamp et al. (1993) FEBS Letters 323:73-76); MPI gene (Corderok et al. (1994) Plant J. 6(2):141-150); and the like, herein incorporated by reference.


Chemical-regulated promoters can be used to modulate the expression of a gene in a plant through the application of an exogenous chemical regulator. Depending upon the objective, the promoter may be a chemical-inducible promoter, where application of the chemical induces gene expression, or a chemical-repressible promoter, where application of the chemical represses gene expression. Chemical-inducible promoters are known in the art and include, but are not limited to, the maize In2-2 promoter, which is activated by benzenesulfonamide herbicide safeners, the maize GST promoter, which is activated by hydrophobic electrophilic compounds that are used as pre-emergent herbicides, and the tobacco PR-la promoter, which is activated by salicylic acid. Other chemical-regulated promoters of interest include steroid-responsive promoters (see, for example, the glucocorticoid-inducible promoter in Schena et al. (1991) Proc. Natl. Acad. Sci. USA 88:10421-10425 and McNellis et al. (1998) Plant J. 14(2):247-257) and tetracycline-inducible and tetracycline-repressible promoters (see, for example, Gatz et al. (1991) Mol. Gen. Genet. 227:229-237, and U.S. Pat. Nos. 5,814,618 and 5,789,156), herein incorporated by reference.


Tissue-preferred promoters can be utilized to target enhanced expression within a particular plant tissue. Tissue-preferred promoters include Yamamoto et al. (1997) Plant J. 12(2):255-265; Kawamata et al. (1997) Plant Cell Physiol. 38(7):792-803; Hansen et al. (1997) Mol. Gen Genet. 254(3):337-343; Russell et al. (1997) Transgenic Res. 6(2):157-168; Rinehart et al. (1996) Plant Physiol. 112(3):1331-1341; Van Camp et al. (1996) Plant Physiol. 112(2):525-535; Canevascini et al. (1996) Plant Physiol. 112(2):513-524; Yamamoto et al. (1994) Plant Cell Physiol. 35(5):773-778; Lam (1994) Results Probl. Cell Differ. 20:181-196; Orozco et al. (1993) Plant Mol Biol. 23(6):1129-1138; Matsuoka et al. (1993) Proc Natl. Acad. Sci. USA 90(20):9586-9590; and Guevara-Garcia et al. (1993) Plant J. 4(3):495-505. Such promoters can be modified, if necessary, for weak expression.


Leaf-preferred promoters are known in the art. See, for example, Yamamoto et al. (1997) Plant J. 12(2):255-265; Kwon et al. (1994) Plant Physiol. 105:357-67; Yamamoto et al. (1994) Plant Cell Physiol. 35(5):773-778; Gotor et al. (1993) Plant J. 3:509-18; Orozco et al. (1993) Plant Mol. Biol. 23(6):1129-1138; and Matsuoka et al. (1993) Proc. Natl. Acad. Sci. USA 90(20):9586-9590.


Root-preferred promoters are known and can be selected from the many available from the literature or isolated de novo from various compatible species. See, for example, Hire et al. (1992) Plant Mol. Biol. 20(2):207-218 (soybean root-specific glutamine synthetase gene); Keller and Baumgartner (1991) Plant Cell 3(10):1051-1061 (root-specific control element in the GRP 1.8 gene of French bean); Sanger et al. (1990) Plant Mol. Biol. 14(3):433-443 (root-specific promoter of the mannopine synthase (MAS) gene of Agrobacterium tumefaciens); and Miao et al. (1991) Plant Cell 3(1):11-22 (full-length cDNA clone encoding cytosolic glutamine synthetase (GS), which is expressed in roots and root nodules of soybean). See also Bogusz et al. (1990) Plant Cell 2(7):633-641, where two root-specific promoters isolated from hemoglobin genes from the nitrogen-fixing nonlegume Parasponia andersonii and the related non-nitrogen-fixing nonlegume Trema tomentosa are described. The promoters of these genes were linked to a β-glucuronidase reporter gene and introduced into both the nonlegume Nicotiana tabacum and the legume Lotus corniculatus, and in both instances root-specific promoter activity was preserved. Leach and Aoyagi (1991) describe their analysis of the promoters of the highly expressed rolC and rolD root-inducing genes of Agrobacterium rhizogenes (see Plant Science (Limerick) 79(1):69-76). They concluded that enhancer and tissue-preferred DNA determinants are dissociated in those promoters. Teeri et al. (1989) used gene fusion to lacZ to show that the Agrobacterium T-DNA gene encoding octopine synthase is especially active in the epidermis of the root tip and that the TR2′ gene is root specific in the intact plant and stimulated by wounding in leaf tissue, an especially desirable combination of characteristics for use with an insecticidal or larvicidal gene (see EMBO J. 8(2):343-350). The TR1′ gene, fused to nptII (neomycin phosphotransferase II) showed similar characteristics. Additional root-preferred promoters include the VfENOD-GRP3 gene promoter (Kuster et al. (1995) Plant Mol. Biol. 29(4):759-772); and rolB promoter (Capana et al. (1994) Plant Mol. Biol. 25(4):681-691. See also U.S. Pat. Nos. 5,837,876; 5,750,386; 5,633,363; 5,459,252; 5,401,836; 5,110,732; and 5,023,179.


In one embodiment of this invention the plant-expressed promoter is a vascular-specific promoter such as a phloem-specific promoter. A “vascular-specific” promoter, as used herein, is a promoter which is at least expressed in vascular cells, or a promoter which is preferentially expressed in vascular cells. Expression of a vascular-specific promoter need not be exclusively in vascular cells, expression in other cell types or tissues is possible. A “phloem-specific promoter” as used herein, is a plant-expressible promoter which is at least expressed in phloem cells, or a promoter which is preferentially expressed in phloem cells.


Expression of a phloem-specific promoter need not be exclusively in phloem cells, expression in other cell types or tissues, e.g., xylem tissue, is possible. In one embodiment of this invention, a phloem-specific promoter is a plant-expressible promoter at least expressed in phloem cells, wherein the expression in non-phloem cells is more limited (or absent) compared to the expression in phloem cells. Examples of suitable vascular-specific or phloem-specific promoters in accordance with this invention include but are not limited to the promoters selected from the group consisting of: the SCSV3, SCSV4, SCSV5, and SCSV7 promoters (Schunmann et al. (2003) Plant Functional Biology 30:453-60; the rolC gene promoter of Agrobacterium rhizogenes(Kiyokawa et al. (1994) Plant Physiology 104:801-02; Pandolfini et al. (2003) BioMedCentral (BMC) Biotechnology 3:7, (www.biomedcentral.com/1472-6750/3/7); Graham et al. (1997) Plant Mol. Biol. 33:729-35; Guivarc'h et al. (1996); Almon et al. (1997) Plant Physiol. 115:1599-607; the rolA gene promoter of Agrobacterium rhizogenes (Dehio et al. (1993) Plant Mol. Biol. 23:1199-210); the promoter of the Agrobacterium tumefaciens T-DNA gene 5 (Korber et al. (1991) EMBO J. 10:3983-91); the rice sucrose synthase RSs1 gene promoter (Shi et al. (1994) J. Exp. Bot. 45:623-31); the CoYMV or Commelina yellow mottle badnavirus promoter (Medberry et al. (1992) Plant Cell 4:185-92; Zhou et al. (1998) Chin. J. Biotechnol. 14:9-16); the CFDV or coconut foliar decay virus promoter (Rohde et al. (1994) Plant Mol. Biol. 27:623-28; Hehn and Rhode (1998) J. Gen. Virol. 79:1495-99); the RTBV or rice tungro bacilliform virus promoter (Yin and Beachy (1995) Plant J. 7:969-80; Yin et al. (1997) Plant J. 12:1179-80); the pea glutamin synthase GS3A gene (Edwards et al. (1990) Proc. Natl. Acad. Sci. USA 87:3459-63; Brears et al. (1991) Plant J. 1:235-44); the inv CD111 and inv CD141 promoters of the potato invertase genes (Hedley et al. (2000) J. Exp. Botany 51:817-21); the promoter isolated from Arabidopsis shown to have phloem-specific expression in tobacco by Kertbundit et al. (1991) Proc. Natl. Acad. Sci. USA 88:5212-16); the VAHOX1 promoter region (Tornero et al. (1996) Plant J. 9:639-48); the pea cell wall invertase gene promoter (Zhang et al. (1996) Plant Physiol. 112:1111-17); the promoter of the endogenous cotton protein related to chitinase of US published patent application 20030106097, an acid invertase gene promoter from carrot (Ramloch-Lorenz et al. (1993) The Plant J. 4:545-54); the promoter of the sulfate transporter geneSultr1; 3 (Yoshimoto et al. (2003) Plant Physiol. 131:1511-17); a promoter of a sucrose synthase gene (Nolte and Koch (1993) Plant Physiol. 101:899-905); and the promoter of a tobacco sucrose transporter gene (Kuhn et al. (1997) Science 275-1298-1300).


Possible promoters also include the Black Cherry promoter for Prunasin Hydrolase (PH DL1.4 PRO) (U.S. Pat. No. 6,797,859), Thioredoxin H promoter from cucumber and rice (Fukuda A et al. (2005). Plant Cell Physiol. 46(11):1779-86), Rice (RSs1) (Shi, T. Wang et al. (1994). J. Exp. Bot. 45(274): 623-631) and maize sucrose synthese −1 promoters (Yang., N-S. et al. (1990) PNAS 87:4144-4148), PP2 promoter from pumpkin Guo, H. et al. (2004) Transgenic Research 13:559-566), At SUC2 promoter (Truernit, E. et al. (1995) Planta 196(3):564-70., At SAM-1 (S-adenosylmethionine synthetase) (Mijnsbrugge KV. et al. (1996) Planr. Cell. Physiol. 37(8): 1108-1115), and the Rice tungro bacilliform virus (RTBV) promoter (Bhattacharyya-Pakrasi et al. (1993) Plant J. 4(1):71-79).


The expression cassette can also comprise a selectable marker gene for the selection of transformed cells. Selectable marker genes are utilized for the selection of transformed cells or tissues. Marker genes include genes encoding antibiotic resistance, such as those encoding neomycin phosphotransferase II (NEO) and hygromycin phosphotransferase (HPT), as well as genes conferring resistance to herbicidal compounds, such as glufosinate ammonium, bromoxynil, imidazolinones, and 2,4-dichlorophenoxyacetate (2,4-D). Additional selectable markers include phenotypic markers such as β-galactosidase and fluorescent proteins such as green fluorescent protein (GFP) (Su et al. (2004) Biotechnol Bioeng 85:610-9 and Fetter et al. (2004) Plant Cell 16:215-28), cyan florescent protein (CYP) (Bolte et al. (2004) J. Cell Science 117:943-54 and Kato et al. (2002) Plant Physiol 129:913-42), and yellow florescent protein (PhiYFP™ from Evrogen, see, Bolte et al. (2004) J. Cell Science 117:943-54). For additional selectable markers, see generally, Yarranton (1992) Curr. Opin. Biotech. 3:506-511; Christopherson et al. (1992) Proc. Natl. Acad. Sci. USA 89:6314-6318; Yao et al. (1992) Cell 71:63-72; Reznikoff (1992) Mol. Microbiol. 6:2419-2422; Barkley et al. (1980) in The Operon, pp. 177-220; Hu et al. (1987) Cell 48:555-566; Brown et al. (1987) Cell 49:603-612; Figge et al. (1988) Cell 52:713-722; Deuschle et al. (1989) Proc. Natl. Acad. Sci. USA 86:5400-5404; Fuerst et al. (1989) Proc. Natl. Acad. Sci. USA 86:2549-2553; Deuschle et al. (1990) Science 248:480-483; Gossen (1993) Ph.D. Thesis, University of Heidelberg; Reines et al. (1993) Proc. Natl. Acad. Sci. USA 90:1917-1921; Labow et al. (1990) Mol. Cell. Biol. 10:3343-3356; Zambretti et al. (1992) Proc. Natl. Acad. Sci. USA 89:3952-3956; Bairn et al. (1991) Proc. Natl. Acad. Sci. USA 88:5072-5076; Wyborski et al. (1991) Nucleic Acids Res. 19:4647-4653; Hillenand-Wissman (1989) Topics Mol. Struc. Biol. 10:143-162; Degenkolb et al. (1991) Antimicrob. Agents Chemother. 35:1591-1595; Kleinschnidt et al. (1988) Biochemistry 27:1094-1104; Bonin (1993) Ph.D. Thesis, University of Heidelberg; Gossen et al. (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551; Oliva et al. (1992) Antimicrob. Agents Chemother. 36:913-919; Hlavka et al. (1985) Handbook of Experimental Pharmacology, Vol. 78 (Springer-Verlag, Berlin); Gill et al. (1988) Nature 334:721-724. Such disclosures are herein incorporated by reference. The above list of selectable marker genes is not meant to be limiting. Any selectable marker gene can be used in the present invention.


VI. Compositions Comprising Silencing Elements

One or more of the polynucleotides comprising the silencing element can be provided as an external composition such as a spray or powder to the plant, plant part, seed, a pest, or an area of cultivation. In another example, a plant is transformed with a DNA construct or expression cassette for expression of at least one silencing element. In either compositions, the silencing element, when ingested by an insect, can reduce the level of a target pest sequence and thereby control the pest (i.e., any pest from the Lepidoptera order, such as, Spodoptera frugiperda). It is recognized that the composition can comprise a cell (such as plant cell or a bacterial cell), in which a polynucleotide encoding the silencing element is stably incorporated into the genome and operably linked to promoters active in the cell. Compositions comprising a mixture of cells, some cells expressing at least one silencing element are also encompassed. In other embodiments, compositions comprising the silencing elements are not contained in a cell. In such embodiments, the composition can be applied to an area inhabited by a pest. In one embodiment, the composition is applied externally to a plant (i.e., by spraying a field or area of cultivation) to protect the plant from the pest.


In one embodiment, the composition comprising the silencing element that controls a pest from the Lepidoptera order does not comprise a heterologous cationic oligopeptide to facilitate uptake of the RNAi into the insect cells. Accordingly, in such embodiments, insecticidal activity occurs in the compositions of the invention (i.e., the plant, plant part, plant cell, or microbe) in the absence of a cationic oligopeptide that is heterologous to the plant, plant part or microbe. The cationic oligopeptide is target non-specific and interacts non-specifically with RNA via electrostatic interactions and neutralization of charge to penetrate membranes and lacks a specific activity that promotes a specific interaction with a cell membrane.


The composition of the invention can further be formulated as bait. In this embodiment, the compositions comprise a food substance or an attractant which enhances the attractiveness of the composition to the pest.


The composition comprising the silencing element can be formulated in an agriculturally suitable and/or environmentally acceptable carrier. Such carriers can be any material that the animal, plant or environment to be treated can tolerate. Furthermore, the carrier must be such that the composition remains effective at controlling a pest. Examples of such carriers include water, saline, Ringer's solution, dextrose or other sugar solutions, Hank's solution, and other aqueous physiologically balanced salt solutions, phosphate buffer, bicarbonate buffer and Tris buffer. In addition, the composition may include compounds that increase the half-life of a composition.


It is recognized that the polynucleotides comprising sequences encoding the silencing element can be used to transform organisms to provide for host organism production of these components, and subsequent application of the host organism to the environment of the target pest(s). Such host organisms include baculoviruses, bacteria, and the like. In this manner, the combination of polynucleotides encoding the silencing element may be introduced via a suitable vector into a microbial host, and said host applied to the environment, or to plants or animals.


The term “introduced” in the context of inserting a nucleic acid into a cell, means “transfection” or “transformation” or “transduction” and includes reference to the incorporation of a nucleic acid into a eukaryotic or prokaryotic cell where the nucleic acid may be stably incorporated into the genome of the cell (e.g., chromosome, plasmid, plastid, or mitochondrial DNA), converted into an autonomous replicon, or transiently expressed (e.g., transfected mRNA).


Microbial hosts that are known to occupy the “phytosphere” (phylloplane, phyllosphere, rhizosphere, and/or rhizoplana) of one or more crops of interest may be selected. These microorganisms are selected so as to be capable of successfully competing in the particular environment with the wild-type microorganisms, provide for stable maintenance and expression of the sequences encoding the silencing element, and desirably, provide for improved protection of the components from environmental degradation and inactivation.


Such microorganisms include bacteria, algae, and fungi. Of particular interest are microorganisms such as bacteria, e.g., Pseudomonas, Erwinia, Serratia, Klebsiella, Xanthomonas, Streptomyces, Rhizobium, Rhodopseudomonas, Methylius, Agrobacterium, Acetobacter, Lactobacillus, Arthrobacter, Azotobacter, Leuconostoc, and Alcaligenes, fungi, particularly yeast, e.g., Saccharomyces, Cryptococcus, Kluyveromyces, Sporobolomyces, Rhodotorula, and Aureobasidium. Of particular interest are such phytosphere bacterial species as Pseudomonas syringae, Pseudomonas fluorescens, Serratia marcescens, Acetobacter xylinum, Agrobacteria, Rhodopseudomonas spheroides, Xanthomonas campestris, Rhizobium melioti, Alcaligenes entrophus, Clavibacter xyli and Azotobacter vinlandir, and phytosphere yeast species such as Rhodotorula rubra, R. glutinis, R. marina, R. aurantiaca, Cryptococcus albidus, C. diffluens, C. laurentii, Saccharomyces rosei, S. pretoriensis, S. cerevisiae, Sporobolomyces rosues, S. odorus, Kluyveromyces veronae, and Aureobasidium pollulans. Of particular interest are the pigmented microorganisms.


A number of ways are available for introducing the polynucleotide comprising the silencing element into the microbial host under conditions that allow for stable maintenance and expression of such nucleotide encoding sequences. For example, expression cassettes can be constructed which include the nucleotide constructs of interest operably linked with the transcriptional and translational regulatory signals for expression of the nucleotide constructs, and a nucleotide sequence homologous with a sequence in the host organism, whereby integration will occur, and/or a replication system that is functional in the host, whereby integration or stable maintenance will occur.


Transcriptional and translational regulatory signals include, but are not limited to, promoters, transcriptional initiation start sites, operators, activators, enhancers, other regulatory elements, ribosomal binding sites, an initiation codon, termination signals, and the like. See, for example, U.S. Pat. Nos. 5,039,523 and 4,853,331; EPO 0480762A2; Sambrook et al. (2000); Molecular Cloning: A Laboratory Manual (3rd ed.; Cold Spring Harbor Laboratory Press, Plainview, N.Y.); Davis et al. (1980) Advanced Bacterial Genetics (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.); and the references cited therein.


Suitable host cells include the prokaryotes and the lower eukaryotes, such as fungi. Illustrative prokaryotes, both Gram-negative and Gram-positive, include Enterobacteriaceae, such as Escherichia, Erwinia, Shigella, Salmonella, and Proteus; Bacillaceae; Rhizobiceae, such as Rhizobium; Spirillaceae, such as photobacterium, Zymomonas, Serratia, Aeromonas, Vibrio, Desulfovibrio, Spirillum; Lactobacillaceae; Pseudomonadaceae, such as Pseudomonas and Acetobacter; Azotobacteraceae and Nitrobacteraceae. Among eukaryotes are fungi, such as Phycomycetes and Ascomycetes, which includes yeast, such as Saccharomyces and Schizosaccharomyces; and Basidiomycetes yeast, such as Rhodotorula, Aureobasidium, Sporobolomyces, and the like.


Characteristics of particular interest in selecting a host cell for purposes of the invention include ease of introducing the coding sequence into the host, availability of expression systems, efficiency of expression, stability in the host, and the presence of auxiliary genetic capabilities. Characteristics of interest for use as a pesticide microcapsule include protective qualities, such as thick cell walls, pigmentation, and intracellular packaging or formation of inclusion bodies; leaf affinity; lack of mammalian toxicity; attractiveness to pests for ingestion; and the like. Other considerations include ease of formulation and handling, economics, storage stability, and the like.


Host organisms of particular interest include yeast, such as Rhodotorula spp., Aureobasidium spp., Saccharomyces spp., and Sporobolomyces spp., phylloplane organisms such as Pseudomonas spp., Erwinia spp., and Flavobacterium spp., and other such organisms, including Pseudomonas aeruginosa, Pseudomonas fluorescens, Saccharomyces cerevisiae, Bacillus thuringiensis, Escherichia coli, Bacillus subtilis, and the like.


The sequences encoding the silencing elements encompassed by the invention can be introduced into microorganisms that multiply on plants (epiphytes) to deliver these components to potential target pests. Epiphytes, for example, can be gram-positive or gram-negative bacteria.


The silencing element can be fermented in a bacterial host and the resulting bacteria processed and used as a microbial spray in the same manner that Bacillus thuringiensis strains have been used as insecticidal sprays. Any suitable microorganism can be used for this purpose. Pseudomonas has been used to express Bacillus thuringiensis endotoxins as encapsulated proteins and the resulting cells processed and sprayed as an insecticide Gaertner et al. (1993), in Advanced Engineered Pesticides, ed. L. Kim (Marcel Decker, Inc.).


Alternatively, the components of the invention are produced by introducing heterologous genes into a cellular host. Expression of the heterologous sequences results, directly or indirectly, in the intracellular production of the silencing element. These compositions may then be formulated in accordance with conventional techniques for application to the environment hosting a target pest, e.g., soil, water, and foliage of plants. See, for example, EPA 0192319, and the references cited therein.


In the present invention, a transformed microorganism can be formulated with an acceptable carrier into separate or combined compositions that are, for example, a suspension, a solution, an emulsion, a dusting powder, a dispersible granule, a wettable powder, and an emulsifiable concentrate, an aerosol, an impregnated granule, an adjuvant, a coatable paste, and also encapsulations in, for example, polymer substances.


Such compositions disclosed above may be obtained by the addition of a surface-active agent, an inert carrier, a preservative, a humectant, a feeding stimulant, an attractant, an encapsulating agent, a binder, an emulsifier, a dye, a UV protectant, a buffer, a flow agent or fertilizers, micronutrient donors, or other preparations that influence plant growth. One or more agrochemicals including, but not limited to, herbicides, insecticides, fungicides, bactericides, nematicides, molluscicides, acaracides, plant growth regulators, harvest aids, and fertilizers, can be combined with carriers, surfactants or adjuvants customarily employed in the art of formulation or other components to facilitate product handling and application for particular target pests. Suitable carriers and adjuvants can be solid or liquid and correspond to the substances ordinarily employed in formulation technology, e.g., natural or regenerated mineral substances, solvents, dispersants, wetting agents, tackifiers, binders, or fertilizers. The active ingredients of the present invention (i.e., at least one silencing element) are normally applied in the form of compositions and can be applied to the crop area, plant, or seed to be treated. For example, the compositions may be applied to grain in preparation for or during storage in a grain bin or silo, etc. The compositions may be applied simultaneously or in succession with other compounds. Methods of applying an active ingredient or a composition that contains at least one silencing element include, but are not limited to, foliar application, seed coating, and soil application. The number of applications and the rate of application depend on the intensity of infestation by the corresponding pest.


Suitable surface-active agents include, but are not limited to, anionic compounds such as a carboxylate of, for example, a metal; carboxylate of a long chain fatty acid; an N-acylsarcosinate; mono- or di-esters of phosphoric acid with fatty alcohol ethoxylates or salts of such esters; fatty alcohol sulfates such as sodium dodecyl sulfate, sodium octadecyl sulfate, or sodium cetyl sulfate; ethoxylated fatty alcohol sulfates; ethoxylated alkylphenol sulfates; lignin sulfonates; petroleum sulfonates; alkyl aryl sulfonates such as alkyl-benzene sulfonates or lower alkylnaphtalene sulfonates, e.g., butyl-naphthalene sulfonate; salts of sulfonated naphthalene-formaldehyde condensates; salts of sulfonated phenol-formaldehyde condensates; more complex sulfonates such as the amide sulfonates, e.g., the sulfonated condensation product of oleic acid and N-methyl taurine; or the dialkyl sulfosuccinates, e.g., the sodium sulfonate or dioctyl succinate. Non-ionic agents include condensation products of fatty acid esters, fatty alcohols, fatty acid amides or fatty-alkyl- or alkenyl-substituted phenols with ethylene oxide, fatty esters of polyhydric alcohol ethers, e.g., sorbitan fatty acid esters, condensation products of such esters with ethylene oxide, e.g., polyoxyethylene sorbitan fatty acid esters, block copolymers of ethylene oxide and propylene oxide, acetylenic glycols such as 2,4,7,9-tetraethyl-5-decyn-4,7-diol, or ethoxylated acetylenic glycols. Examples of a cationic surface-active agent include, for instance, an aliphatic mono-, di-, or polyamine such as an acetate, naphthenate or oleate; or oxygen-containing amine such as an amine oxide of polyoxyethylene alkylamine; an amide-linked amine prepared by the condensation of a carboxylic acid with a di- or polyamine; or a quaternary ammonium salt.


Examples of inert materials include, but are not limited to, inorganic minerals such as kaolin, phyllosilicates, carbonates, sulfates, phosphates, or botanical materials such as cork, powdered corncobs, peanut hulls, rice hulls, and walnut shells.


The compositions comprising the silencing element can be in a suitable form for direct application or as a concentrate of primary composition that requires dilution with a suitable quantity of water or other dilutant before application.


The compositions (including the transformed microorganisms) can be applied to the environment of an insect pest (such as a pest from the Lepidoptera order) by, for example, spraying, atomizing, dusting, scattering, coating or pouring, introducing into or on the soil, introducing into irrigation water, by seed treatment or general application or dusting at the time when the pest has begun to appear or before the appearance of pests as a protective measure. For example, the composition(s) and/or transformed microorganism(s) may be mixed with grain to protect the grain during storage. It is generally important to obtain good control of pests in the early stages of plant growth, as this is the time when the plant can be most severely damaged. The compositions can conveniently contain another insecticide if this is thought necessary. In an embodiment of the invention, the composition(s) is applied directly to the soil, at a time of planting, in granular form of a composition of a carrier and dead cells of a Bacillus strain or transformed microorganism of the invention. Another embodiment is a granular form of a composition comprising an agrochemical such as, for example, a herbicide, an insecticide, a fertilizer, in an inert carrier, and dead cells of a Bacillus strain or transformed microorganism of the invention.


VII. Plants, Plant Parts, and Methods of Introducing Sequences into Plants


In one embodiment, the methods of the invention involve introducing a polypeptide or polynucleotide into a plant. “Introducing” is intended to mean presenting to the plant the polynucleotide or polypeptide in such a manner that the sequence gains access to the interior of a cell of the plant. The methods of the invention do not depend on a particular method for introducing a sequence into a plant, only that the polynucleotide or polypeptides gains access to the interior of at least one cell of the plant. Methods for introducing polynucleotide or polypeptides into plants are known in the art including, but not limited to, stable transformation methods, transient transformation methods, and vim s-mediated methods.


“Stable transformation” is intended to mean that the nucleotide construct introduced into a plant integrates into the genome of the plant and is capable of being inherited by the progeny thereof. “Transient transformation” is intended to mean that a polynucleotide is introduced into the plant and does not integrate into the genome of the plant or a polypeptide is introduced into a plant.


Transformation protocols as well as protocols for introducing polypeptides or polynucleotide sequences into plants may vary depending on the type of plant or plant cell, i.e., monocot or dicot, targeted for transformation. Suitable methods of introducing polypeptides and polynucleotides into plant cells include microinjection (Crossway et al. (1986) Biotechniques 4:320-334), electroporation (Riggs et al. (1986) Proc. Natl. Acad. Sci. USA 83:5602-5606, Agrobacterium-mediated transformation (U.S. Pat. No. 5,563,055 and U.S. Pat. No. 5,981,840), direct gene transfer (Paszkowski et al. (1984) EMBO J. 3:2717-2722), and ballistic particle acceleration (see, for example, U.S. Pat. No. 4,945,050; U.S. Pat. No. 5,879,918; U.S. Pat. Nos. 5,886,244; and, 5,932,782; Tomes et al. (1995) in Plant Cell, Tissue, and Organ Culture: Fundamental Methods, ed. Gamborg and Phillips (Springer-Verlag, Berlin); McCabe et al. (1988) Biotechnology 6:923-926); and Lecl transformation (WO 00/28058). Also see Weissinger et al. (1988) Ann. Rev. Genet. 22:421-477; Sanford et al. (1987) Particulate Science and Technology 5:27-37 (onion); Christou et al. (1988) Plant Physiol. 87:671-674 (soybean); McCabe et al. (1988) Bio/Technology 6:923-926 (soybean); Finer and McMullen (1991) In Vitro Cell Dev. Biol. 27P:175-182 (soybean); Singh et al. (1998) Theor. Appl. Genet. 96:319-324 (soybean); Datta et al. (1990) Biotechnology 8:736-740 (rice); Klein et al. (1988) Proc. Natl. Acad. Sci. USA 85:4305-4309 (maize); Klein et al. (1988) Biotechnology 6:559-563 (maize); U.S. Pat. Nos. 5,240,855; 5,322,783; and, 5,324,646; Klein et al. (1988) Plant Physiol. 91:440-444 (maize); Fromm et al. (1990) Biotechnology 8:833-839 (maize); Hooykaas-Van Slogteren et al. (1984) Nature (London) 311:763-764; U.S. Pat. No. 5,736,369 (cereals); Bytebier et al. (1987) Proc. Natl. Acad. Sci. USA 84:5345-5349 (Liliaceae); De Wet et al. (1985) in The Experimental Manipulation of Ovule Tissues, ed. Chapman et al. (Longman, N.Y.), pp. 197-209 (pollen); Kaeppler et al. (1990) Plant Cell Reports 9:415-418 and Kaeppler et al. (1992) Theor. Appl. Genet. 84:560-566 (whisker-mediated transformation); D'Halluin et al. (1992) Plant Cell 4:1495-1505 (electroporation); Li et al. (1993) Plant Cell Reports 12:250-255 and Christou and Ford (1995) Annals of Botany 75:407-413 (rice); Osjoda et al. (1996) Nature Biotechnology 14:745-750 (maize via Agrobacterium tumefaciens); all of which are herein incorporated by reference.


In specific embodiments, the silencing element sequences of the invention can be provided to a plant using a variety of transient transformation methods. Such transient transformation methods include, but are not limited to, the introduction of the protein or variants and fragments thereof directly into the plant or the introduction of the transcript into the plant. Such methods include, for example, microinjection or particle bombardment. See, for example, Crossway et al. (1986) Mol Gen. Genet. 202:179-185; Nomura et al. (1986) Plant Sci. 44:53-58; Hepler et al. (1994) Proc. Natl. Acad. Sci. 91: 2176-2180 and Hush et al. (1994) The Journal of Cell Science 107:775-784, all of which are herein incorporated by reference. Alternatively, polynucleotides can be transiently transformed into the plant using techniques known in the art. Such techniques include viral vector system and the precipitation of the polynucleotide in a manner that precludes subsequent release of the DNA. Thus, the transcription from the particle-bound DNA can occur, but the frequency with which it is released to become integrated into the genome is greatly reduced. Such methods include the use of particles coated with polyethylimine (PEI; Sigma #P3143).


In other embodiments, the polynucleotide of the invention may be introduced into plants by contacting plants with a virus or viral nucleic acids. Generally, such methods involve incorporating a nucleotide construct of the invention within a viral DNA or RNA molecule. Further, it is recognized that promoters of the invention also encompass promoters utilized for transcription by viral RNA polymerases. Methods for introducing polynucleotides into plants and expressing a protein encoded therein, involving viral DNA or RNA molecules, are known in the art. See, for example, U.S. Pat. Nos. 5,889,191, 5,889,190, 5,866,785, 5,589,367, 5,316,931, and Porta et al. (1996) Molecular Biotechnology 5:209-221; herein incorporated by reference.


Methods are known in the art for the targeted insertion of a polynucleotide at a specific location in the plant genome. In one embodiment, the insertion of the polynucleotide at a desired genomic location is achieved using a site-specific recombination system. See, for example, WO99/25821, WO99/25854, WO99/25840, WO99/25855, and WO99/25853, all of which are herein incorporated by reference. Briefly, the polynucleotide of the invention can be contained in transfer cassette flanked by two non-recombinogenic recombination sites. The transfer cassette is introduced into a plant having stably incorporated into its genome a target site which is flanked by two non-recombinogenic recombination sites that correspond to the sites of the transfer cassette. An appropriate recombinase is provided and the transfer cassette is integrated at the target site. The polynucleotide of interest is thereby integrated at a specific chromosomal position in the plant genome.


The cells that have been transformed may be grown into plants in accordance with conventional ways. See, for example, McCormick et al. (1986) Plant Cell Reports 5:81-84. These plants may then be grown, and either pollinated with the same transformed strain or different strains, and the resulting progeny having constitutive expression of the desired phenotypic characteristic identified. Two or more generations may be grown to ensure that expression of the desired phenotypic characteristic is stably maintained and inherited and then seeds harvested to ensure expression of the desired phenotypic characteristic has been achieved. In this manner, the present invention provides transformed seed (also referred to as “transgenic seed”) having a polynucleotide of the invention, for example, an expression cassette of the invention, stably incorporated into their genome.


As used herein, the term plant includes plant cells, plant protoplasts, plant cell tissue cultures from which plants can be regenerated, plant calli, plant clumps, and plant cells that are intact in plants or parts of plants such as embryos, pollen, ovules, seeds, leaves, flowers, branches, fruit, kernels, ears, cobs, husks, stalks, roots, root tips, anthers, and the like. Grain is intended to mean the mature seed produced by commercial growers for purposes other than growing or reproducing the species. Progeny, variants, and mutants of the regenerated plants are also included within the scope of the invention, provided that these parts comprise the introduced polynucleotides.


The present invention may be used for transformation of any plant species, including, but not limited to, monocots and dicots. Examples of plant species of interest include, but are not limited to, corn (Zea mays), Brassica sp. (e.g., B. napus, B. rapa, B. juncea), particularly those Brassica species useful as sources of seed oil, alfalfa (Medicago sativa), rice (Oryza sativa), rye (Secale cereale), sorghum (Sorghum bicolor, Sorghum vulgare), millet (e.g., pearl millet (Pennisetum glaucum), proso millet (Panicum miliaceum), foxtail millet (Setaria italica), finger millet (Eleusine coracana)), sunflower (Helianthus annuus), safflower (Carthamus tinctorius), wheat (Triticum aestivum), soybean (Glycine max), tobacco (Nicotiana tabacum), potato (Solanum tuberosum), peanuts (Arachis hypogaea), cotton (Gossypium barbadense, Gossypium hirsutum), sweet potato (Ipomoea batatus), cassava (Manihot esculenta), coffee (Coffea spp.), coconut (Cocos nucifera), pineapple (Ananas comosus), citrus trees (Citrus spp.), cocoa (Theobroma cacao), tea (Camellia sinensis), banana (Musa spp.), avocado (Persea americana), fig (Ficus casica), guava (Psidium guajava), mango (Mangifera indica), olive (Olea europaea), papaya (Carica papaya), cashew (Anacardium occidentale), macadamia (Macadamia integrifolia), almond (Prunus amygdalus), sugar beets (Beta vulgaris), sugarcane (Saccharum spp.), oats, barley, vegetables, ornamentals, and conifers.


Vegetables include tomatoes (Lycopersicon esculentum), lettuce (e.g., Lactuca sativa), green beans (Phaseolus vulgaris), lima beans (Phaseolus limensis), peas (Lathyrus spp.), and members of the genus Cucumis such as cucumber (C. sativus), cantaloupe (C. cantalupensis), and musk melon (C. melo). Ornamentals include azalea (Rhododendron spp.), hydrangea (Macrophylla hydrangea), hibiscus (Hibiscus rosasanensis), roses (Rosa spp.), tulips (Tulipa spp.), daffodils (Narcissus spp.), petunias (Petunia hybrida), carnation (Dianthus caryophyllus), poinsettia (Euphorbia pulcherrima), and chrysanthemum.


Conifers that may be employed in practicing the present invention include, for example, pines such as loblolly pine (Pinus taeda), slash pine (Pinus elliotii), ponderosa pine (Pinus ponderosa), lodgepole pine (Pinus contorta), and Monterey pine (Pinus radiata); Douglas-fir (Pseudotsuga menziesii); Western hemlock (Tsuga canadensis); Sitka spruce (Picea glauca); redwood (Sequoia sempervirens); true firs such as silver fir (Abies amabilis) and balsam fir (Abies balsamea); and cedars such as Western red cedar (Thuja plicata) and Alaska yellow-cedar (Chamaecyparis nootkatensis). In specific embodiments, plants of the present invention are crop plants (for example, corn, alfalfa, sunflower, Brassica, soybean, cotton, safflower, peanut, sorghum, wheat, millet, tobacco, etc.). In other embodiments, corn and soybean plants are optimal, and in yet other embodiments corn plants are optimal.


Other plants of interest include grain plants that provide seeds of interest, oil-seed plants, and leguminous plants. Seeds of interest include grain seeds, such as corn, wheat, barley, rice, sorghum, rye, etc. Oil-seed plants include cotton, soybean, safflower, sunflower, Brassica, maize, alfalfa, palm, coconut, etc. Leguminous plants include beans and peas. Beans include guar, locust bean, fenugreek, soybean, garden beans, cowpea, mungbean, lima bean, fava bean, lentils, chickpea, etc.


VIII. Methods of Use

The methods of the invention comprise methods for controlling a pest (i.e., pest from the Lepidoptera order, such as, Spodoptera frugiperda). The method comprises feeding to a pest a composition comprising a silencing element of the invention, wherein said silencing element, when ingested by a pest (i.e., pests from the Lepidoptera order, such as, Spodoptera frugiperda), reduces the level of a target polynucleotide of the pest and thereby controls the pest. The pest can be fed the silencing element in a variety of ways. For example, in one embodiment, the polynucleotide comprising the silencing element is introduced into a plant. As the Lepidoptera feeds on the plant or part thereof expressing these sequences, the silencing element is delivered to the pest. When the silencing element is delivered to the plant in this manner, it is recognized that the silencing element can be expressed constitutively or alternatively, it may be produced in a stage-specific manner by employing the various inducible or tissue-preferred or developmentally regulated promoters that are discussed elsewhere herein. In specific embodiments, the silencing element expressed in the roots, stalk or stem, leaf including pedicel, xylem and phloem, fruit or reproductive tissue, silk, flowers and all parts therein or any combination thereof.


In another method, a composition comprising at least one silencing element of the invention is applied to a plant. In such embodiments, the silencing element can be formulated in an agronomically suitable and/or environmentally acceptable carrier, which is preferably, suitable for dispersal in fields. In addition, the carrier can also include compounds that increase the half life of the composition. In specific embodiments, the composition comprising the silencing element is formulated in such a manner such that it persists in the environment for a length of time sufficient to allow it to be delivered to a pest. In such embodiments, the composition can be applied to an area inhabited by a pest. In one embodiment, the composition is applied externally to a plant (i.e., by spraying a field) to protect the plant from pests.


In certain embodiments, the constructs of the present invention can be stacked with any combination of polynucleotide sequences of interest in order to create plants with a desired trait. A trait, as used herein, refers to the phenotype derived from a particular sequence or groups of sequences. For example, the polynucleotides of the present invention may be stacked with any other polynucleotides encoding polypeptides having pesticidal and/or insecticidal activity, such as other Bacillus thuringiensis toxic proteins (described in U.S. Pat. Nos. 5,366,892; 5,747,450; 5,737,514; 5,723,756; 5,593,881; and Geiser et al. (1986) Gene 48:109), lectins (Van Damme et al. (1994) Plant Mol. Biol. 24:825, pentin (described in U.S. Pat. No. 5,981,722), and the like. The combinations generated can also include multiple copies of any one of the polynucleotides of interest. The polynucleotides of the present invention can also be stacked with any other gene or combination of genes to produce plants with a variety of desired trait combinations including, but not limited to, traits desirable for animal feed such as high oil genes (e.g., U.S. Pat. No. 6,232,529); balanced amino acids (e.g., hordothionins (U.S. Pat. Nos. 5,990,389; 5,885,801; 5,885,802; and 5,703,409); barley high lysine (Williamson et al. (1987) Eur. J. Biochem. 165:99-106; and WO 98/20122) and high methionine proteins (Pedersen et al. (1986) J. Biol. Chem. 261:6279; Kirihara et al. (1988) Gene 71:359; and Musumura et al. (1989) Plant Mol. Biol. 12:123)); increased digestibility (e.g., modified storage proteins (U.S. application Ser. No. 10/053,410, filed Nov. 7, 2001); and thioredoxins (U.S. application Ser. No. 10/005,429, filed Dec. 3, 2001)); the disclosures of which are herein incorporated by reference.


The polynucleotides of the present invention can also be stacked with traits desirable for disease or herbicide resistance (e.g., fumonisin detoxification genes (U.S. Pat. No. 5,792,931); avirulence and disease resistance genes (Jones et al. (1994) Science 266:789; Martin et al. (1993) Science 262:1432; Mindrinos et al. (1994) Cell 78:1089); acetolactate synthase (ALS) mutants that lead to herbicide resistance such as the S4 and/or Hra mutations; inhibitors of glutamine synthase such as phosphinothricin or basta (e.g., bar gene); and glyphosate resistance (EPSPS gene)); and traits desirable for processing or process products such as high oil (e.g., U.S. Pat. No. 6,232,529); modified oils (e.g., fatty acid desaturase genes (U.S. Pat. No. 5,952,544; WO 94/11516)); modified starches (e.g., ADPG pyrophosphorylases (AGPase), starch synthases (SS), starch branching enzymes (SBE), and starch debranching enzymes (SDBE)); and polymers or bioplastics (e.g., U.S. Pat. No. 5,602,321; beta-ketothiolase, polyhydroxybutyrate synthase, and acetoacetyl-CoA reductase (Schubert et al. (1988) J. Bacteriol. 170:5837-5847) facilitate expression of polyhydroxyalkanoates (PHAs)); the disclosures of which are herein incorporated by reference. One could also combine the polynucleotides of the present invention with polynucleotides providing agronomic traits such as male sterility (e.g., see U.S. Pat. No. 5,583,210), stalk strength, flowering time, or transformation technology traits such as cell cycle regulation or gene targeting (e.g., WO 99/61619, WO 00/17364, and WO 99/25821); the disclosures of which are herein incorporated by reference.


These stacked combinations can be created by any method including, but not limited to, cross-breeding plants by any conventional or TopCross methodology, or genetic transformation. If the sequences are stacked by genetically transforming the plants, the polynucleotide sequences of interest can be combined at any time and in any order. For example, a transgenic plant comprising one or more desired traits can be used as the target to introduce further traits by subsequent transformation. The traits can be introduced simultaneously in a co-transformation protocol with the polynucleotides of interest provided by any combination of transformation cassettes. For example, if two sequences will be introduced, the two sequences can be contained in separate transformation cassettes (trans) or contained on the same transformation cassette (cis). Expression of the sequences can be driven by the same promoter or by different promoters. In certain cases, it may be desirable to introduce a transformation cassette that will suppress the expression of the polynucleotide of interest. This may be combined with any combination of other suppression cassettes or overexpression cassettes to generate the desired combination of traits in the plant. It is further recognized that polynucleotide sequences can be stacked at a desired genomic location using a site-specific recombination system. See, for example, WO99/25821, WO99/25854, WO99/25840, WO99/25855, and WO99/25853, all of which are herein incorporated by reference.


Methods and compositions are further provided which allow for an increase in RNAi produced from the silencing element. In such embodiments, the methods and compositions employ a first polynucleotide comprising a silencing element for a target pest sequence operably linked to a promoter active in the plant cell; and, a second polynucleotide comprising a suppressor enhancer element comprising the target pest sequence or an active variant or fragment thereof operably linked to a promoter active in the plant cell. The combined expression of the silencing element with suppressor enhancer element leads to an increased amplification of the inhibitory RNA produced from the silencing element over that achievable with only the expression of the silencing element alone. In addition to the increased amplification of the specific RNAi species itself, the methods and compositions further allow for the production of a diverse population of RNAi species that can enhance the effectiveness of disrupting target gene expression. As such, when the suppressor enhancer element is expressed in a plant cell in combination with the silencing element, the methods and composition can allow for the systemic production of RNAi throughout the plant; the production of greater amounts of RNAi than would be observed with just the silencing element construct alone; and, the improved loading of RNAi into the phloem of the plant, thus providing better control of phloem feeding insects by an RNAi approach. Thus, the various methods and compositions provide improved methods for the delivery of inhibitory RNA to the target organism. See, for example, U.S. Provisional Application No. 61/021,676, entitled “Compositions and Methods for the Suppression of Target Polynucleotides”, filed Jan. 17, 2008 and herein incorporated by reference in its entirety.


As used herein, a “suppressor enhancer element” comprises a polynucleotide comprising the target sequence to be suppressed or an active fragment or variant thereof. It is recognize that the suppressor enhancer element need not be identical to the target sequence, but rather, the suppressor enhancer element can comprise a variant of the target sequence, so long as the suppressor enhancer element has sufficient sequence identity to the target sequence to allow for an increased level of the RNAi produced by the silencing element over that achievable with only the expression of the silencing element. Similarly, the suppressor enhancer element can comprise a fragment of the target sequence, wherein the fragment is of sufficient length to allow for an increased level of the RNAi produced by the silencing element over that achievable with only the expression of the silencing element. Thus, in specific embodiments, the suppressor enhancer element comprises a fragment or a variant of a polynucleotide encoding a juvenile hormone polypeptide, a vacuolar polypeptide, a cadherin polypeptide, a cuticle polypeptide, a translation initiation factor, a SARI polypeptide, an elongation factor, a phosphooligosaccharide, a myosin polypeptide, a potassium channel amino acid transporter, a potassium inwardly rectifier polypeptide, an amino acid transporter, a tubulin polypeptide, a ubiquitin polypeptide, small nuclear ribonucleoprotein, or any other polynucleotide fo interest disclosed herein. In still other embodiments, the suppressor enhancer element comprises a polynucleotide set forth in SEQ ID NO: 1-50 or an active variant or fragment thereof.


It is recognized that multiple suppressor enhancer elements from the same target sequence or from different target sequences, or from different regions of the same target sequence can be employed. For example, the suppressor enhancer elements employed can comprise fragments of the target sequence derived from different region of the target sequence (i.e., from the 3′UTR, coding sequence, intron, and/or 5′UTR). Further, the suppressor enhancer element can be contained in an expression cassette, as described elsewhere herein, and in specific embodiments, the suppressor enhancer element is on the same or on a different DNA vector or construct as the silencing element. The suppressor enhancer element can be operably linked to a promoter as disclosed herein. It is recognized that the suppressor enhancer element can be expressed constitutively or alternatively, it may be produced in a stage-specific manner employing the various inducible or tissue-preferred or developmentally regulated promoters that are discussed elsewhere herein.


In specific embodiments, employing both a silencing element and the suppressor enhancer element the systemic production of RNAi occurs throughout the entire plant. In further embodiments, the plant or plant parts of the invention have an improved loading of RNAi into the phloem of the plant than would be observed with the expression of the silencing element construct alone and, thus provide better control of phloem feeding insects by an RNAi approach. In specific embodiments, the plants, plant parts, and plant cells of the invention can further be characterized as allowing for the production of a diversity of RNAi species that can enhance the effectiveness of disrupting target gene expression.


In specific embodiments, the combined expression of the silencing element and the suppressor enhancer element increases the concentration of the inhibitory RNA in the plant cell, plant, plant part, plant tissue or phloem over the level that is achieved when the silencing element is expressed alone.


As used herein, an “increased level of inhibitory RNA” comprises any statistically significant increase in the level of RNAi produced in a plant having the combined expression when compared to an appropriate control plant. For example, an increase in the level of RNAi in the plant, plant part or the plant cell can comprise at least about a 1%, about a 1%-5%, about a 5%-10%, about a 10%-20%, about a 20%-30%, about a 30%-40%, about a 40%-50%, about a 50%-60%, about 60-70%, about 70%-80%, about a 80%-90%, about a 90%-100% or greater increase in the level of RNAi in the plant, plant part, plant cell, or phloem when compared to an appropriate control. In other embodiments, the increase in the level of RNAi in the plant, plant part, plant cell, or phloem can comprise at least about a 1 fold, about a 1 fold-5 fold, about a 5 fold-10 fold, about a 10 fold-20 fold, about a 20 fold-30 fold, about a 30 fold-40 fold, about a 40 fold-50 fold, about a 50 fold-60 fold, about 60 fold-70 fold, about 70 fold-80 fold, about a 80 fold-90 fold, about a 90 fold-100 fold or greater increase in the level of RNAi in the plant, plant part, plant cell or phloem when compared to an appropriate control. Methods to assay for an increase in the level of RNAi are discussed elsewhere herein.


The following examples are offered by way of illustration and not by way of limitation.


EXPERIMENTAL
Example 1. Specific Target Genes and Silencing Elements that Cause Insecticidal Activity Against Spodoptera frugiperda

Disruption of insect gene function via RNAi can produce specific activity against target insects. This specificity is enhanced by delivery of the dsRNAs via transgenic plants. Identification of gene function in insects via RNAi has been largely limited to injection of dsRNAs. In fact, past experiments have indicated that insects are not capable of systemic RNAi response based on exposure to dsRNAs.


As described below, we have demonstrated acute activity of numerous dsRNA pairs through injection experiments and additionally have demonstrated insect antagonism through ingestion of dsRNAs. This evidence identifies several gene/primer pair combinations with clear insecticidal properties. The use of dsRNAs in transgenic plants also addresses the potential complication of heterologous protein expression and the possible risks of allergic reaction, non-target activity, and environmental- or bioaccumulation. The data presented below represents the first test of disruption of these particular genes resulting in insecticidal activity in whole organisms and the first report of insecticidal activity of dsRNAs against Spodoptera frugiperda.


The invention describes specific target genes and the dsRNA sequences causing insecticidal activity against the Lepidopteran Spodoptera frugiperda through RNA interference of the target gene's expression. Disruption of the genes targeted by the dsRNA sequences may be broadly insecticidal in numerous species. The specific dsRNA sequences display insecticidal activity upon ingestion and can be utilized with a transgenic plant mode of delivery. Table 1 provides the polynucleotide of non-limiting examples of target sequence from Spodoptera frugiperda, a brief description of the function of the protein encoded by the target sequence, and a SEQ ID NO. Table 2 provides a summary of primers used to suppress the target polynucleotides.









TABLE 1 





Target Polynucleotides from Spodoptera frugiperda.















SEQ ID NO: 1


>ise1c.pk002.m13 Juvenile hormone query


CAAGCATCCAACATGGTATCCGACTTCAGGAAGAAGAAGCTCCTCCACGTGTTCAAGTCCTTCTTCGACACGGAC


GGCAGCGGCAACATCGAGAAGGATGACTTCCTGATGGCCATCGAAAGGATAACCAAGACCAGAGGCTGGAAAGCT


GGAGACGACAAATACAAATTTGTCGAGGAGACCCTATTGAAGATCTGGGACGGCATCCAGAAGGTCGCTGACGAG


AACAAGGACGGACAGGTCAGCCAGGACGAGTGGATCGCTATGTGGGACAAGTACTCCAAGAACCCGTCCGAGGCG


TTCGAGTGGCAGACCCTGTACTGCAAGTTCGCGTTCACTCTTGAAGACGCCAGCGACGATGGATCCATCGACAGC


GAGGAGTTCTCCTCTGTGTACGCCTCCTTCGGCCTGGACAANGACGANGCTGTGGCTGCCTTCAAGAAAGATGGC


TAACGGTAAGTCCGAAGTGTCCTGGGCTTGAGTTCCACGACCTGTGGAANGAGTACTTCTCATCCGGAAGACTNG


AACGCTGCCGGCAAN





SEQ ID NO: 2


>ise1c.pk003.f7 Juvenile hormone query


CCAACATGGTATCCGACTTCAGGAAGAAGAAGCTCCTCCACGTGTTCAAGTCCTTCTTCGACACGGACGGCAGCG


GCAACATCGAGAAGGATGATTTCCTGATGGCCATCGAAAGGATAACCAAGACCAGAGGCTGGAAAGCTGGAGACA


ACAAATACAAATTTGTCGAGGAAACCCTATTGAAGATCTGGGACGGCATCCAGAAGGTCGCTGACGAGAACAAGG


ACGGACAGGTCAGCCAGGACGAGTGGATCGCTATGTGGGACAAGTACTCCAAGAACCCATCCGAGGCGTTCGAGT


GGCAGACCCTGTACTGCAAGTTCGCGTTCACTCTTGAAGACGCCAGCGACGACGGATNCATCGACAGCGAAGAGT


TCTCCTCTGTGTACGCCTCCTTCGGGCTGGACAANGGACGAGGCGGTGGCTGCCTTCAAGAAGATGNTAACGGTA


AGTCCGAATGTCCTGGGGCTGAGTTTCAAGANCTGTTGGAAGGATACTTCTCAAC





SEQ ID NO: 3


>ise1c.pk005.a15 Juvenile hormone query


CAACATGGTATCCGACTTCAGGAAGAATAAGCTCCTCCACGTGTTCAAGTCCTTCTTCGACACGGACGGCAGCGG


CAACATCGAGAAGGATGACTTCCTGATGGCCATCGAAAGGATAACCAAGACCAGAGGCTGGAAAGCTGGAGACGA


CAAATACAAATTTGTCGAGGAGACCCTATTGAAGATCTGGGACGGCATCCAGAAGGTCGCTGACGAGAACAAGGA


CGGACAGGTCAGCCAGGACGAGTGGATCGCTATGTGGGACAAGTANTCCAAGAACCCGTCCGAGGCGTTCGAGTG


GCAGACCCTGTACTGCAAGTTCGCGTTCACTCTTGAAGACGCCAGNGACGATGGATCCATCGACAGCGAGGAGTT


CTCCTCTGTGTACGCCTCCTTCGGCCTGGACAAGG





SEQ ID NO: 4


>ise1c.pk006.d24 Juvenile hormone query


GAGAGAGAGAGAGAGAGAGAACTAGTCTCGAGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTNGGAAANTAC


TATTTTATTGTACCAACTGCCCCTTAACCTCATCTATGAGTCACCCATAAATGTTATTTTGGTAAAATGTTTGAC


ACACTTCACACTAATATTTATAAATGTGAAAGTTTGTTTGTTTGAATGTTTGTATATTTGTCTGTCAATCACGCT


GAAACCACTGTATAGAATTTGACCTAATTTGGTATACANACAGGGTATGAGCTGACTTGGGTGATAGGATACTTT


TTATCCCACAGGAACGCGGGTAAAGTCCNTGGGCAGAAGCTAGTATGTAATAATTATNTCCCTCTACCTACCCTA


TATGGGGGTGGACCGTCATGTTCTTTACNCNACAACCNGTTTGTCCACCTCNCCTTTAAAGTTTTGTNAG





SEQ ID NO: 5


>ise2c.pk009.i4 Juvenile hormone query


GCACGAGGGCCGTGTCGACTTCGCACCAGTCCCCTATTTATTTACCTTGACAAAAATATGGCGCGCCTATTGTTT


ATTGCGCCTATCCTGGCGTTGGCTATAATGCCAGTATACTTCTTATTCCTAAAGGGACCACCCCCACTACCCGAA


CTAGATATGAACGAGTGGTGGGGCCCAGAGAAGCTAAAAGCAAAACCTGACACTAGTATAAAACCCTTTAAAATT


GCTTTTGGAGACACTGTTGTAAAAGACTTAAAAGACCGTCTCAAACGTTCTCGGTCTTTCACTGCTCCGCTGGAG


GGTGTGGCATTCCAGTACGGCTTCAACACTGCTCAGCTGGATGGTTGGCTGAAGTACTGGGCTAATGAGTATAAG


TTCAAGGAGAGAGAGACCTTCCTCAACCAGTACCCTCAGTACAAAACCAATATCCAGGGTCTTGACATCCACTTC


ATCAGGGTTACACCGAAGGTACCGGCAGGAGTGGAGGTGGTACCCATGCTACTCCTCCACGGCTGGCCAGGCTCT


GTCAGGGAGTTCTACGAGGCTATTCCTCTCATCACAGCAGTCAGCAAGGACCGTGACTTCGCTGTGGAAGTCATC


GTTCCAAGTCTACCTGGCTATGGATTCTCTGATGCCGCAGTTCGTCCCGGCnnnnnnnCCCCACAAATGnnn





SEQ ID NO: 6


>ise2c.pk001.d19 vacuolar query


GCACGAGGCTTGGACGTGATGTTACCTGGGAATTCAACCCCTTGAATGTTAAGGTCGGCTCCCACATCACCGGAG


GAGACTTGTACGGTATCGTACACGAGAACACATTGGTTAAGCACAAGATGTTGATCCCACCCAAGGCCAAGGGTA


CCGTCACCTACGTCGCGCCCTCCGGCAACTACAAAGTCACTGACGTAGTGTTGGAGACGGAGTTCGACGGCGAGA


AGGAGAAGTACACCATGTTGCAAGTATGGCCGGTGCGCCAGCCGCGCCCCGTCACTGAGAAGCTGTCCGCCAACC


ACCCCCTGCTCACCGGACAGAGAGTGCTCGACTCTCTCTTCCCTTGTGTCCAGGGTGGTACCACGGCCATCCCCG


GCGCCTTCGGTTGTGGCAAGACTGTCGTCTCACAGGCTCTGTCCAAGTACTCCAACTCTGACGTCATCATCTACG


TCGGATGCGGTGAACGTGGTAACGAGATGTCTGAGGTACTGCGTGACTTCCCCGAGCTGACGGTGGAGATCGAGG


GCATGACCGAGTCCATCATGAAGCGTACCGCGCTCGTCGCCAACACCTCCAACATGCCTGTAGCCGCCCGAGAGG


CTTCCATCTACACCGGTATCACCCTCTCCGAGTACTTCCGTGACATGGGTTACAACGTGTCCATGATGGCTGACT


CCACCTCTCGTTGGGCCG





SEQ ID NO: 7


>ise2c.pk001.e14 vacuolar query


GCACGAGGCAGATAGTCATCACTGTTTTTGGGACCTGTnnnTACTCCCTCAATAAACCTACAAAATGGCCGAAAA


CCCAATCTACGGACCCTTCTTTGGAGTTATGGGGGCGGCGTCTGCTATCATCTTTAGCGCGCTGGGAGCTGCCTA


TGGAACTGCTAnGnCnnnnACCGGTATCGCCGCCATGTCGGTGATGCGGCCCGAGCTCATCATGAAGTCCAACAA


CTACACCCTTTACAAGnGGTTCATCCACCTTGGCGCTGGTCTnnnCGTAAGTTTCTCCGGTCTAGCGnnnGGCnn





SEQ ID NO: 8


>ise2c.pk001.f20 vacuolar query


GCACGAGGCTCACAGGCTCTGTCCAAGTACTCCAACTCTGACGTCATCATCTACGTCGGATGCGGTGAACGTGGT


AACGAGATGTCTGAGGTACTGCGTGACTTCCCCGAGCTGACGGTGGAGATCGAGGGCATGACCGAGTCCATCATG


AAGCGTACCGCGCTCGTCGCCAACACCTCCAACATGCCTGTAGCCGCCCGAGAGGCTTCCATCTACACCGGTATC


ACCCTCTCCGAGTACTTCCGTGACATGGGTTACAACGTGTCCATGATGGCTGACTCCACCTCTCGTTGGGCCGAG


GCTCTTCGTGAGATCTCnnnnCGTCTGGCTGAGATGCCTGCCGACTCGGGTTACCCCGCCTACCTGGGAGCCCGT


CTGGCCTCGTTCTACGAGCGTGCCGGACGTGTGAAGTGCTTGGGTAACCCCGACAGGGAGGGCTCCGTGTCCATC


GTGGGCGCCGTGTCGCCGCCCGGAGGTGACTTCTCCGACCCCGTGACGGCCGCCACGCTGGGTATCGTGCAGGTG


TTCTGGGGGTTGGACAAGAAGCTCGCGCAGCGCAAGCACTTCCCCGCCATCAACTGGCTCATCTCCTACAGCAAG


TACATGCGAGCGCTGGACGACTTCTATGAGAAGAACTACCCCGAGTTCGTGCCCCTCnnnnnCAAGGGTCAAGGA


GATCCTGCAGnnn





SEQ ID NO: 9


>ise2c.pk010.h3 cadherin query


GCACGAGGTATCTAAAACAGTGCGTCGTAATATATTCAAGATGTCTCGTCTTAGGTTTTGTTTTTTATTAGCAGT


ACTATGCAGTTGTTTGCAGAATGGTTACGGTTTTACAACAGAAAAGCCAGTTACCCAGCATGTAGATCCTAAACC


AGAAGTTCCTGAAACGTTGCCTGAAACAACACGAGTGCCTGCGCCGAGCTCGTCGACGGCAGCGCCGACCACACC


AGCTCCGACACCGGCACCAACGCCAGCACCCACACCAGCTCCTACACCAGCTCCTACTCCAGCTCCTACCCCTGC


GCCTACTCCTGCGCCTACTCCTGCGCCTACTCCTGCGCCTACCCCCGCACCTACACCAGCGCCCACTCCTGCTCC


CACCCCAGCTCCCCTCCCCGCCCCCGACCAAGGCACATGGTCCTTCACTGATGAAAAGGCCAATCAGACATGCAT


TGTGGCCCAATTCGCAGCCCAACTGAATGTCACATACACCAAGTTAGTGGAGAATGCAACGTCTCTATCGTACGT


GAGGCTCAACGTGCCCGCGAACGCGTCGGTCCTCAACGGCAGCTGTTCGGACCCCGACCAATGGATCCAGATCAC


CTGGAAGACCAACGACGACAGCGAGACGAACAACACCATGACCCTCGTGTACAACAAGAATGCCACCACCAAGnn


CTACGGCCTG





SEQ ID NO: 10


>ise2c.pk011.a10 cuticle protein


GCACGAGGGCGGTTTGAAGTGATCTAGTTCGTCAGAAAAAACACAGACCACGTTCACAATGAAATCGATGGTGGT


GTTATTCGCTGTGTGCGCCGTGGCGTGCGGCTCCCTGGTGCCGCTGGCGCAGCCTCCTCATCACCCCGCCGTCGT


GCTGGACCCGCACGGCCGCCCGCTCGACACCGCCGAGGTGATCAACGCCCGCGCCCTCCACCTGCAGGCTAAGGC


CCTGGATGGACACTACGCTCCCCTCGCGCACGCTGCCGTCGTGCCTGTTGCCCACTCCGTGGTAGCCGCCCCCGC


TGTGGTCGCCGCTCCCGCCGCCGTGTCCCACCAGTCCCGTGTGGATGTGCGCACCAGCCCCGCCATCGTGAGCCA


CGCCGTCGCTGCTCCCGTAGTAGCCCACGGTGTCTACTCCGCTCCCCTGCTGGCCCACTCCGCTCTCGGCTACGC


CGGTCACGGACACTACCTGAAGAAGCGCTCCCTGGGACACCTCGCCTACGCCGCTCCCGTCGTCGCCCACGTAGC


TCCCTCCGCGGTGTCGCACCAGTCCCGCGTGGnCnTCGTCTCCAGCCnnnCTGTCGTGTCTCAnnnnnTnnnTnC


CGTnnTGTCCCn





SEQ ID NO: 11


>ise2c.pk011.h12 cuticle protein


GCACGAGGGGACGTTGAACGAAAGAAAATGCTACGCGTTACGATTTTAGCCGCAGTGGTGGTGTTCGCCTCAGGC


GCGCCCCAGAACAACTTCATCTTCAAGAATGACATCACTCCTGAGGAAGCCCAGCAGTACCTCAAACAACTGCCG


TTCACCTCACCCCAGCTCTCTGGACGCACCGCTGTACTGCCTCTGGTTCGCTACGACGACCCCAGGTTTCGTTCA


GCTGAAGCTGGCCCAACCCTTGGACACTACTGGAAGAATGGACAGGAGATCCAGAACACAGAGGACTACTTAGAA


GAGGTCTACAACGCGGCTCAATACCACGGCCAGGACGGTCTTGGCAACTACGCCTACGGTTATGAGACCCCTGAA


TCTTCCAAGGTTGAGAACCGTGAAGGTTCCGGAGTCGTCCAAGGATCCTATGTGTACCAGGTTCCCGGAATGAAG


GATCTCGTCnnGGTCCGTTACTGGGCTGACAGCCnnnnnTTCCACCAGnAnGACAATCTTCCCAAGGTTGAACTG


AnnnCCGCTnnnnnnnnCCCGCTCT





SEQ ID NO: 12


>ise2c.pk001.d22 translation initiation factor


GCACGAGGTATCACTCCTGACCGTATCTAAAACTCGGCACACAACACAATGGCTGACATCGAAGATACACATTTC


GAGACCGGGGACTCCGGTGCCTCCGCCACCTTCCCTATGCAATGCTCGGCCCTGCGCAAGAACGGTTTCGTCATG


CTTAAGGGTCGCCCCTGCAAAATCGTCGAGATGTCCACTTCCAAAACCGGAAAGCACGGCCACGCTAAAGTTCAC


TTGGTTGGAATCGATATTTTTAACGGCAAGAAATACGAAGATATCTGCCCTTCCACCCACnnnCATGGACGTGCC


CCACGTGAAGCGTGAGGACTACCAGCTCACCGATATCTCTGACGACGGCTACCTTACCCTCATGGCTGACAACGG


CGATCTCCGCGAGGACCTCAAGATCCCAGACGGTGACCTCGGCACCCAGTTGCGTTCTGACTTCGATAGCGGCAA


AGAGCTGTTGTGCACTGTGCTGAAGTCTTGCGGTGAGGAGTGTGTAATCGCAGTCAAGGCAAACACAGCTCTCGA


CAAATAAACCAACTCAGCATTTATAGGGATATACATACATATAATTTTTTTACAATCAACAGCTCTTACATAAAT


GTAAAACATAATACTATGTATAATTTAACATnnnnnATTATGGTGTGACGCGGTGCTGGCTTGTCGCCGTCCACT


CCACCCCCGAAG





SEQ ID NO: 13


>ise2c.pk001.d9 translation initiation factor


GCACGAGGCGCGATTGTAACATGTCGTATTCACCAGAAAGAAGATCAGAAGATTGGCCGGAAGATTCCAAAAATG


GCCCGTCTAAGGATCAAGGCAACTATGATGGGCCTCCAGGAATGGAACCCCAAGGGGCACTTGATACAAACTGGC


ACCAGGTCGTGGAAAGCTTTGACGACATGAATCTGAAGGAAGAATTGTTGAGAGGAATTTATGCTTACGGTTTTG


AAAAGCCGTCTGCTATCCAACAACGCGCTATTATGCCTTGCATTCAAGGCCGTGATGTCATAGCTCAAGCCCAGT


CTGGTACTGGGAAGACTGCTACCTTCTCTATTTCAATTCTTCAGCAAATCGATACCAGTATTCGTGAATGCCAAG


CACTGATTTTGGCCCCTACTAGAGAGCTGGCTCAGCAGATCCAAAAGGTGGTGATTGCTCTTGGGGATCACTTGA


ATGCTAAATGCCATGCTTGCATCGGCGGCACTAATnnnGCGCGAAGATGTTCGTCAGCTnnnnn





SEQ ID NO: 14


>ise2c.pk001.i23 translation initiation factor


GCACGAGGGTCGTATTCACCAGAAAGAAGATCAGAAGATTGGCCGGAAGATTCCAAAAATGGCCCGTCTAAGGAT


CAAGGCAACTATGATGGGCCTCCAGGAATGGAACCCCAAGGGGCACTTGATACAAACTGGCACCAGGTCGTGGAA


AGCTTCGACGACATGAATCTGAAGGAAGAATTGTTGAGAGGAATTTATGCTTACGGTTTTGAAAAGCCGTCTGCT


ATCCAACAACGCGCTATTATGCCTTGCATTCAAGGCCGTGATGTCATAGCTCAAGCCCAGTCTGGTACTGGGAAG


ACTGCTACCTTCTCTATTTCAATTCTTCAGCAAATCGATACCAGTATTCGTGAATGCCAAGCACTGATTTTGGCC


CCTACTAGAGAGCTGGCTCAGCAGATCCAAAAGGTGGTGATTGCTCTTGGGGATCACTTGAATGCTAAATGCCAT


GCTTGCATCGGCGGCACTAATGTGCGCGAAGATGTTCGTCAGCTGGAGAGTGGTGTGCATGTGGTGGTGGGTACA


CCTGGTCGCGTGTACGACATGATAACTCGTCGTGCTCTCCGTGCTAACACTATCAAGCTGTTTGTACTTGATGAA


GCTGATGAAATGCTGTCAAGAGGATTTAAAGATCnn





SEQ ID NO: 15


>ise2c.pk001.l24 translation initiation factor


GCACGAGGGCCATCCTGTCACACATCTACCACCACGCCCTGCACGATAACTGGTTCCAAGCTCGAGACTTGCTCT


TGATGTCACACTTGCAAGAGACTGTTCAACATTCAGACCCGAGCACTCAGATTTTGTACAATCGTACTATGGCCA


ATCTAGGTTTGTGCGCTTTTCGAAGGGGCAATGTTAAAGAAGCCCATGGCTGCCTAGCTGAACTGATGATGACTG


GCAAACCCAAGGAACTGTTAGCTCAAGGTCTGCTACCTCAGCGTCAACACGAGCGTTCAAAGGAACAGGAAAAGA


TAGAGAAGCAACGCCAAATGCCGTTCCACATGCACATCAACTTGGAACTGCTTGAATGTGTGTATTTAGTGTCTG


CCATGCTGATTGAAATTCCATACATGGCCGCCCACGAATTCGATGCTCGCCGGCGCATGATTAGTAAGACTTTCT


ATCAGAATTTGCGCGCAAGTGAGCGTCAGGCTTTGGTAGGCCCGCCCGAATCCATGCGTGAGCATGCTGTGGCTG


CCGCCAGGGCGATGCGCCGCGGAGACTGGCGTGCTTGCCTCAATTTTATTGTnnnTGnnnAATGAAT





SEQ ID NO: 16


>ise2c.pk005.b9 translation initiation factor


GCACGAGGCTGATAGCCACCTGCCAAATTATCTTGAAATATAACCATTCACTAAAATATTTAACGTAATTTAGTG


GTTAATTCTAAACTTAATCATGGACGACGACATGGTATTTGATCCATCTTTAAAGAAAAAGAAGAAGAAGAAGAC


CGGTTTCGACTTAGATGCCGCTCTCGCAGGCGAACAAGGTGAGAGCACGAGCGTGGAGGCGCCCGCTGGGTCGGG


TGACGTCGACTTGCCTGAGGATGATAACCTCGATTTGGATAATTTTGGAAAGAAAAAGAAGAAGAAGAAGAAGGG


AGTCTTCAACATGGAAGAACTTGAAAGTACGTTACCGGAAACACCTCCGGCCGAAGAGCCGGAACAGCAGGAGGA


CGAAGTTATTGACGATTTAGATCTAGATATTGACTTCTCTAAAACGAAAAAGAAGAAGAAGAAGAAAAACATnnn


AnGAGCTCGTCCTTGAAGATGACACCAAGGGAGAAGATCAAGAGAATGTCGAGGATGTTAGTGGTGATTTATGGA


GCGGCACAGACCGTGACTACACGTACGACGAGCTACTAGAGCGAGTGTTCGACATCATGCGAGAAAAGAnnnnnA


GCATGGTTT





SEQ ID NO: 17


>ise2c.pk002.m10 SAR1


GCACGAGGCAGATTCATATTTCCATCGCTTATTCGTTGCTGAGAAAAATCGTCGGTTTTAGCGACGTAACATATT


GCTAATAAGTGTGAAATATTGTGATAAACTTCCTTTTAGCATTAGTTAATCTAGTTCAATTTTAAATAATTCAAA


ATGTTTATCTTGGATTGGTTCACTGGTGTTCTCGGATTCCTTGGTCTGTGGAAGAAATCAGGCAAGCTACTGTTC


CTGGGACTGGACAATGCTGGCAAGACCACACTCCTGCACATGCTGAAGGATGACAGATTGGCGCAGCATGTACCC


ACATTGCATCCCACGTCGGAGGAACTGTCAATAGGCAGTATGCGTTTCACGACGTTCGACTTGGGCGGGCATCAG


CAGGCGCGGCGCGTGTGGCGCGACTACTTCCCGGCGGTGGACGCCATCGTGTTCCTGGTGGACGCGTGCGACCGC


CCGCGCCTGCCCGAGTCCAAGGCCGAGCTGGACTCGCTGCTCACTGACGAGACGCTCAGCnnACTGCCCCGTGCT


CATCCTCGGCAACAAGATCGACAAGCCCGGCGCAGCTAGTGAGGACGAGCTCCGTCAGTTCTTCAACCTGTACCA


ACAGACCACTGGAnAnGnCAAAGTATCnAGnTCAnnnnT





SEQ ID NO: 18


>ise2c.pk001.c14 Elongation factor


GCACGAGGGTCTATCTCGGATATTACACGTGGATTGTAATCCGTGACTAACCAAAAATGGGCAAGGAAAAGnnnC


ACATTAACATTGTCGTCATTGGACACGTCGACTCCGGCAAGTCCACCACCACCGGTCACTTGATCTACAAATGCG


GTGGTATCGACAAACGTACCATCGAGAAGTTCGAGAAGGnnnCCCAGGAAATGGGGTAAGGGTTCCTTCAAATAC


GCCTGGGTATTGGACAAACTGAAGGCTGAGCGTGAACGTGGTATCACCATCGATATTGCTCTGTGGAAGTTCGAA


ACCGCTAAATACTATGTCACCATCATTGACGCTCCCGGACACAGAGATTTCATCAAGAACATGATCACTGGAACT


TCCCAGGCTGATTGCGCCGTACTCATTGTCGCCGCTGGTACCGGTGAGTTCGAGGCTGGTATCTCGAAGAACGGA


CAGACCCGTGAGCACGCTCTGCTCGCTTTCACACTCGGTGTCAAGCAGCTGATTGTGGGCGTCAACAAAATGGAC


TCCACTGAGCCCCCATACAGCGAATCCCGTTTCGAGGAAATCnnnnnnn





SEQ ID NO: 19


>ise2c.pk001.d16 Elongation factor


GCACGAGGCGGATATTACACGTGGATTGTAATCCGTGACTAACCAAAAATGGGCAAGGAAAAGnTTCACATTAAC


ATTGTCGTCATTGGACACGTCGACTCCGGCAAGTCCACCACCACCGGTCACTTGATCTACAAATGCGGTGGTATC


GAnnnACGTACCATnnnnn





SEQ ID NO: 20


>ise2c.pk001.j9 myosin


GCACGAGGCTCTAGTCCCGTCACCGTCGCCAGTAGGGGGCGCCACAAGAACAGAAAGAGAATTATTTCAAACTCC


AATTATAACCTACTAGATAACTCCAAAAGTTCTGTCAGTTCTAACTTTAATTTAACGGGGACGTCAGAGTTTATG


GATAGGACCGATAAGATAATATCGGACGCGACTGAGCTACAAGCAATGCAGAACTTTATCATGGAGAAGATTTAC


GAAATGGAACCTAATGAGAAGAAGAAGCAATCTGAGGTCGACAGGGTATTCAAACACGCATTATTAGAATTCAAA


GACAATTTAGTAGCGACGTACAGCATAGTGGAGACGCGGGGCTCTGCGCTGAAGTACAAGGATCTGATCGGCAAC


TTCCTGCACGTCATGGAGACGGTTTGTGCCAGGGAGGGGTCCACGCTCTCCATCACCATGGGGGTCAACGCCTTT


AGGGGTTTCATGGACGAGTTTATGAGCCAACATGACACTGATAAAGCTAGGACGnnnnGnnnAAGGATAAAAAGA


nnnnnnTGGACGATCCAATACAATACAAAGGCCATACGTTCATACTGTCCATGATCAACATACCAAnnnnAGTGT


GAGATCTGCAAGACTTTCTTCATGTGGCCCATAGAGCGGTCACTCATATGCCAGACGTGTAAACTTGCCTCGCAT


AAnnnTnnnACACTA





SEQ ID NO: 21


>ise2c.pk001.b14 potassium channel amino acid transporter


TGACTCCACAGTGGGACAAACTCATAGAGCTTGATGTGTGGTACGCTGCTGTGACCCAAGTGTTCTTCTCTCTGT


CTGTGTGCACCGGTGCCATCATTATGTTCTCGTCCTACAATGGATTCAGACAAAATGTTTACAGAGACGCGATGA


TTGTCACTACTTTGGACACCTTCACCAGTTTGTTATCCGGTTTCACGATCTTCGGTATCCTGGGTAACTTGGCGT


ACGAGTTGGACAAAGATGTGGATGACGTCACTGGTTCTGCAGGAACTGGACTTGCCTTCATTTCATACCCTGACG


CGATCTCCAAAACTTTCCAGCCACAGTTGTTCGCAGTGCTGTTCTTCTTGATGATGACGGTACTAGGTATCGGAT


CAGCAGTTGCTTTACTTTCCACCATCAACACCGTGATGATGGACGCGTTCCCTCGCATCAAGACCATCTACATGT


CCGCCTTCTGCTGCACTATTGGATTTGCCATCGGTCTCATTTACGTCACACCTGGTGGCCAATATATTCTCGAGC


TGGTGGATTACTTCGGTGGAACCTTCCTGATTCTCTTCTGTGCTATCGCTGAAATTATTGGTGTATTCTGGATTT


ACGGCTTGGAGnnnTATGCCTGGATATTGAGTACATGTTGGGAGTTAAACTTCTTCTACTGGnnnTnnTGTTGGG


GCGTTATTATGCCTGCCATGATGATnACCGnnnnnn





SEQ ID NO: 22


>ise2c.pk003.f2 potassium inwardly rectifier . . .


GCACGAGGGTAAACAGATTTTAACACTACATTAATTTGTTCTAGAGTTAAATGTATTAATTCCGACTTAAAAACA


GTGCTTGTGATAAGTGAACACAAATTATTGAGCAATGACTGACTTTATAAAACAATATTTCAAGGAACAATATGA


AATAAATGAAAAAATGCTTTCGAAAATTGACGCGGATCTGCGAACCTGCGGAGCACACTTAGTAGCAGTGAAGTT


AATGGTGACTGCCCTCGAGTTGAAAATGACTTCGATGAAGACAATGTATCAGGATCTAATGGAACTCAGAGAAAT


AATCGTTCTTTTAAATCCACACTTGAAGAAACCGAGATAATAATACAATACAGTAAGGTTAACGAATACTATCTT


TTAATTTCCTTAAATTATGTTCATAAAAATGATTAAGTTGTTTAGCTGAACACAGTGGTGTACTGACAGGATAGG


TTTCATTAAACTTTGCATAATCGATCAGAAAACCGTGCTTTTCTTTTTTGTACTCGACCATTTCAATAAAGCGAT


GACCCCATAGGATTnnnnTGGGTGGTGTAGCTCGACTTCGCTTGGACAGGCTGACCAGTTGATTCTATAGTGCCT


TCAAACACTACGAnnATTTCCATAT





SEQ ID NO: 23


>ise2c.pk005.l20 amino acid transporter


GCACGAGGATTTTCTTAAAACGGTACTGCAGCAAAAAGACGGCATTGAAGGTGGACTCGGTCTGCCTATCTGGTA


CCTGGTGGTTTGTCTGTTCGGGTCATGGTTTATCATCTTCGTGATTGTGTCCCGAGGTGTAAAGAGTTCCGGTAA


AGCTGCATACTTCTTGGCTCTCTTCCCCTACGTTGTGATGCTCATTTTGCTTATAACGACCTCTATTCTGCCCGG


AGCCGGCACCGGCATTCTTTTCTTCCTGACTCCACAGTGGGACAAACTCATAGAGCTTGATGTGTGGTACGCTGC


CGTGACCCAAGTGTTCTTCTCTCTGTCTGTGTGCACCGGTGCCATCATTATGTTCTCGTCCTACAATGGATTCAG


ACAAAATGTTTACAGAGACGCGATGATTGTCACTACTTTGGACACCTTCACCAGTTTGTTATCCGGTTTCACGAT


CTTnnnTATCCTnnnTAACTTG





SEQ ID NO: 24


>ise2c.pk001.d1 tubulin


GCACGAGGCCGGTCTTCAGGGCTTCCTTATCTTCCACTCCTTCGGTGGAGGTACTGGATCTGGTTTCACTTCCCT


CCTGATGGAGCGACTCTCCGTGGACTACGGCAAGAAGTCCAAGCTGGAGTTCGCCATCTACCCGGCGCCTCAGGT


GTCCACCGCTGTCGTGGAGCCCTACAACTCCATCCTCACCACCCACACCACCCTTGAGCACTCCGACTGCGCCTT


CATGGTCGACAACGAGGCCATCTACGACATCTGCCGCCGCAACCTCGACATCGAGCGCCCCACGTACACCAACCT


GAACCGTCTCATCGGGCAGATCGTGTCCTCCATCACGGCCTCCCTGCGCTTCGACGGCGCCCTCAACGTCGATCT


TACCGAGTTCCAGACCAACTTGGTGCCCTACCCCCGTATCCACTTCCCTCTGGTCACATACGCCCCGGTCATCTC


TGCCGAGAAGGCGTACCACGAGCAGCTGTCGGTGGCTGAAATCACCAACGCATGCTTCGAGCCCGCCAACCAGAT


GGTCAAGTGCGACCCTCGTCACGGCAAGTACATGGCTnnnnTGCATGTTGTACCGTGGTGACGTCGTCCCCAAGG


ACGTGAACGCCGCCATCGCCACCATCAAGACCAAGCGTACCATCCAGnnnCGTCnnTTGGTGTCCnnCnnnGTnn


n





SEQ ID NO: 25


>ise2c.pk001.k6 tubulin


GCACGAGGATTCGTTTGGCAAGCCTCTTAACCGGTCGCGCTGAACGACGACTGATATTTAATTAATTTATATTCT


ACGTTAAGTTCAACAAAACTCAATTCAAAATGCGTGAGTGCATCTCAGTACACGTTGGACAAGCCGGAGTCCAGA


TCGGTAATGCCTGCTGGGAATTATATTGCCTTGAGCATGGAATCCAGCCTGACGGCCAGATGCCCACAGACAAGA


CCGTGGGCGGTGGTGATGACTCCTTCAACACCTTCTTCAGCGAGACCGGTGCCGGCAAGCACGTCCCCAGGGCTG


TGTTTGTTGACTTGGAACCCACAGTAGTTGATGAGGTCCGCACTGGCACATACAGACAGTTGTTTCATCCAGAAC


AACTTATCACTGGTAAGGAAGATGCGGCCAACAACTACGCCCGTGGTCACTACACCATCGGCAAGGAAATCGTAG


ACCTAGTCCTCGACCGCATCCGTAAGCTCGCCGACCAGTGCACCGGTCTCCAGGGCTTCCTTATCTTCCACnnnn


nTCGGTGnnnnnACTGGGATCTGGTTTCACTTCCCTCCTGATGGAGCGACTCTCCGTGGACTACGGCAAGAAGTn


nAAGCTGGAGTTCGCCATCTnnnCnGCnnCTCnnnnnTCnnnnnnCTGTC





SEQ ID NO: 26


>ise2c.pk001.l2 tubulin


TTCGGCACGAGGGGCAAGCCTCTTAACCGGTCGCGCTGAACGACGACTGATATTTAATTAATTTATATTCTACGT


TAAGTTCAACAAAACTCAATTCAAAATGCGTGAGTGCATCTCAGTACACGTTGGACAAGCCGGAGTCCAGATCGG


TAATGCCTGCTGGGAATTATATTGCCTTGAGCATGGAATCCAGCCTGATGGCCAGATGCCCACAGACAAGACCGT


GGGCGGTGGTGATGACTCCTTCAACACCTTCTTCAGCGAGACCGGTGCCGGCAAGCACGTCCCCAGGGCTGTGTT


TGTTGACTTGGAACCCACAGTAGTTGATGAGGTCCGCACTGGCACATACAGACAGTTGTTTCATCCAGAACAACT


TATCACTGGTAAGGAAGATGCGGCCAACAACTACGCCCGTGGTCACTACACCATCGGCAAGGAAATCGTAGACCT


AGTCCTCGACCGCATCCGTAAGCTCGCCGACCAGTGCACCGGTCTCCAGGGCTTCCTTATCTTCCACTCCnnnCn


GTGGAGnTnnnTGGATCTGGTTTCACTTCCCTCCTGATGGAGCGACTCTCCGTGGACTACGGCAAGAAGTnnAAG


CTGGAGTTCGCCATCTAnnnn





SEQ ID NO: 27


>ise2c.pk002.b4 ubiquitin


GCACGAGGATCAAAGAGTTACGAACCGTCACCATACTGAAGGAGATACCATTCGTCGTGCCATTCTCAACACGCG


TCCTTATATTCCAAGGACTTTTAGCGAGAGAGAAGCACGACCACTGGTACGAAATGACGAACTTCAACGAGGGGC


CCTCGATCAACATCAGTGTTCGAAGGACGCATTTATATGAAGATGCATTTGATAAACTTAGTCCGGATAATGAAC


CTGATTTGAAGTTGAAACTTCGCGTGCAACTGATCAACCAGGCCGGTGCGGAGGAAGCTGGTGTCGACGGCGGTG


GACTATTCCGAGAGTTTCTTTCTGAGCTCTTAAAATCTGCATTTGATCCGAACAGGGGTCTGTTCCGGCTGACAA


TAGACAACATGTTGTATCCGAACCCCGCCGTACATCTACTGTACGATGACTTCCCCATGCACTACTACTTCGTCG


GCAGGATGCTGGGAAAGGCGATGTACGAGAACCTGTTGGTGGAGCTGCCGCTGGCGGAGTTCTTCCTGGGCAAGC


TGTGCGGCTGCGGGGAGGCCGACGTGCACGCGCTGGCCTCGCTCGACCCCGCGCTGCACCGCGGGTTGTTACTAC


TC





SEQ ID NO: 28


>ise2c.pk001.j16 small nuclear ribonucleoprotein


GCACGAGGGCCGGCCGCCGTGTTCGTGCCGTCCCGCCGGGCCGCGCGCCTACTGGCCGCCGACCTGCTGGCGCTG


GCCGCGGCGCACGCGCAGCCCGCCGCCTTCCTGCGCGCGCGCCCCGACGTGCTGCAGCCCTTCCTCAAGAGGATC


AACGACAAGATGCTGAAGGAGACGGTGGCTGCGGGCGTGGCGTACCTGCACGAGGGCGTGGACCCGGCGGAnnGG


CGCCTGGTGCAACAACTGCTGGAGTCGGGCGCGCTGGCGCTCTGCGTCGTGGCCGCCGAGCTGGCCTGGGGACT





SEQ ID NO: 29


>ise2c.pk006.h23 small nuclear ribonucleoprotein


GCACGAGGCGAAGATAAAGGTCGCGTGTGGACCTTAGGTTTAAGTTTATTATTAAATAATTTAGCCTAAACATAA


GTCATGGCCAATAACGACAACTTTGCACAAGATGTTACTGATAATCAACTAAATGGAAATGCCGAAAATGGTGGT


GGCGATACGCAAGAACATAATAGTGCCGAAGCCCCTGGGCGTGATGATGACAGAAAACTTTTTGTCGGAGGCCTG


AGCTGGGAAACCACAGACAAGGAGTTACGTGACCACTTCAGTGCATATGGTGAGATTGAGAGCATCAATGTCAAG


ACTGATCCAAACACTGGCAGATCAAGAGGATTTGCCTTTATTGTGTTCAAGGCACCAGATTCAATAGACAAAGTG


ATGGCTGCTGGAGAGCACACTATTAACAACAAAAAAGTTGATCCGAAAAAAGCAAAGGCTAGACATGGAAAGATC


TTTGTTGGTGGTCTTAGCAGTGAAATATCAGATGATGAGATCAAAAACTTCTTCAGTAATTTTGGAACAATAATT


GAAGTCGAGATGCCCTTTGACAAAACCAAGAATCAGnnnAAGGGATTCTGCTTTATAACATTCGAGTCTGAACAG


GTGGTCAATGAGCTGCTGAnnnCn





SEQ ID NO: 30


>ise2c.pk006.m8


GCACGAGGCGCGTGTGGACCTTAGGTTTAAGTTTATTATTAAATAATTTAGCCTAAACATAAGTCATGGCCAATA


ACGACAACTTTGCACAAGATGTTACTGATAATCAACTAAATGGAAATGCCGAAAATGGTGGTGGCGATACGCAAG


AACATAATAGTGCCGAAGCCCCTGGGCGTGATGATGACAGAAAACTTTTTGTCGGAGGCCTGAGCTGGGAAACCA


CAGACAAGGAGTTACGTGACCACTTCAGTGCATATGGTGAGATTGAGAGCATCAATGTCAAGACTGATCCAAACA


CTGGCAGATCAAGAGGATTTGCCTTTATTGTGTTCAAGGCACCAGATTCAATAGACAAAGTGATGGCTGCTGGAG


AGCACACTATTAACAACAAAAAAGTTGATCCGAAAAAAGCAAAGGCTAGACATGGAAAGATCTTTGTTGGTGGTC


TTAGCAGTGAAATATCAGATGATGAGATCAAAAACTTCTTCAGTAATTTTGGAACAATAATTGAAGTCGAGATGC


CCTTTGACAAAACTAAGAATCAGAGGAAGGGATTCTGCTTTATAACATTCGAGTCTGAACAGGTGGTCAATGAGC


TGCTGAnGACTCCTAAGCAGnnnATTGGTGGCAnnnnnnnCGAC





SEQ ID NO: 31


>ise2c.pk001.a23


GCACGAGGATGAAGTTGGCTCTGACACTCTTGGCTCTGGCGGCGGTGGCCACCGCTAAAAACATCAACGTCGAGG


ATGCCATCGACCTAGAGGACATCACCGCCTACGGATACTTGGCTAAGATCGGTAAACCTCTTGCCGACGAAATCC


GCAAAGCTGAGGAGGCAGAGAGCGCATCCAGAATTGTTGGTGGTCAGGCCTCCAGCCTCGGACAGTTCCCCTACC


AGGCTGGTCTTCTCGCTGACTTCTCCGCTGGCCAAGGTGTGTGTGGTGGTTCCTTGGTGCGTGCCAACCGTGTTC


TTACTGCTGCTCACTGCTGGTTCGATGGCCAGAACCAGGCCTGGAGATTCACCGTTGTTCTTGGCTCCATCCGTT


TGTTCTCCGGTGGTACCAGAGTTCAAACCTCCAACGTTGTTATGCATGGAAGCTGGAACCCCAGTAACATCCGTA


ATGACGTCGCCATGATCAGGCTGAACTCCAACGTTGGTCTTTCAAACACCATTGCACTCATCGCTCTGCCCAGCG


GTAGCCAGCTCAACGAAAACTTCGCCGGTGAAAACGCCGTCGCnnnCTGGATTCG





SEQ ID NO: 32


>ise2c.pk001.a7


GCACGAGGATCAAAATGAAACTGTTCCTCGCAGTCGTGTGCTTGGCCGTTGCCGCATCCGCGGTGGAGATTGGAG


TTCCGTCTCAGGAAAACCCAGTCTTTGGCTACCATCAAAACTTCGGTATTGCCGAAGCTGCCAGGATCAAGAAGG


CTGAGGAAGAAACCAGCCCTAGCGCCCAGAGGATCGTCGGAGGATCTGTCACTGACATTTCCAACGTCCCTTACC


AGGCTGGTCTCGTGATCCAAGTTTTGGTCATCTTCCAATCCGTGTGCGGTGGTTCCATCATCTCCCACAACCGCA


TCGTGACCGCTGCTCACTGCAACTGGGACGGTTCTATCACCGCTAACTCTTTCACCGTCGTACTTGGCTCCAACT


TCCTCTTCTCCGGCGGTAACCGCATCACCACCAGAGATGTTGTCATGCACCCCAACTGGACCCCAACCACCGCTG


CCAACGACATTGCTGTCCTCCGCATTAGCTCCGTTACTTTCACCAACGTGATCCAGCCCATCGCTCTGCCCAGCG


GCAACGAGCTCAACAACGACTTCGTCAACTGGAACGCTATCGCTTCCGGATACGGTCTTACCGCTGATGGTGCTA


ACATCGGTACTACCCAACGTGTCAGCTCCGTGGTACTCCCCGTGATCnnnnnnCGCCAGnnCGCTACCGTnnnnn


n





SEQ ID NO: 33


>ise2c.pk004.c4


GCACGAGGAATCTTAGTTACATTGGAGTGACTTTTATTTATCAATAACATTTTTATTTGAAGACTCAGTACGTAT


TATCGCGTAGTTCAACAGAGTTGCTAGTGTAGTTTTCTGAAAGTTGCCATCTTGCTTTTGCAACTTTTAAATATA


AAAGTCTTATTAGATCGTTTTTACTACCGATAAATTTACTAAAAATATAAAAGTGCAATTTACAATTACTCTGTT


AGTGTCAGTTTGTGTGAATTTGTCGTAGTTATAAAAGGACACTGTATTGATTTTGTCAATCAGTTTGACGCATGC


GCTCATTGGGTGCCGTAAAAAAGGGTTGGCCAACATTCCGAACAGTGTCGTTCCGGTCGCCGTTGTCGTGGTGTC


GGTGAAGTTAGTGGTGGAATTTTTACGTGTATAACATCAAAAAATGGCGTCTGGTGTGACAGTTTCGGACGCGTG


CAAAACGACGTACGAGGAGATTAAGAAAGACAAGAAGCACCGCTACGTGGTGTTCTACATCAGGGATGAGAAACA


AATTGACGTAGAGACCGTCGGCGAACGTAACGCGGAATACGATCAGTTCCTTGAGGATCTGCAGnnnGGTGGCAC


CGGnnAGTGCn





SEQ ID NO: 34


>ise2c.pk004.l4


GCACGAGGCTGATATCTAATCTTAGTTACATTGGATTGACTTTTATTTATCAATAACATTTTTATTTGAAGACTC


AGTACGTATTATCGCGTAGTTCAACGGAGTTGCTAGTGTAGTTTTCTGAAAGTTGCCATCTTGCTTTTGCAACTT


TTAAATATAAAAGTCTTATTAGATCGTTTTTACTACCGATAAATTTATCAAAAATATAAAAGTGCAATTTACAAT


TACTCTGTTAGTGTCAGTTTGTGTGAATTTGTCTTAGTTATAAAAGGACACTGTATTGATTTTGTCAATCAGTTT


GACGCATGCGCTCATTGGGTGCCGTAAAAAAGGGTTGGCCAACATTCCGAACAGTGTCGTTCCGGTCGCCGTTGT


CGTGGTGTCGGTGAAGTTAGTGGTGGAATTTTTACGTGTATAACATCAAAAAATGGCGTCTGGTGTGACAGTTTC


GGACGCGTGCAAAACGACGTACGAGGAGATTAAGAAAGACAAGAAGnnnCCGCTACGTGGTGTTCTACATCAGGG


ATGAGAAACAAATTGACGTAGAGACCGTCGGCGAACGTAACGCGGAATACGATCAGTTCCTTGAGGATCTGCAGA


AGGGTGGCACCGGAGAGTGCAGATATGGCCTCTTCGACTTCGAGTACACGCACCAGTGCCAAGGCACGTCGnnn





SEQ ID NO: 35


>ise2c.pk004.n19


GCACGAGGCCTCGTGCCGCGCGAATAGACAGTTTTGTGTGCACAATGTTGATCCTTTGGCTAAATATCATCGCAA


TAATTTGTGTCATACCCTACGCAAATGGAGAAGGAAGGGTTGCAATAGCGCATTTACAATCGCTAAAGTCAGTGA


CTGGTCAAATTCAATTTACGGAGACGGCAAAAGGGCTTCATGTCGAAGGAGTTATATTTGGTTTACCACCCGGTG


CCTACGGGTTTCACGTTCACGAATTAGGAGATGTTGCACCTGGTTGCGACCAGGCGGGCCGGCACTTCAACCCTG


AGGGATCCACCCACGGTGGCAGGAACTCCACCGTACGCCATGTCGGTGACCTCGGAAATGTAGTGTTCGTTAGCG


AGCGAGCCGCTTATGCTACAGTAGACTTTGTAGATAGTCTATTGGCACTTCAAGGACGTAATAGTATATTGGGGC


GCTCTTTGGTCTTGCATGAACAAACGGATGACCTAGGTTTGGGAGGAAACGCGACGTCTTTGACTACAGGTAACT


CGGGGCCCCGGATAGCATGTGGTGCTATTGGAATCAAATCACCTTATGACCCTTGGAATGCTGCTAGCTCTATGT


CTCCGTCGATGCTACTATTTATCACATCTTTAACTTTATTTACTTTAnnnTnnnAAnTnnnnGTATnAGTATTTA


ATTTnnnnn





SEQ ID NO: 36


>ise2c.pk005.f21


GCACGAGGCTTCCACATACGCGAATAGACAGTTTTGTGTGCACAATGTTGGTCCTTTGGCTAAATATCATCGCAA


TAATTTGTGTCATACCCTACGCAAATGGAGAAGGAAGGGTTGCAATAGCGCATTTACAATCGCTAAAGTCAGTGA


CTGGTCAAATTCAATTTACGGAGACGGCAAAAGGGCTTCATGTCGAAGGAGTTATATTTGGTTTACCACCCGGTG


CCTACGGGTTTCATGTTCACGAATTAGGAGATGTTGCACCTGGTTGCGACCAGGCGGGCCGGCACTTCAACCCTG


AGGGATCCAACCACGGTGGCnnnnnCTCCACCGTGCGCCATGTCGGTGACCTCnnAAATGTAGTGnTTGTTAGCG


AGCGAGCCGCTTATGCTACAGTnnnCn





SEQ ID NO: 37


>ise2c.pk010.h5


GCACGAGGGTCGAGAGATACGGTGCGCACATAGCAACAATATCAAAGTACAAAGGTCAGTAACTATGAGTGGTAA


ATTGTTAAAAACTCTAATCCTTGGGGCACCTGCTTCAGGCAAGGGGACTATATCGTCTCGGATAGTGAAGAAATA


TGCTGTGGCACACGTGTCCAGTGGGGACAAGCTGAGGGACCACATTGAGAAACAAACTGACCTAGGTAAAGAAGT


CAAAAAGTACTTGAATGAAGGGAAACTTGTACCTGATGATGTCATGATAAAGTTTATGATCACAGAATTAAAAAA


AGTTGAAGATAAACCATGGCTACTGGATGGATTCCCGAGGACTGTGGGACAGGCTGATGCTTTGTGGAAGGTACA


ACCTGTTGATGTAGTAGnnnnnTTAGTAGTGCCTTTTGAGGTAATCATAGACAGAGTGAnnnAnCGCTGGGTGCA


CTTGCCTTCGGGCCGAGTGTATAACATTGGCTTCAACACTCCTAAAGTGGAAGGTAAGGATGATGAGACAGGTGA


GGACTTGGTTCAGAGACCTGACGACAAGCCAGAGGCTGTGCGCAAGCGGCTGGAGATCTATGAGAGTGTGACGAG


GCCAGTCATAGAGTTCTAnnnnGCTAA





SEQ ID NO: 38


>ise2c.pk001.c18


TGCTGCTGCTGGAAGCTGGGCCCAACCCTCCCGAGGAGAGCATTATACCAGGCTTAAGACAAACCTTGAAAGAAA


CGCCCTACGACTGGAACTTCACCACCATTGACGACGGGGTCACGAGCCAGGCGCTGGCGGGCCACGTGCAGAGAC


AGCCGCGGGGCAAGATGCTGGGCGGCAGCGGCTCGCTCAACGACATGGTGTACGCGCGGGGCCACCCCGAGGACT


ACTACGAGTGGGCCGACATCGCCGGCGACGTCTGGAACTGGACCAACGTGCTGGACTACTTCAAGCGGACGGAGC


ACATGACGGACGCCAATATCGTTCACAACnnnnAGCTCATGCAGTACCACGGCACGGnnnnnnCCATnnnnnnnT


nnnGnnnCCAnTnnnnnnnn





SEQ ID NO: 39


>ise2c.pk004.pl


GCACGAGGGGAAAACATGGGAAGGAGGTCGCATCAAGATGTTAGTGCTCGACTTGAACTGCCCGGTCGTTGGAGA


CGACTGCAAAGACAGCCGCAAGAAGTTGCTTGTGGACTACTTCCATACAAACCTGCATACCCAGAACTTCTACGC


GTTCCGCTTCTTTATCTGCGAAGTGTTGAACTTCATCAACGTCGTGGGCCAGATCTTCTTCATGGACTTTTTCCT


GGACGGCGAGTTCTCCACGTACGGCAGTGACGTGGTCAGTTTCACCGAGATGGAGCCCGAGGAGCGTGTGGACCC


GATGGCTAGAGTGTTCCCGAAAGTGACCAAGTGCACCTTCCACAAATACGGTCCTTCAGGAACCGTGCAGAAGTT


CGACGGTCTGTGCGTGCTGCCATTGAACATCGTCAATGAAAAGATCTACGTGTTCCTGTGGTTCTGGTTTATGAT


CCTGTCGATCCTGAGTGGAATTTCGCTGATTTACCGCATGGCCGTGGTGGCTGGACCGCGCGTGCGCCTGTACCT


GCTGCGTGCGCGCAGCCGCCTGGCCCCGCnnnCGCnnnnnGnnnn





SEQ ID NO: 40


>ise2c.pk005.p13


GCACGAGGATTTTAATAGCTATTATGACTTTACAGACTAGACGGATCAAGGCCATGCCTCTCGCTTGCATACTCA


CCATCCGCACATACCGTATTGCGGTATGTCAATAAGTTGCAAATAATGTCTGTTCAGTTTTACAAGGATAAGATC


AGCAGTATTTGCGAACTGTACCTACTACTAAGCTGATAATGTAATAATTAAACTTTATTATTGAAATAGATATGT


ATAATTGACATCTTTCTCAAATGGGTGTCAATACTGCCAACTCTATTACCACAATTTCTTTTCGTATTTGCTTTT


ATACTGAGCCTGATGACGTACTGTACTTTTTATTAGAATTTAATTTTTCTTATTTTTCTTACTACGTAGTCATTA


AATCTGAGAAATTAAAAATTACTAATTTAGAACTCCCAAATTCTGAATGAGGTTCTAAAAAGTTGTTAGGAATAC


TAAATACCATTTTACCAACATAAATCTAATTTCGTTACTTAAAATATTAAATGTATAATGAAATGTCTATGATAA


GTGTTTACTATCTTTATATCGACAAAATTTATTTTCCATGTTTTAAAATTTATTTTTCAGATGTTTTGACGTGAT


AAGTTTGTATTTTATCAATATCTGATAGTCGAGAGTTAnnnAnTATTG





SEQ ID NO: 41


>ise2c.pk001.f12


GCACGAGGGAGGAGAGGTGGTGGCTGGCTTCCTTGCAAACGAAGCGTCGTAAATTACATCTTATTTGTAAATTTT


AATAAAAATTTGATCGTTAAACGATCGAATCAGTAGTGATTTAAGTGCTCAAGCAGTTTCACATCCAATCGACAA


TGAGTTCGAGTGTATGCTACAAGTGTAACCGGACAGGGCACTTCGCCCGCGAGTGCACCCAGGGTGGTGTTGCCG


CTCGTGACTCTGGTTTCAACCGTCAGCGCGAAAAGTGCTTCAAGTGCAACCGCGCTGGGCACTTCGCTCGGGATT


GCAAGGAGGAGGCCGACCGTTGCTACAGATGTAACGGCACGGGACACATAGCGCGTGAGTGCGCGCAAAGTCCGG


ACGAGCCGTCGTGTTACACTTGCAACAAGACCGGGCACATCGCACGGAACTGCCCAGAGGGCGGGCGCGACAGCT


CCAACCAGACCTGCTACAACTGCAACAAGTCCGGCCACATCTCACGCAACTGCCCCGACGGCACCAAGACTTGTT


ACGTGTGCGGAAAGCCCGGACACATCTCCCGCGATTGCGATGAGGAGCGGAACTAACACACGCCTCTTCGCGACT


GCCTATATATAnnnTAAACTATGTATATTATGATGCCACGCACGGACGATAAGCAAAGGACGCGATACGCGACAC


TAGATCGTAAGACCACACGACTGTATGnnnnTAATGCAACG





SEQ ID NO: 42


>ise2c.pk001.n21


GCACGAGGATAATAAACGTTAATATTTAACAAGTTGAAAAGTTTGTCTTTCAATTTGTGATTTTGTAAAGATCAT


TCTATGGAATGGACAGTTTGCTATCTGTGAAACATCCATTAGCTTTGTGTTGAGAGCAGAGGTCGCGGCGGCGGG


GTGATGCGGCCATGGCTTCGCGGCGCGTGACGCGCAAGTGGGAGGTGTTCGCGGGACGGAACCGATTCTGGTGCG


ACGGCCGCCTCATGACGGCGCCGCACCCCGGCGTGTTCCTGCTCACGCTCGCGCTCATCTGCGGCACGTGCGCCC


TGCACTTCGCCTTCGACTGCCCCTTCCTGGCCGTGCGCGTGTCGCCCGCCGTGCCCGCGGCCGGCGCCGCGCTGT


GCGCGCTGACGCTGGCGGCGCTGCTGCGCACGGCGCTGTCCGACCCCGGCATCATCCCGCGCGCCGCCGCGGCCG


AGGCGGCGGCGCTGGAGGCGGnG





SEQ ID NO: 43


>ise2c.pk004.e20


CGCGCACGTCGCTCnnCAAGCCCGCTGCAGCGCCGGCCAAGCCCGCCCCCGCGGCGGCGCGCGCCACCAGTGCGA


CCAGCCGCGCGGCCCCCGCGGCCCGGCCGGCCCCCAAGTCCGCAGTAGGCGCAGCGCGGCCCGCAGCACAAAAGA


CAGATGCGGCCGCCAAACCCGCGGCGACCCGGGTTGCGGCTCCGCGTCCCGCGCTGTCGGCGCCCAGGCCCCAGC


CTAAGCCGGCAGACAAGAAGCCAGTACCGAATGGTGACGTGAAAGACTCCAAGCCAGCCGCGCGGCCCGCGCCCC


GGCCGGCCGCGGCCGCGCGCCCCGCGCCGCGCCCCACTCCCCGCGCCCCCGCCGCACnGGTCGCACCCACTACTn


nnnnGAGTGCCCCCAAGCCGGCGCCGCGTGCTCCCCTGGACAAGCAGAGCnnnGACCTCGCTAACAAACGCATCn


nnGnCAnGGCAGCACCGCCTAGGACTGCTCCCCCTAAGACGACAACGACGACAACAGGnnnnnnnnnnnnnGTnn


CGAAGnnnnn





SEQ ID NO: 44


>ise2c.pk005.n11


GCACGAGGCTATAACAAGCAGCATATAAAAATGAAATTCTTGCTGTCTTTCGCTGCCGTCATCGCCGTGGCCGCC


GCTGGCCTGGTGCCCGTTGGACCCGCCGGCCCTGCGCCCGCTCCTGAGGCCCCTGAGGTCTTCGAGCCCGTCGCT


ATTGGACCCGCTGTCATTGACTCCTTCGAGCCCATCGCCATCGGACCCGCTATCATCGACTCCTTCGAGCCCATC


GCCATCGGACCCGCTATTGTTCCATCTCCCGAGCCCGTCGCCATCGGACCCGCCATCATTGAGAGCCCAGAGCCC


GTTGCTGTCGGACCTGCATGGATTGACTTCCCCCTGCCCGACGGTGGTGCTGCCGTTGCCCCCGTTGAGCCCTCT


CCCGTGGCTGTTATCCCCGGTCCCGTGTCCACTGAGGTTGCTTCAGGCACTCCCCTCGTTCAGATCATCCTGAAC


ATCAACnnnnnnTCTGCTGACGTTAGCCCCGTTGCTGTnGGCCCCGCTGTCGAGnnnACACCCGTGCACGTTGTG


GACTCTGCCCCTGAACCCGTCCACGTTGTGnnnnnnGCCCCnnnnnCnATCnnnnnGTCGn





SEQ ID NO: 45


>ise2c.pk003.l14


GCACGAGGCTTAGAGTAAGCATAGGTGTATTTATGTATTGAGTCGGAAGAAGCAATGGACGATCCAAATAGGATG


ATGGCGCATAGCGGCGGGCTTATGGGGCCGCAGGGCTACGGCCTGCCTGGCGGCGAGGGAACTCCAACCGCAGGC


GAAGGTGAAGCCCGCAAGCAAGATATTGGTGAAATATTGCAACAGATCATGAATATTACAGATCAAAGTCTTGAT


GAAGCGCAAGCGAGAAAACATACTCTCAACTGTCACAGAATGAAGCCTGCCCTATTTTCAGTGTTGTGTGAAATC


AAAGAGAAAACAGTGCTGTCCCTCCGCAACACGCAAGAGGAGGAGCCCCCAGATCCCCAGCTGATGCGCTTGGAC


AACATGCTCATAGCCGAGGGGGTCGCTGGCCCTGAAAAGGGTGGTGGTGCGGGCGCTGCAGCTTCGGCATCAGCT


GCTGCTGGTGAATGGGACAATGCCATCGAGCACTCTGACTACCGTGCGAAGTTGGCGCAGATCCGCCAGATCTAC


CACCAGGAGCTGGACAAGTATGAGAATGCTTGTAATGnnnnnnCCACCCACGTGATGAACTTACTCCGCGAGCAG


AGCCGCACCAGGCCTATCACAnn





SEQ ID NO: 46


>ise2c.pk003.e24


GCACGAGGCCAGGTTTGAGAAAAACGCTTAAACTGCCACAAAATCCCGTTCTCGAAGAAGCACTTTTCACTTATT


AATAAGTAACTTGTGTAAAATGTGGTTTAAATGTGTATTTTACTAAACCTCAATAAATATATTTATATCAAAATA


TTTTTTTTCTATACTGTATTATTTATTCCTATAGTACATATTATAATCCGAACGCTCCGTGAGTCCGAACAGGGG


TAATTTTTTGGTAGTTCGGATTATCGAGGCTCTACTGTATACCTACTTTTTGTTAAAATATTTTAGTCTTATATA


CGACTTCCTAACTAATCCATATCTCTTAGAGCTTTCGAATATCCATTTGCCTTTTTCTTAAAAAGATTAATAACT


ATTTATATATATCCCAAATATATAAAAACAACCACTCCAATTATTATTATTCAAATATGACAAACTAGATAGAAT


GTCCCAAGAAATTTGCAAAAAAGTAATGTTCAAATTATTAACCGAAGAACGAATTnnnGAGTGTATAATATTATA


CAGACATTTAGAAATTTTTAATAGGCTCCAATCGCATGAGAGGTCGCTTTAAAATTCGGCATTGGTGTGTGCGTT


GCAATTTAATCTTTAACACCCnnn





SEQ ID NO: 47


>ise2c.pk005.l5


GCACGAGGGGACGTGTTTACAATTTACTTTCGTGCTCGTGTGATTTTAATTAAAACAGTGCTAAGTGCTCTAGGA


CGCTGAATAACTGATATTTGTTTTAAAAGTTGATATAAATTAATCACAATGAATAGAGATAAACGAGAACCAGAG


TATCCAACGGAGTTGGAGTCTCAATTCGTAATGCGTTTACCTGAGGAGCCTGCAAAAGTTTTGAGAGAAGTGTTG


AAATCCGGAGAGAACCTGAAAAACAGACTGACGATACAAATAGAAAACGACATGCGCACGGGCGAGGTAAGGTTT


GATCACTGGTTGATGCACGCCAAGATCGTGGATCTACCAACCATCATAGAATCTCTAAAAACGATCGACAACAAG


AGTTTCTACAAAACAGCAGATATATGCCAAATGATGATTTGTAAAGAAGAACCTGACCAACCATCCACAGAGGAA


GAGTCACCAGCTAAAAATAAGAAAAAAGATCCATACAAAGTTGACAAAAAGTTCCTATGGCCACACGGCATCACA


CCGCCTACGAAGAACGTACGGAAGCGTCGATTTAGAAAAACCCTTAAAAAGAAATATGTAGAAGCACCAGAAATT


GAAAAGGAAGTGAAGAGGCTGCTGAGnGCAnnCnATGAGGCTGTTAGTGTTAACTGGGAGGTCATCAAnnnnnnn


GAT





SEQ ID NO: 48


>ise2c.pk006.k12


GCACGAGGGTCGAATGGAACATGGCGGTGCTAGGCAGGATGTGCATAAGTTTTTGATTTTTGCATTTTTAACGAG


TTGCTTATATCAGTTAGCTTTCTAAATAATTTCTGACTTATTTCGTGTGTTATAATATTTGTTATAGTGTAAAAG


CTTATCCACCCCAGGAATTTCCTATCTGGACTTACTTAGTTCTGCAATGAAAATTATTATTCGTTGGTAGTGTAA


AAATAATTGTGACAAATATATCACTTTGCTTCAGTGTGCCGTGTTGGTCATGGCTACGCTCCTCCAAGAGAATGG


TATAAAGGAGTTAAGCAAAGTTGTGCCTAACCGTGGTATATCCTCACATAGTGTAACAAATCATATGGTGCCTGA


TCATGAATATTGCGAAGCTGGGTCAACTAGCACGTCACAGATGAAGTGTACCGATACAAGTGAGGCGATGGCGCC


ACCCGCCGCCATTGAAGAAGAGGAGGATACACCAGAAATAGATATAATGATAAACAATGTTGTGTGCAGTTTTAG


TGTTAAGTGCCACCTGAACCTTAGACAGATAGCATTnnnTGGTGTGAACGTTGAATTTCGCCGCGAGAACGGCAT


GGTAACTATGAAGTTACGGCGTCCATACACTACTGCGTCCATCTGGTCGTCCGGCCGCGTGACGTGCACTGGTGC


AACCAGCG





SEQ ID NO: 49


>ise2c.pk010.i8


GCACGAGGGAATATTGCGAAGCTGGGTCAACTAGCACGTCACAGATGAAGTGTACCGATACAAGTGAGGCGATGG


CGCCACCCGCCGCCATTGAAGAAGAGGAGGATACACCAGAAATAGATATAATGATAAACAATGTTGTGTGCAGTT


TTAGTGTTAAGTGCCACCTGAACCTTAGACAGATAGCATTAAATGGTGTGAACGTTGAATTTCGCCGCGAGAACG


GCATGGTAACTATGAAGTTACGGCGTCCATACACTACTGCGTCCATCTGGTCGTCCGGCCGCGTGACGTGCACTG


GTGCAACCAGCGAGGACCAGGCGAAGGTTGCCGCACGACGGTATGCGCGCGCCCTTCAGAAGCTCGGCTTCCAAG


TGCGTTTCCGCAATTTCCGTGTAGTCAATGTATTAGGCACCTGTCGGATGCCGTTTGGTATAAGGATCATATCTT


TTTCGAAAAAATACAAGGAAGCAGACTATGAACCTGAGCTCCATCCTGGAGTCACATATAAGTTATACAATCCTA


AAGCCACACTCAAGATATTCTCCACTGGTGGTGTGACTATCACAGCTCGGAGTGTGAGTGACGTTCAGTCAGCCG


TGGAACGCATCTTCCCTTTGnTGTACGAGTTCCGCAAGCCTCnnnnACCGGCAnnnnA





SEQ ID NO: 50


>ise2c.pk010.b12


GCACGAGGGTACCAAAAGCTCTTTTCATTGCAGCTGAAGGGTCACTGCAACTTGGCCAATCAGAATTAGCATTGA


AACTATTCAAAGAACTAAAACAAGAAGGAATGGAAATCAGGCAACATTTCTATTGGCCTTTGTTAGTTCAGAAGG


CAAAGGAAAATGATGAGGAAGGCCTCTTGCAAATTTTAAAAGAAATGAGCAGCAATGACTTTACTGTTACTGGAG


AAGCGTTAAGAGACTATGTTATCCCTTACTTGATAAAAAAAGATTCTCCACAGAATGTCTTACTTAAACTTCAAA


TTGCAAATGTACCAACAATCCATGCTGCAAGAAATCTAATGGTTGATCTTTTGGATTCTGGAGACATAAAAGGCG


CAGCGGAAATAGCTCTGCAATATAGACCTTGGGGCAACTACTCTCTTGTTGCCAGGTCCCTCATCAATGCAGTGA


ATAAGACAAAAGATGTAGAATCGTTTGCTAAAATTCTTCATGCTATAAGCAGTAAACCTTTGTCACAGGGTGAAG


AAGATGTTGCTGCCAACAATGAGGAAGGTCAAAGTGATGAAAATAATGATATTCATGAAGTCGGCCGTATTGTGA


GGTCGTCTGCCAAGAGTTTGGCTAAACCAGACTTAATAGnAAnnnnTTTAGA
















TABLE 2 







List of dsRNA primers.













Primer





SEQ ID NO


#
Target Gene ID
Seq ID
Target
Sense strand
Antisense strand
Target/sense/antisense





0075
juvenile
ise1c.pk002.m13
AACATGGTATCCGACTTC
CAUGGUAUCCGACUUCAG
CCUGAAGUCGGAUA
51/52/53



hormone diol

AGGAA
G
CCAUG




kinase










0076
juvenile
ise1c.pk002.m13
AAGGTCGCTGACGAGAA
GGUCGCUGACGAGAACAA
CUUGUUCUCGUCAG
54/55/56



hormone diol

CAAGGA
G
CGACC




kinase










0077
juvenile
ise1c.pk002.m13
AAGTGTCCTGGGCTTGAG
GUGUCCUGGGCUUGAGUU
GAACUCAAGCCCAG
57/58/59



hormone diol

TTCCA
C
GACAC




kinase










0078
juvenile
ise1c.pk003.f7
AAGAAGAAGCTCCTCCA
GAAGAAGCUCCUCCACGU
CACGUGGAGGAGCU
60/61/62



hormone diol

CGTGTT
G
UCUUC




kinase










0079
juvenile
ise1c.pk003.f7
AAGGTCGCTGACGAGAA
GGUCGCUGACGAGAACAA
CUUGUUCUCGUCAG
63/64/65



hormone diol








kinase

CAAGGA
G
CGACC






0080
juvenile
ise1c.pk003.f7
AATGTCCTGGGGCTGAGT
UGUCCUGGGGCUGAGUUU
GAAACUCAGCCCCA
66/67/68



hormone diol

TTCAA
C
GGACA




kinase










0081
juvenile
ise1c.pk005.a15
AAGAATAAGCTCCTCCA
GAAUAAGCUCCUCCACGU
CACGUGGAGGAGCU
69/70/71



hormone diol

CGTGTT
G
UAUUC




kinase










0082
juvenile
ise1c.pk005.a15
AATTTGTCGAGGAGACC
UUUGUCGAGGAGACCCUA
AUAGGGUCUCCUCG
72/73/74



hormone diol

CTATTG
U
ACAAA




kinase










0083
juvenile
ise1c.pk005.a15
AAGTTCGCGTTCACTCTT
GUUCGCGUUCACUCUUGA
UUCAAGAGUGAACG
75/76/77



hormone diol

GAAGA
A
CGAAC




kinase










0084
ribosomal
ise1c.pk006.d24
AACTGCCCCTTAACCTCA
CUGCCCCUUAACCUCAUCU
AGAUGAGGUUAAGG
78/79/80



protein L18a

TCTAT

GGCAG






0085
ribosomal
ise1c.pk006.d24
AATCACGCTGAAACCAC
UCACGCUGAAACCACUGU
UACAGUGGUUUCAG
81/82/83



protein L18a

TGTATA
A
CGUGA






0086
epoxide
ise2c.pk009.i4
AAAATATGGCGCGCCTA
AAUAUGGCGCGCCUAUUG
ACAAUAGGCGCGCC
84/85/86



hydrolase

TTGTTT
U
AUAUU






0087
epoxide
ise2c.pk009.i4
AACGTTCTCGGTCTTTCA
CGUUCUCGGUCUUUCACU
CAGUGAAAGACCGA
87/88/89



hydrolase

CTGCT
G
GAACG






0088
epoxide
ise2c.pk009.i4
AAGTCATCGTTCCAAGTC
GUCAUCGUUCCAAGUCUA
GUAGACUUGGAACG
90/91/92



hydrolase

TACCT
C
AUGAC






0089
V-ATPase A
ise2c.pk001.d19
AACCCCTTGAATGTTAAG
CCCCUUGAAUGUUAAGGU
GACCUUAACAUUCA
93/94/95



subunit

GTCGG
C
AGGGG






0090
V-ATPase A
ise2c.pk001.d19
AAGTACACCATGTTGCA
GUACACCAUGUUGCAAGU
UACUUGCAACAUGG
96/97/98



subunit

AGTATG
A
UGUAC






0091
V-ATPase A
ise2c.pk001.d19
AACGTGTCCATGATGGCT
CGUGUCCAUGAUGGCUGA
GUCAGCCAUCAUGG
99/100/101



subunit

GACTC
C
ACACG






0092
H+-ATPase V-
ise2c.pk001.e14
AAACCTACAAAATGGCC
ACCUACAAAAUGGCCGAA
UUUCGGCCAUUUUG
102/103/104



type subunit

GAAAAC
A
UAGGU






0093
H+-ATPase V-
ise2c.pk001.e14
AATCTACGGACCCTTCTT
UCUACGGACCCUUCUUUG
CCAAAGAAGGGUCC
105/106/107



type subunit

TGGAG
G
GUAGA






0094
V-ATPase A
ise2c.pk001.f20
AACTCTGACGTCATCATC
CUCUGACGUCAUCAUCUA
GUAGAUGAUGACGU
108/109/110



subunit

TACGT
C
CAGAG






0095
V-ATPase A
ise2c.pk001.f20
AAGTGCTTGGGTAACCCC
GUGCUUGGGUAACCCCGA
GUCGGGGUUACCCA
111/112/113



subunit

GACAG
C
AGCAC






0096
V-ATPase A
ise2c.pk001.f20
AACTGGCTCATCTCCTAC
CUGGCUCAUCUCCUACAGC
GCUGUAGGAGAUGA
114/115/116



subunit

AGCAA

GCCAG






0097
novel sequence
ise2c.pk010.h3
AAACAGTGCGTCGTAAT
ACAGUGCGUCGUAAUAUA
AUAUAUUACGACGC
117/118/119





ATATTC
U
ACUGU






0098
novel sequence
ise2c.pk010.h3
AAGGCACATGGTCCTTCA
GGCACAUGGUCCUUCACU
CAGUGAAGGACCAU
120/121/122





CTGAT
G
GUGCC






0099
novel sequence
ise2c.pk010.h3
AACACCATGACCCTCGTG
CACCAUGACCCUCGUGUAC
GUACACGAGGGUCA
123/124/125





TACAA

UGGUG






0100
Larval cuticle
ise2c.pk007.k24
AACGAGGCCGGATCTCTT
CGAGGCCGGAUCUCUUAA
CUUAAGAGAUCCGG
457/458/459



protein LCP-17

AAGCA
G
CCUCG






0101
Larval cuticle
ise2c.pk007.k24
AACTTCACACATAACTAG
CUUCACACAUAACUAGAC
UGUCUAGUUAUGUG
460/461/462



protein LCP-17

ACAAA
A
UGAAG






0102
Larval cuticle
ise2c.pk007.k24 
AATGCGTGGCGATTTCAA
UUAGAAAUUAUAAGCCCA
CUGGGCUUAUAAUU
463/464/465



protein LCP-17

ACTTA
G
UCUAA






0103
transcriptional
ise2c.pk011.a10
AAAAAACACAGACCACG
AAAACACAGACCACGUUC
UGAACGUGGUCUGU
126/127/128



repressor

TTCACA
A
GUUUU






0104
transcriptional
ise2c.pk011.a10
AATCGATGGTGGTGTTAT
UCGAUGGUGGUGUUAUUC
CGAAUAACACCACC
129/130/131



repressor

TCGCT
G
AUCGA






0105
novel sequence
ise2c.pk011.h12
AAAGAAAATGCTACGCG
AGAAAAUGCUACGCGUUA
GUAACGCGUAGCAU
132/133/134





TTACGA
C
UUUCU






0106
novel sequence
ise2c.pk011.h12
AACCCTTGGACACTACTG
CCCUUGGACACUACUGGA
UUCCAGUAGUGUCC
135/136/137





GAAGA
A
AAGGG






0107
novel sequence
ise2c.pk011.h12
AAGGATCCTATGTGTACC
GGAUCCUAUGUGUACCAG
CCUGGUACACAUAG
138/139/140





AGGTT
G
GAUCC






0108
translation
ise2c.pk001.d22
AAACTCGGCACACAACA
ACUCGGCACACAACACAA
AUUGUGUUGUGUGC
141/142/143



initiation factor

CAATGG
U
CGAGU




5A










0109
translation
ise2c.pk001.d22
AATACGAAGATATCTGC
UACGAAGAUAUCUGCCCU
AAGGGCAGAUAUCU
144/145/146



initiation factor

CCTTCC
U
UCGUA




5A










0110
translation
ise2c.pk001.d22
AATCAACAGCTCTTACAT
UCAACAGCUCUUACAUAA
UUUAUGUAAGAGCU
147/148/149



initiation factor

AAATG
A
GUUGA




5A










0111
eukaryotic
ise2c.pk001.d9
AAAGAAGATCAGAAGAT
AGAAGAUCAGAAGAUUGG
GCCAAUCUUCUGAU
150/151/152



initiation factor

TGGCCG
C
CUUCU




eIF-4A










0112
eukaryotic
ise2c.pk001.d9
AAAAGCCGTCTGCTATCC
AAGCCGUCUGCUAUCCAA
GUUGGAUAGCAGAC
153/154/155



initiation factor

AACAA
C
GGCUU




eIF-4A










0113
eukaryotic
ise2c.pk001.d9
AATGCTAAATGCCATGCT
UGCUAAAUGCCAUGCUUG
GCAAGCAUGGCAUU
156/157/158



initiation factor

TGCAT
C
UAGCA




eIF-4A










0114
Eukaryotic
ise2c.pk001.i23
AAGATCAGAAGATTGGC
GAUCAGAAGAUUGGCCGG
UCCGGCCAAUCUUC
159/160/161



initiation factor

CGGAAG
A
UGAUC




4A










0115
Eukaryotic
ise2c.pk001.i23
AATTCTTCAGCAAATCGA
UUCUUCAGCAAAUCGAUA
GUAUCGAUUUGCUG
162/163/164



initiation factor

TACCA
C
AAGAA




4A










0116
Eukaryotic
ise2c.pk001.i23
AAATGCTGTCAAGAGGA
AUGCUGUCAAGAGGAUUU
UAAAUCCUCUUGAC
165/166/167



initiation factor

TTTAAA
A
AGCAU




4A










0117
RNA








polymerase
ise2c.pk001.l24
AAGCTCGAGACTTGCTCT
GCUCGAGACUUGCUCUUG
UCAAGAGCAAGUCU
168/169/170



sigma subunit

TGATG
A
CGAGC




SigE










0118
RNA
ise2c.pk001.l24
AACTGTTAGCTCAAGGTC
CUGUUAGCUCAAGGUCUG
GCAGACCUUGAGCU
171/172/173



polymerase

TGCTA
C
AACAG




sigma subunit








SigE










0119
RNA
ise2c.pk001.l24
AAGACTTTCTATCAGAAT
GACUUUCUAUCAGAAUUU
CAAAUUCUGAUAGA
174/175/176



polymerase

TTGCG
G
AAGUC




sigma subunit








SigE










0120
translation
ise2c.pk005.b9
AAACTTAATCATGGACG
ACUUAAUCAUGGACGACG
UCGUCGUCCAUGAU
177/178/179



initiation factor

ACGACA
A
UAAGU




2, subunit 2 beta










0121
translation
ise2c.pk005.b9
AAAGAAGAAGAAGAAGA
AGAAGAAGAAGAAGAAGG
CCCUUCUUCUUCUU
180/181/182



initiation factor

AGGGAG
G
CUUCU




2, subunit 2 beta










0122
translation
ise2c.pk005.b9
AAGATCAAGAGAATGTC
GAUCAAGAGAAUGUCGAG
CCUCGACAUUCUCU
183/184/185



initiation factor

GAGGAT
G
UGAUC




2, subunit 2 beta










0123
Putative sari
ise2c.pk002.m10
AAAATCGTCGGTTTTAGC
AAUCGUCGGUUUUAGCGA
GUCGCUAAAACCGA
186/187/188



protein

GACGT
C
CGAUU






0124
Putative sari
ise2c.pk002.m10
AACTGTCAATAGGCAGT
CUGUCAAUAGGCAGUAUG
GCAUACUGCCUAUU
189/190/191



protein

ATGCGT
C
GACAG






0125
Putative sari
ise2c.pk002.m10
AACCTGTACCAACAGAC
CCUGUACCAACAGACCACU
AGUGGUCUGUUGGU
192/193/194



protein

CACTGG

ACAGG






0126
elongation factor
ise2c.pk001.c14
AACCAAAAATGGGCAAG
CCAAAAAUGGGCAAGGAA
UUUCCUUGCCCAUU
195/196/197



1-alpha

GAAAAG
A
UUUGG






0127
elongation factor
ise2c.pk001.c14
AACGTGGTATCACCATCG
CGUGGUAUCACCAUCGAU
UAUCGAUGGUGAUA
198/199/200



1-alpha

ATATT
A
CCACG






0128
elongation factor
ise2c.pk001.c14
AACAAAATGGACTCCAC
CAAAAUGGACUCCACUGA
CUCAGUGGAGUCCA
201/202/203



1-alpha

TGAGCC
G
UUUUG






0129
elongation
ise2c.pk001.d16
AATCCGTGACTAACCAA
UCCGUGACUAACCAAAAA
AUUUUUGGUUAGUC
204/205/206



factor-lalpha F2

AAATGG
U
ACGGA






0130
elongation
ise2c.pk001.d16
AACATTGTCGTCATTGGA
CAUUGUCGUCAUUGGACA
GUGUCCAAUGACGA
207/208/209



factor-lalpha F3

CACGT
C
CAAUG






0131
Oligosaccharyl
ise2c.pk005.h3
AATTTGTGAGACTGGTGG
UUUGUGAGACUGGUGGCC
CGGCCACCAGUCUC
421/422/423



transferase 48

CCGAA
G
ACAAA




kDa subunit










0132
Oligosaccharyl
ise2c.pk005.h3
AATCTGATTGTATTCGCC
UCUGAUUGUAUUCGCCCC
GGGGGCGAAUACAA
424/425/426



transferase 48

CCCTC
C
UCAGA




kDa subunit










0133
Oligosaccharyl
ise2c.pk005.h3
AACACTCTAGTTCTGCCT
CACUCUAGUUCUGCCUAU
AAUAGGCAGAACUA
427/428/429



transferase 48

ATTCT
U
GAGUG




kDa subunit










0134
Myosin
ise2c.pk001.d21 
AACACACATCACAATGG
CACACAUCACAAUGGCGG
UCCGCCAUUGUGAU
430/431/432



regulatory light

CGGATA
A
GUGUG




chain










0135
Myosin
ise2c.pk001.d21 
AAGGATGGCATCATCGG
GGAUGGCAUCAUCGGCAA
CUUGCCGAUGAUGC
433/434/435



regulatory light

CAAGAA
G
CAUCC




chain










0136
Myosin
ise2c.pk001.d21 
AAAGGCTTCATCGACAC
AGGCUUCAUCGACACCGC
CGCGGUGUCGAUGA
436/437/438



regulatory light

CGCGAA
G
AGCCU




chain










0137
novel sequence
ise2c.pk001.j9
AAACTCCAATTATAACCT
ACUCCAAUUAUAACCUAC
AGUAGGUUAUAAUU
210/211/212





ACTAG
U
GGAGU






0138
novel sequence
ise2c.pk001.j9
AAGTACAAGGATCTGAT
GUACAAGGAUCUGAUCGG
GCCGAUCAGAUCCU
213/214/215





CGGCAA
C
UGUAC






0139
novel sequence
ise2c.pk001.j9
AAGACTTTCTTCATGTGG
GACUUUCUUCAUGUGGCC
GGGCCACAUGAAGA
216/217/218





CCCAT
C
AAGUC






0140
novel sequence
ise2c.pk002.f12
AAACAAAGTATCGCCTA
ACAAAGUAUCGCCUACAC
GGUGUAGGCGAUAC
439/440/441





CACCGC
C
UUUGU






0141
novel sequence
ise2c.pk002.f12 
AATAGCGTCGATCTTCAA
UAGCGUCGAUCUUCAACG
UCGUUGAAGAUCGA
442/443/444





CGACT
A
CGCUA






0142
potassium
ise2c.pk001.b14
AACTCATAGAGCTTGATG
CUCAUAGAGCUUGAUGUG
ACACAUCAAGCUCU
219/220/221



coupled amino

TGTGG
U
AUGAG




acid transporter










0143
potassium
ise2c.pk001.b14
AAGATGTGGATGACGTC
GAUGUGGAUGACGUCACU
CAGUGACGUCAUCC
222/223/224



coupled amino

ACTGGT
G
ACAUC




acid transporter










0144
potassium
ise2c.pk001.b14 
AACCTTCCTGATTCTCTT
CCUUCCUGAUUCUCUUCU
CAGAAGAGAAUCAG
225/226/227



coupled amino

CTGTG
G
GAAGG




acid transporter










0145
inwardly
ise2c.pk003.f2
AACAGTGCTTGTGATAA
CAGUGCUUGUGAUAAGUG
UCACUUAUCACAAG
228/229/230



rectifying K +

GTGAAC
A
CACUG




channel protein










0146
inwardly
ise2c.pk003.f2
AAGTTAATGGTGACTGCC
GUUAAUGGUGACUGCCCU
GAGGGCAGUCACCA
231/232/233



rectifying K +

CTCGA
C
UUAAC




channel protein







0147
inwardly
ise2c.pk003.f2
AATAAAGCGATGACCCC
UAAAGCGAUGACCCCAUA
CUAUGGGGUCAUCG
234/235/236



rectifying K +

ATAGGA
G
CUUUA




channel protein







0148
potassium
ise2c.pk005.l20 
AAACGGTACTGCAGCAA
ACGGUACUGCAGCAAAAA
CUUUUUGCUGCAGU
237/238/239



coupled amino

AAAGAC
G
ACCGU




acid transporter







0149
potassium
ise2c.pk005.l20
AAGCTGCATACTTCTTGG
GCUGCAUACUUCUUGGCU
GAGCCAAGAAGUAU
240/241/242



coupled amino

CTCTC
C
GCAGC




acid transporter







0150
potassium
ise2c.pk005.120
AAATGTTTACAGAGACG
AUGUUUACAGAGACGCGA
AUCGCGUCUCUGUA
243/244/245



coupled amino

CGATGA
U
AACAU




acid transporter










0151
alpha tubulin
ise2c.pk001.d1
AACGTCGATCTTACCGAG
CGUCGAUCUUACCGAGUU
GAACUCGGUAAGAU
246/247/248





TTCCA
C
CGACG






0152
tubulin alpha
ise2c.pk001.k6
AATTCAAAATGCGTGAG
UUCAAAAUGCGUGAGUGC
UGCACUCACGCAUU
249/250/251



chain

TGCATC
A
UUGAA






0153
tubulin alpha
ise2c.pk001.k6
AAATCGTAGACCTAGTCC
AUCGUAGACCUAGUCCUC
CGAGGACUAGGUCU
252/253/254



chain

TCGAC
G
ACGAU






0154
tubulin alpha
ise2c.pk001.l2
AAACTCAATTCAAAATG
ACUCAAUUCAAAAUGCGU
CACGCAUUUUGAAU
255/256/257



chain

CGTGAG
G
UGAGU






0155
tubulin alpha
ise2c.pk001.l2
AACTTATCACTGGTAAGG
CUUAUCACUGGUAAGGAA
CUUCCUUACCAGUG
258/259/260



chain

AAGAT
G
AUAAG






0156
ubiquitin kinase
ise2c.pk002.b4
AAGAGTTACGAACCGTC
GAGUUACGAACCGUCACC
UGGUGACGGUUCGU
261/262/263





ACCATA
A
AACUC



0157
ubiquitin kinase
ise2c.pk002.b4
AAACTTAGTCCGGATAAT
ACUUAGUCCGGAUAAUGA
UUCAUUAUCCGGAC
264/265/266





GAACC
A
UAAGU



0158
ubiquitin kinase
ise2c.pk002.b4
AAGGCGATGTACGAGAA
GGCGAUGUACGAGAACCU
CAGGUUCUCGUACA
267/268/269





CCTGTT
G
UCGCC



0159
nuclear
ise2c.pk001.j16
AACGACAAGATGCTGAA
CGACAAGAUGCUGAAGGA
CUCCUUCAGCAUCU
270/271/272



ribonucleoprotein 

GGAGAC
G
UGUCG




200 kDa








helicase










0160
Sqd protein
ise2c.pk006.h23
AAGATAAAGGTCGCGTG
GAUAAAGGUCGCGUGUGG
UCCACACGCGACCU
273/274/275



homologue

TGGACC
A
UUAUC




(RNA binding)










0161
Sqd protein
ise2c.pk006.h23
AATGTCAAGACTGATCC
UGUCAAGACUGAUCCAAA
GUUUGGAUCAGUCU
276/277/278



homologue

AAACAC
C
UGACA




(RNA binding)










0162
Sqd protein
ise2c.pk006.h23
AACATTCGAGTCTGAAC
CAUUCGAGUCUGAACAGG
ACCUGUUCAGACUC
279/280/281



homologue

AGGTGG
U
GAAUG




(RNA binding)










0163
pre-mRNA-
ise2c.pk006.m8
AACATAAGTCATGGCCA
CAUAAGUCAUGGCCAAUA
UUAUUGGCCAUGAC
282/283/284



binding protein

ATAACG
A
UUAUG






0164
pre-mRNA-
ise2c.pk006.m8
AAGAACATAATAGTGCC
GAACAUAAUAGUGCCGAA
CUUCGGCACUAUUA
285/286/287



binding protein

GAAGCC
G
UGUUC






0165
pre-mRNA-
ise2c.pk006.m8
AAACACTGGCAGATCAA
ACACUGGCAGAUCAAGAG
CCUCUUGAUCUGCC
288/289/290



binding protein

GAGGAT
G
AGUGU






0166
pre-mRNA-
ise2c.pk006.m8
AAGATCTTTGTTGGTGGT
GAUCUUUGUUGGUGGUCU
AAGACCACCAACAA
291/292/293



binding protein

CTTAG
U
AGAUC






0167
pre-mRNA-
ise2c.pk006.m8
AACAGGTGGTCAATGAG
CAGGUGGUCAAUGAGCUG
GCAGCUCAUUGACC
294/295/296



binding protein

CTGCTG
C
ACCUG






0168
chymotrypsin-
ise2c.pk001.a23
AAGTTGGCTCTGACACTC
GUUGGCUCUGACACUCUU
CAAGAGUGUCAGAG
297/298/299



like; protease

TTGGC
G
CCAAC






0169
chymotrypsin-
ise2c.pk001.a23
AAATCCGCAAAGCTGAG
AUCCGCAAAGCUGAGGAG
CCUCCUCAGCUUUG
300/301/302



like; protease

GAGGCA
G
CGGAU






0170
chymotrypsin-
ise2c.pk001.a23
AACCGTGTTCTTACTGCT
CCGUGUUCUUACUGCUGC
AGCAGCAGUAAGAA
303/304/305



like; protease

GCTCA
U
CACGG






0171
chymotrypsin-
ise2c.pk001.a23
AACGTTGTTATGCATGGA
CGUUGUUAUGCAUGGAAG
GCUUCCAUGCAUAA
306/307/308



like; protease

AGCTG
C
CAACG






0172
chymotrypsin-
ise2c.pk001.a23
AAAACTTCGCCGGTGAA
AACUUCGCCGGUGAAAAC
CGUUUUCACCGGCG
309/310/311



like; protease

AACGCC
G
AAGUU






0173
chymotrypsinogen; 
ise2c.pk001.a7
AAATGAAACTGTTCCTCG
AUGAAACUGUUCCUCGCA
CUGCGAGGAACAGU
312/313/314



protease

CAGTC
G
UUCAU






0174
chymotrypsinogen; 
ise2c.pk001.a7
AAGAAGGCTGAGGAAGA
GAAGGCUGAGGAAGAAAC
GGUUUCUUCCUCAG
315/316/317



protease

AACCAG
C
CCUUC






0175
chymotrypsinogen; 
ise2c.pk001.a7
AACTCTTTCACCGTCGTA
CUCUUUCACCGUCGUACU
AAGUACGACGGUGA
318/319/320



protease

CTTGG
U
AAGAG






0176
chymotrypsinogen; 
ise2c.pk001.a7
AACGACATTGCTGTCCTC
CGACAUUGCUGUCCUCCGC
GCGGAGGACAGCAA
321/322/323



protease

CGCAT

UGUCG






0177
chymotrypsinogen; 
ise2c.pk001.a7
AACATCGGTACTACCCA
CAUCGGUACUACCCAACG
ACGUUGGGUAGUAC
324/325/326



protease

ACGTGT
U
CGAUG






0178
actin-
ise2c.pk004.c4
AAGACTCAGTACGTATTA
GACUCAGUACGUAUUAUC
CGAUAAUACGUACU
327/328/329



depolymerizing

TCGCG
G
GAGUC






0179
actin-
ise2c.pk004.c4
AAGTTGCCATCTTGCTTT
GUUGCCAUCUUGCUUUUG
GCAAAAGCAAGAUG
330/331/332



depolymerizing

TGCAA
C
GCAAC






0180
actin-
ise2c.pk004.c4
AATCAGTTTGACGCATGC
UCAGUUUGACGCAUGCGC
AGCGCAUGCGUCAA
333/334/335



depolymerizing

GCTCA
U
ACUGA






0181
actin-
ise2c.pk004.c4
AATGGCGTCTGGTGTGAC
UGGCGUCUGGUGUGACAG
ACUGUCACACCAGA
336/337/338



depolymerizing

AGTTT
U
CGCCA






0182
actin-
ise2c.pk004.c4
AACGCGGAATACGATCA
CGCGGAAUACGAUCAGUU
GAACUGAUCGUAUU
339/340/341



depolymerizing

GTTCCT
C
CCGCG






0183
actin
ise2c.pk004.l4
AAGACTCAGTACGTATTA
GACUCAGUACGUAUUAUC
CGAUAAUACGUACU
342/343/344



depolymerizing

TCGCG
G
GAGUC




factor










0184
actin
ise2c.pk004.l4
AAGTTGCCATCTTGCTTT
GUUGCCAUCUUGCUUUUG
GCAAAAGCAAGAUG
345/346/347



depolymerizing

TGCAA
C
GCAAC




factor










0185
actin
ise2c.pk004.l4
AATCAGTTTGACGCATGC
UCAGUUUGACGCAUGCGC
AGCGCAUGCGUCAA
348/349/350



depolymerizing

GCTCA
U
ACUGA




factor










0186
actin
ise2c.pk004.l4
AAAAATGGCGTCTGGTG
AAAUGGCGUCUGGUGUGA
GUCACACCAGACGC
351/352/353



depolymerizing

TGACAG
C
CAUUU




factor










0187
actin
ise2c.pk004.l4
AATACGATCAGTTCCTTG
UACGAUCAGUUCCUUGAG
CCUCAAGGAACUGA
354/355/356



depolymerizing

AGGAT
G
UCGUA




factor










0188
dismutase;
ise2c.pk004.n19
AATAATTTGTGTCATACC
UAAUUUGUGUCAUACCCU
UAGGGUAUGACACA
357/358/359



superoxide

CTACG
A
AAUUA






0189
dismutase;
ise2c.pk004.n19
AAGTCAGTGACTGGTCA
GUCAGUGACUGGUCAAAU
AAUUUGACCAGUCA
360/361/362



superoxide

AATTCA
U
CUGAC






0190
dismutase;
ise2c.pk004.n19
AATTAGGAGATGTTGCA
UUAGGAGAUGUUGCACCU
CAGGUGCAACAUCU
363/364/365



superoxide

CCTGGT
G
CCUAA






0191
dismutase;
ise2c.pk004.n19
AACAAACGGATGACCTA
CAAACGGAUGACCUAGGU
AACCUAGGUCAUCC
366/367/368



superoxide

GGTTTG
U
GUUUG






0192
dismutase;
ise2c.pk004.n19
AATGCTGCTAGCTCTATG
UGCUGCUAGCUCUAUGUC
AGACAUAGAGCUAG
369/370/371



superoxide

TCTCC
U
CAGCA






0193
superoxide
ise2c.pk005.f21
AATTTGTGTCATACCCTA
UUUGUGUCAUACCCUACG
GCGUAGGGUAUGAC
372/373/374



dismutase

CGCAA
C
ACAAA






0194
superoxide
ise2c.pk005.f21
AAAAGGGCTTCATGTCG
AAGGGCUUCAUGUCGAAG
CCUUCGACAUGAAG
375/376/377



dismutase

AAGGAG
G
CCCUU






0195
superoxide
ise2c.pk005.f21
AATTAGGAGATGTTGCA
UUAGGAGAUGUUGCACCU
CAGGUGCAACAUCU
378/379/380



dismutase

CCTGGT
G
CCUAA






0196
adenylate kinase
ise2c.pk010.h5
AAAGGTCAGTAACTATG
AGGUCAGUAACUAUGAGU
CACUCAUAGUUACU
381/382/383



isozyme 3

AGTGGT
G
GACCU






0197
adenylate kinase
ise2c.pk010.h5
AAGAAATATGCTGTGGC
GAAAUAUGCUGUGGCACA
GUGUGCCACAGCAU
384/385/386



isozyme 3

ACACGT
C
AUUUC






0198
adenylate kinase
ise2c.pk010.h5
AACTTGTACCTGATGATG
CUUGUACCUGAUGAUGUC
UGACAUCAUCAGGU
387/388/389



isozyme 3

TCATG
A
ACAAG






0199
adenylate kinase
ise2c.pk010.h5
AACATTGGCTTCAACACT
CAUUGGCUUCAACACUCC
AGGAGUGUUGAAGC
390/391/392



isozyme 3

CCTAA
U
CAAUG






0200
adenylate kinase
ise2c.pk010.h5
AAGCGGCTGGAGATCTA
GCGGCUGGAGAUCUAUGA
CUCAUAGAUCUCCA
393/394/395



isozyme 3

TGAGAG
G
GCCGC






0201
ecdysone
ise2c.pk001.c18
AACCCTCCCGAGGAGAG
CCCUCCCGAGGAGAGCAU
AAUGCUCUCCUCGG
396/397/398



oxidase

CATTAT
U
GAGGG






0202
ecdysone
ise2c.pk001.c18
AACGCCCTACGACTGGA
CGCCCUACGACUGGAACU
AAGUUCCAGUCGUA
399/400/401



oxidase

ACTTCA
U
GGGCG






0203
ecdysone
ise2c.pk001.c18
AACTGGACCAACGTGCT
CUGGACCAACGUGCUGGA
GUCCAGCACGUUGG
402/403/404



oxidase

GGACTA
C
UCCAG






0204
innexin-2
ise2c.pk004.p1
AAAACATGGGAAGGAGG
AACAUGGGAAGGAGGUCG
GCGACCUCCUUCCC
405/406/407





TCGCAT
C
AUGUU






0205
innexin-2
ise2c.pk004.p1
AAGTTGCTTGTGGACTAC
GUUGCUUGUGGACUACUU
GAAGUAGUCCACAA
408/409/410





TTCCA
C
GCAAC






0206
innexin-2
ise2c.pk004.p1
AACGTCGTGGGCCAGAT
CGUCGUGGGCCAGAUCUU
GAAGAUCUGGCCCA
411/412/413





CTTCTT
C
CGACG






0207
innexin-2
ise2c.pk004.p1
AATACGGTCCTTCAGGA
UACGGUCCUUCAGGAACC
CGGUUCCUGAAGGA
415/416/417





ACCGTG
G
CCGUA






0208
innexin-2
ise2c.pk004.p1
AATTTCGCTGATTTACCG
UUUCGCUGAUUUACCGCA
AUGCGGUAAAUCAG
418/419/420





CATGG
U
CGAAA





(Note: the sense RNA primer sequence and the antisense RNA primer sequences shown in table 2 were generated with 2 thymine residues at the 3′ end.)







Droplet Feeding Assay for Evaluation of 21mer dsRNA Insecticidal Properties Against the Fall armyworm Spodoptera frugiperda


10 nanoMole quantities of 21mer desalted primers were purchased from Proligo (Sigma Aldrich, St. Louis, Miss.). The lyophilized sample is solubilized in nuclease free water at a 100uMolar concentration. The stock solution was then diluted in 20% sucrose containing blue McCormick food coloring. 0.5 ul droplets of this solution were dispensed in a circle in a parafilm-lined 65 mm petridish. Sucrose blanks were used as controls. Between 20 and 30 neonate fall armyworms were then added to the middle of the droplet circle and the petri dish sealed with parafilm. After two hours, the neonates with blue digestive tracts were removed and placed on standard multispecies lepidopteran insect diet. Insects were evaluated at 48, 72, and 96 hours post challenge for mortality and growth inhibition.


Serial dilution assays starting with a high dose of 20 uM and including 10, 5, 2.5, 1.25, 0.6, and 0 uMolar concentrations were also performed in this manner.













TABLE 3









Rep 1
Rep 2

















72 H

72 H





Insects
ave.
Insects
ave.
Combined


Primer #
Target gene
treated
weight
treated
weight
ave.
















75
juvenile hormone diol kinase
9
10
11
11
11


83
juvenile hormone diol kinase
15
14
14
12
13


91
V-ATPase A subunit
14
14
11
15
14


99
conserved hypothetical
16
15
19
16
16



protein


107
novel sequence (cuticular
16
14
13
15
14



protein?)


115
Eukaryotic initiation factor 4A
16
9
18
14
12


123
putative sar1 protein
16
15
16
17
16


131
Oligosaccharyl transferase
17
13
14
15
14



48 kDa subunit


139
myosin protein
13
15
16
18
17


147
inwardly rectifying K+
15
11
15
16
14



channel protein


155
alpha tubulin chain
15
10
16
19
15



sucrose control
14
17
15
18
18









Sucrose Droplet Feeding Assay.

Neonate larvae were fed 25 uMolar dsRNAs. Treated insects were weighed en masse at 72 hours and compared to sucrose controls. 2 replicates of the experiment were averaged.


Injection Feeding Assay for Evaluation of 21mer dsRNA Insecticidal Properties Against the Fall armyworm Spodoptera frugiperda


Second instar fall armyworm were injected using a micromanipulator and microinjection needles pulled on a Sutter Instrument (Novato, Calif.) P-2000 horizontal needle puller. The needle was back loaded with dsRNA solution. Initial injection experiments employed a concentration of 2 ug/ul (see Table X). This rate produced high mortality across all primers tested. Subsequent assays were performed with lower concentrations. Blue McCormick food coloring was included in the dsRNA solution to better visualize the injection process. Prior to injection, the insects were affixed to a microscope slide using a glue stick (Office Depot, Delray Beach, Fla.). The injection needle was connected to a 20 ml hypodermic syringe via Teflon tubing. The injection needle was then mounted on a Leitz micromanipulator. The dsRNA solution was dispensed from the microinjection needle by pressing on the plunger of the 20 ml syringe. Injection volumes were variable but averaged approximately 250 nL (based on injection of approximately 20 insects injected from a 5u1 volume loaded into the needle). Following injection, insects were removed from the microscope slide with the aid of a moistened fine camelhair brush. The insects were then placed on multispecies diet and were evaluated for mortality at 24 and 48 hours. Water injections were used as controls. Silencer® Negative Control #1, 2, and 3 siRNA control primers from Ambion (Austin, Tex.) were also included as negative controls.













TABLE 4





Primer #
Target gene
No. injected
Alive
Dead



















75
juvenile hormone diol kinase
6
0
6


83
juvenile hormone diol kinase
6
0
6


91
V-ATPase A subunit
8
3
5


99
conserved hypothetical sequence
8
0
8


107
novel sequence (cuticular protein
8
0
8


115
Eukaryotic initiation factor 4A
8
0
8


123
putative sar1 protein
8
1
8


131
Oligosaccharyl transferase
8
2
8



48 kDa subunit


147
inwardly rectifying K+ channel
8
1
7



protein



Water
8
7
1





Microinjection of dsRNAs [2 ug/ul].










Microinjection Assay using 0.7 ug/ul dose of dsRNA 21mers. Note; On some occasions, the mortality was lower at 48 hours than at 24 hours. This is due to moribund insects recovering at the later time point.


Topical Diet Assay for Evaluation of 21Mer dsRNA Insecticidal Properties Against the Fall armyworm Spodoptera frugiperda


The term “topical diet assay” refers to assays where artificial diets are pipetted into microtiter plates and the dsRNA solution is dispensed on the surface of the diet. In the dsRNA experiments, 100 ul of diet was dispensed per well. The surface of the well was then treated with 10 ul of a dsRNA solution of varying concentrations. The plates were then infested with 1 neonate fall armyworm per well and sealed with mylar. The mylar seal was punctured with a small insect pin to allow for air exchange. Plates were then stored in a growth chamber at 28C and the assay was scored for stunting or mortality at 4 days. Table 6-12 represents several experiments using this method. Table 13 provides a summary of the data.


In topical assay #1, the primers that previously showed activity in injection assays were tested in a FAW topical diet assay. These results are shown in Table 6. A 50uMolar solution (0.66 ug/ul) was used as the test concentration. 5 ul of this sample was loaded onto the top of 100 ul of diet producing a final concentration of 2.5uMolar or 30 ppm. In addition to A1-A11 (A12 is a negative control), the other samples are those with no known human orthologs. The plate was infested with aprox. 5 neonates/well. The scoring period was 72 hours.


In topical assay #2, primers were tested in a FAW topical diet assay, and the results are shown in table 7. In this experiment, the 2.7 ug/ul stock was diluted to a starting concentration of 0.67 ug/ul. 2 fold serial dilution was carried out to produce stocks of 0.32 ug/ul and 0.16 ug/ul. 5 ul of these stocks were added to the 100 ul of diet producing final concentrations of 30, 15, and 8 ppm in diet. The scoring period was 72 hours.


In topical assay #3, primers were tested in a FAW topical diet assay, and the results are shown in table 8. In this experiment, the 2.7 ug/ul stock was diluted to a starting concentration of 0.67 ug/ul. 2 fold serial dilution was carried out to produce stocks of 0.32 ug/ul and 0.16 ug/ul. 5 ul of these stocks were added to the 100 ul of diet producing final concentrations of 30, 15, and 8 ppm in diet. This is a replicate of the previous experiment. The scoring period was 72 hours.


In topical assay #4, primers were tested in a FAW topical diet assay, and the results are shown in table 9. In this experiment, the 2.7 ug/ul stock was diluted to a starting concentration of 0.67 ug/ul. 2 fold serial dilution was carried out to produce stocks of 0.32 ug/ul and 0.16 ug/ul. 5 ul of these stocks were added to the 100 ul of diet producing final concentrations of 30, 15, and 8 ppm in diet. The scoring period was 72 hours.


A summary of the topical assay data shown in tables 6-9 appears in Table 10.


In topical assay #5, primers were tested in a FAW topical diet assay and the results are shown in Table 11. 50 ul of 0.16 ug/ul primers were mixed with 50 ul water and then serially diluted. 10 ul of the sample then added to the wells. Therefore the first concentration was 10 ul×0.08 ug/ul=0.8 ug total dsRNA/100 ul diet=8 ppm. This was ½ the rate of previous experiments (assays #1-4) where 5 ul of 0.32 showed activity. The scoring period was 72 hours. A score of “S” indicates clear stunting compared to untreated controls. A score of “ss” indicates live insects but exhibiting severe stunting defined as little or no growth beyond the neonate body size.


In topical assay #6, primers were tested in a FAW topical diet assay and the results are shown in Table 12. The first rate is 10 ul of the 0.16 ug/ul primer stock. From there, 50 ul of 0.16 ug/ul primer mixed with 50 ul water and then serially diluted. 10 ul of the sample was then added to the wells. Therefore first concentration was 10 ul×0.16 ug/ul=1.6 ug total dsRNA/100 ul diet=16 ppm. The scoring period was 72 hours.
















TABLE 6












SEQ ID NO








30
Target region


Sample
seq id
gene id
Target sequence
forward
reverse
ppm
sense/antisense






















0075
ise1c.pk002.m13
Juvenile
AACATGGTATCCGA
CAUGGUAUCCGA
CCUGAAGUCGG

51/52/53




hormone
CTTCAGGAA
CUUCAGG
AUACCAUG






query










0083
ise1c.pk005.a15
Juvenile
AAGTTCGCGTTCAC
GUUCGCGUUCAC
UUCAAGAGUGA
+
75/76/77




hormone
TCTTGAAGA
UCUUGAA
ACGCGAAC






query










0085
ise1c.pk006.d24
Juvenile
AATCACGCTGAAAC
UCACGCUGAAAC
UACAGUGGUUU
+
81/82/83




hormone
CACTGTATA
CACUGUA
CAGCGUGA






query










0086
ise2c.pk009.i4
Juvenile
AAAATATGGCGCGC
AAUAUGGCGCGC
ACAAUAGGCGC

84/85/86




hormone
CTATTGTTT
CUAUUGU
GCCAUAUU






query










0088
ise2c.pk009.i5
Juvenile
AAGTCATCGTTCCA
GUCAUCGUUCCA
GUAGACUUGGA
+
90/91/92




hormone
AGTCTACCT
AGUCUAC
ACGAUGAC






query










0089
ise2c.pk001.d19
vacuolar
AACCCCTTGAATGT
CCCCUUGAAUGU
GACCUUAACAU
+
93/94/95




query
TAAGGTCGG
UAAGGUC
UCAAGGGG







0091
ise2c.pk001.d20
vacuolar
AACGTGTCCATGAT
CGUGUCCAUGAU
GUCAGCCAUCA
+
99/100/101




query
GGCTGACTC
GGCUGAC
UGGACACG







0094
ise2c.pk001.f20
vacuolar
AACTCTGACGTCAT
CUCUGACGUCAU
GUAGAUGAUGA
+
108/109/110




query
CATCTACGT
CAUCUAC
CGUCAGAG







0095
ise2c.pk001.f21
vacuolar
AAGTGCTTGGGTAA
GUGCUUGGGUAA
GUCGGGGUUAC
+
111/112/113




query
CCCCGACAG
CCCCGAC
CCAAGCAC







0099
ise2c.pk010.h3
cadherin
AACACCATGACCCT
CACCAUGACCCU
GUACACGAGGG

123/124/125




query
CGTGTACAA
CGUGUAC
UCAUGGUG







0107
ise2c.pk011.h12
cuticle
AAGGATCCTATGTG
GGAUCCUAUGUG
CCUGGUACACA
+
138/139/140




protein
TACCAGGTT
UACCAGG
UAGGAUCC







0115
ise2c.pk001.i23
Translation
AATTCTTCAGCAAA
UUCUUCAGCAAA
GUAUCGAUUUG
+
162/163/164




initiation
TCGATACCA
UCGAUAC
CUGAAGAA






factor










0123
ise2c.pk002.m10
SAR1
AAAATCGTCGGTTT
AAUCGUCGGUUU
GUCGCUAAAAC

186/187/188





TAGCGACGT
UAGCGAC
CGACGAUU







0131
ise2c.pk005.h3
phospho-
AATTTGTGAGACTG
UUUGUGAGACUG
CGGCCACCAGU

421/422/423




oligosacc-
GTGGCCGAA
GUGGCCG
CUCACAAA






aride . . .










0139
ise2c.pk001.j9
Myosin
AAGACTTTCTTCAT
GACUUUCUUCAU
GGGCCACAUGA

216/217/218





GTGGCCCAT
GUGGCCC
AGAAAGUC







0147
ise2c.pk003.f2
Potassium
AATAAAGCGATGAC
UAAAGCGAUGAC
CUAUGGGGUCA
+
234/235/236




inwardly
CCCATAGGA
CCCAUAG
UCGCUUUA






rectifying









protein










0155
ise2c.pk001.12
Tubulin
AACTTATCACTGGT
GUUAUCACUGGU
CUUCCUUACCA
+
258/259/260





AAGGAAGAT
AAGGAAG
GUGAUAAG





(Note: the sense RNA primer sequence and the antisen RNA primer sequences shown in table 6 were generated with 2


thymine at the 3′ end.)




















TABLE 7












SEQ ID NO








30
Target region/


Sample
seq id
gene id
Target sequence
forward
reverse
ppm
sense/antisense






















0075
ise1c.pk00
Juvenile
AACATGGTATCCGAC
CAUGGUAUCCGA
CCUGAAGUCGGA

51/52/53



2.m13
hormone
TTCAGGAA
CUUCAGG
UACCAUG






query










0076


AAGGTCGCTGACGAG
GGUCGCUGACGA
CUUGUUCUCGUC

54/55/56





AACAAGGA
GAACAAG
AGCGACC







0077


AAGTGTCCTGGGCTT
GUGUCCUGGGCU
GAACUCAAGCCC

57/58/59





GAGTTCCA
UGAGUUC
AGGACAC







0078
ise1c.pk00
Juvenile
AAGAAGAAGCTCCTC
GAAGAAGCUCCU
CACGUGGAGGAG

60/61/62



3.f7
hormone
CACGTGTT
CCACGUG
CUUCUUC






query










0079


AAGGTCGCTGACGAG
GGUCGCUGACGA
CUUGUUCUCGUC

63/64/65





AACAAGGA
GAACAAG
AGCGACC







0080


AATGTCCTGGGGCTG
UGUCCUGGGGCU
GAAACUCAGCCC

66/67/68





AGTTTCAA
GAGUUUC
CAGGACA







0081
ise1c.pk00
Juvenile
AAGAATAAGCTCCTC
GAAUAAGCUCCU
CACGUGGAGGAG

69/70/71



5.a15
hormone
CACGTGTT
CCACGUG
CUUAUUC






query










0082


AATTTGTCGAGGAGA
UUUGUCGAGGAG
AUAGGGUCUCCU

72/73/74





CCCTATTG
ACCCUAU
CGACAAA







0083


AAGTTCGCGTTCACT
GUUCGCGUUCAC
UUCAAGAGUGAA
+
75/76/77





CTTGAAGA
UCUUGAA
CGCGAAC







0084
ise1c.pk00
Juvenile
AACTGCCCCTTAACC
CUGCCCCUUAAC
AGAUGAGGUUAA
+
78/79/80



6.d24
hormone
TCATCTAT
CUCAUCU
GGGGCAG






query










0085


AATCACGCTGAAACC
UCACGCUGAAAC
UACAGUGGUUUC

81/82/83





ACTGTATA
CACUGUA
AGCGUGA







0086
ise2c.pk00
Juvenile
AAAATATGGCGCGCC
AAUAUGGCGCGC
ACAAUAGGCGCG

84/85/86



9.i4
hormone
TATTGTTT
CUAUUGU
CCAUAUU






query










0087


AACGTTCTCGGTCTT
CGUUCUCGGUCU
CAGUGAAAGACC

87/88/89





TCACTGCT
UUCACUG
GAGAACG







0088


AAGTCATCGTTCCAA
GUCAUCGUUCCA
GUAGACUUGGAA

90/91/92





GTCTACCT
AGUCUAC
CGAUGAC







0089
ise2c.pk00
vacuolar
AACCCCTTGAATGTT
CCCCUUGAAUGU
GACCUUAACAUU

93/94/95



1.d19
query
AAGGTCGG
UAAGGUC
CAAGGGG







0090


AAGTACACCATGTTG
GUACACCAUGUU
UACUUGCAACAU

96/97/98





CAAGTATG
GCAAGUA
GGUGUAC







0091


AACGTGTCCATGATG
CGUGUCCAUGAU
GUCAGCCAUCAU

99/100/101





GCTGACTC
GGCUGAC
GGACACG







0092
ise2c.pk00
vacuolar
AAACCTACAAAATGG
ACCUACAAAAUG
UUUCGGCCAUUU

102/103/104



1.e14
query
CCGAAAAC
GCCGAAA
UGUAGGU







0093


AATCTACGGACCCTT
UCUACGGACCCU
CCAAAGAAGGGU

105/106/107





CTTTGGAG
UCUUUGG
CCGUAGA







0094
ise2c.pk00
vacuolar
AACTCTGACGTCATC
CUCUGACGUCAU
GUAGAUGAUGAC

108/109/110



1.f20
query
ATCTACGT
CAUCUAC
GUCAGAG







0095


AAGTGCTTGGGTAAC
GUGCUUGGGUAA
GUCGGGGUUACC

111/112/113





CCCGACAG
CCCCGAC
CAAGCAC







0096


AACTGGCTCATCTCC
CUGGCUCAUCUC
GCUGUAGGAGAU

114/115/116





TACAGCAA
CUACAGC
GAGCCAG







0097
ise2c.pk01
cadherin
AAACAGTGCGTCGTA
ACAGUGCGUCGU
AUAUAUUACGAC

117/118/119



0.h3
query
ATATATTC
AAUAUAU
GCACUGU







0098


AAGGCACATGGTCCT
GGCACAUGGUCC
CAGUGAAGGACC
+
120/121/122





TCACTGAT
UUCACUG
AUGUGCC







0099


AACACCATGACCCTC
CACCAUGACCCU
GUACACGAGGGU

123/124/125





GTGTACAA
CGUGUAC
CAUGGUG







0100
ise2c.pk00
cuticle
AACGAGGCCGGATCT
CGAGGCCGGAUC
CUUAAGAGAUCC

457/458/459



7.k24
protein
CTTAAGCA
UCUUAAG
GGCCUCG







0101


AACTTCACACATAAC
CUUCACACAUAA
UGUCUAGUUAUG

460/461/462





TAGACAAA
CUAGACA
UGUGAAG







0102


AATGCGTGGCGATTT
UUAGAAAUUAUA
CUGGGCUUAUAA

463/464/465





CAAACTTA
AGCCCAG
UUUCUAA







0103
ise2c.pk01
cuticle
AAAAAACACAGACCA
AAAACACAGACC
UGAACGUGGUCU
+
126/127/128



1.a10
protein
CGTTCACA
ACGUUCA
GUGUUUU







0104


AATCGATGGTGGTGT
UCGAUGGUGGUG
CGAAUAACACCA
+
129/130/131





TATTCGCT
UUAUUCG
CCAUCGA







0105
ise2c.pk01
cuticle
AAAGAAAATGCTACG
AGAAAAUGCUAC
GUAACGCGUAGC

132/133/134



1.h12
protein
CGTTACGA
GCGUUAC
AUUUUCU







0106


AACCCTTGGACACTA
CCUUGGACACUA
UUCCAGUAGUGU
+
135/136/137





CTGGAAGA
CUGGAA
CCAAGGG







0107


AAGGATCCTATGTGT
GGAUCCUAUGUG
CCUGGUACACAU

138/139/140





ACCAGGTT
UACCAGG
AGGAUCC







0108
ise2c.pk00
translation
AAACTCGGCACACAA
ACUCGGCACACA
AUUGUGUUGUGU

141/142/143



1.d22
initiation
CACAATGG
ACACAAU
GCCGAGU






factor










0109


AATACGAAGATATCT
UACGAAGAUAUC
AAGGGCAGAUAU
+
144/145/146





GCCCTTCC
UGCCCUU
CUUCGUA







0110


AATCAACAGCTCTTA
UCAACAGCUCUU
UUUAUGUAAGAG

147/148/149





CATAAATG
ACAUAAA
CUGUUGA







0111
ise2c.pk00
translation
AAAGAAGATCAGAAG
AGAAGAUCAGAA
GCCAAUCUUCUG

150/151/152



1.d9
initiation
ATTGGCCG
GAUUGGC
AUCUUCU






factor










0112


AAAAGCCGTCTGCTA
AAGCCGUCUGCU
GUUGGAUAGCAG
+
153/154/155





TCCAACAA
AUCCAAC
ACGGCUU







0113


AATGCTAAATGCCAT
UGCUAAAUGCCA
GCAAGCAUGGCA

156/157/158





GCTTGCAT
UGCUUGC
UUUAGCA







0114
ise2c.pk00
translation
AAGATCAGAAGATTG
GAUCAGAAGAUU
UCCGGCCAAUCU
+
159/160/161



1.i23
initiation
GCCGGAAG
GGCCGGA
UCUGAUC






factor










0115


AATTCTTCAGCAAAT
UUCUUCAGCAAA
GUAUCGAUUUGC

162/163/164





CGATACCA
UCGAUAC
UGAAGAA







0116


AAATGCTGTCAAGAG
AUGCUGUCAAGA
UAAAUCCUCUUG

165/166/167





GATTTAAA
GGAUUUA
ACAGCAU







0117
ise2c.pk00
translation
AAGCTCGAGACTTGC
GCUCGAGACUUG
UCAAGAGCAAGU

168/169/170



1.124
initiation
TCTTGATG
CUCUUGA
CUCGAGC






factor










0118


AACTGTTAGCTCAAG
CUGUUAGCUCAA
GCAGACCUUGAG

171/172/173





GTCTGCTA
GGUCUGC
CUAACAG







0119


AAGACTTTCTATCAG
GACUUUCUAUCA
CAAAUUCUGAUA
+
174/175/176





AATTTGCG
GAAUUUG
GAAAGUC







0120
ise2c.pk00
translation
AAACTTAATCATGGA
ACUUAAUCAUGG
UCGUCGUCCAUG

177/178/189



5.b9
initiation
CGACGACA
ACGACGA
AUUAAGU






factor










0121


AAAGAAGAAGAAGAA
AGAAGAAGAAGA
CCCUUCUUCUUC
+
180/181/182





GAAGGGAG
AGAAGGG
UUCUUCU







0122


AAGATCAAGAGAATG
GAUCAAGAGAAU
CCUCGACAUUCU
+
183/184/185





TCGAGGAT
GUCGAGG
CUUGAUC







0123
ise2c.pk00
SAR1
AAAATCGTCGGTTTT
AAUCGUCGGUUU
GUCGCUAAAACC

186/187/188



2.m10

AGCGACGT
UAGCGAC
GACGAUU







0124


AACTGTCAATAGGCA
CUGUCAAUAGGC
GCAUACUGCCUA

189/190/191





GTATGCGT
AGUAUGC
UUGACAG







0125


AACCTGTACCAACAG
CCUGUACCAACA
AGUGGUCUGUUG
+
192/193/194





ACCACTGG
GACCACU
GUACAGG







0126
ise2c.pk00
Elongation
AACCAAAAATGGGCA
CCAAAAAUGGGC
UUUCCUUGCCCA
+
195/196/197



1.c14
factor
AGGAAAAG
AAGGAAA
UUUUUGG







0127


AACGTGGTATCACCA
CGUGGUAUCACC
UAUCGAUGGUGA
+
198/199/200





TCGATATT
AUCGAUA
UACCACG







0128


AACAAAATGGACTCC
CAAAAUGGACUC
CUCAGUGGAGUC

201/202/203





ACTGAGCC
CACUGAG
CAUUUUG







0129
ise2c.pk00
Elongation
AATCCGTGACTAACC
UCCGUGACUAAC
AUUUUUGGUUAG
+
204/205/206



1.d16
factor
AAAAATGG
CAAAAAU
UCACGGA







0130


AACATTGTCGTCATT
CAUUGUCGUCAU
GUGUCCAAUGAC

207/208/209





GGACACGT
UGGACAC
GACAAUG







0131
ise2c.pk00
phospho-
AATTTGTGAGACTGG
UUUGUGAGACUG
CGGCCACCAGUC

421/422/423



5.h3
oligosacch-
TGGCCGAA
GUGGCCG
UCACAAA






aride









. . .










0132


AATCTGATTGTATTC
UCUGAUUGUAUU
GGGGGCGAAUAC

424/245/426





GCCCCCTC
CGCCCCC
AAUCAGA







0133


AACACTCTAGTTCTG
CACUCUAGUUCU
AAUAGGCAGAAC

427/228/429





CCTATTCT
GCCUAUU
UAGAGUG







0134
ise2c.pk00
myosin
AACACACATCACAAT
CACACAUCACAA
UCCGCCAUUGUG

430/431/432



1.d21

GGCGGATA
UGGCGGA
AUGUGUG







0135


AAGGATGGCATCATC
GGAUGGCAUCAU
CUUGCCGAUGAU

433/434/435





GGCAAGAA
CGGCAAG
GCCAUCC







0136


AAAGGCTTCATCGAC
AGGCUUCAUCGA
CGCGGUGUCGAU

436/437/438





ACCGCGAA
CACCGCG
GAAGCCU







0137
ise2c.pk00
myosin
AAACTCCAATTATAA
ACUCCAAUUAUA
AGUAGGUUAUAA

210/211/212



1.j9

CCTACTAG
ACCUACU
UUGGAGU







0138


AAGTACAAGGATCTG
GUACAAGGAUCU
GCCGAUCAGAUC
+
213/214/215





ATCGGCAA
GAUCGGC
CUUGUAC







0139


AAGACTTTCTTCATG
GACUUUCUUCAU
GGGCCACAUGAA

216/217/218





TGGCCCAT
GUGGCCC
GAAAGUC







0140
ise2c.pk00
myosin
AAACAAAGTATCGCC
ACAAAGUAUCGC
GGUGUAGGCGAU

439/440/441



2.f12

TACACCGC
CUACACC
ACUUUGU







0141


AATAGCGTCGATCTT
UAGCGUCGAUCU
UCGUUGAAGAUC

442/443/444





CAACGACT
UCAACGA
GACGCUA







0142
ise2c.pk00
potassium
AACTCATAGAGCTTG
CUCAUAGAGCUU
ACACAUCAAGCU

219/220/221



1.b14
channel
ATGTGTGG
GAUGUGU
CUAUGAG






amino acid









transporter










0143


AAGATGTGGATGACG
GAUGUGGAUGAC
CAGUGACGUCAU

221/223/224





TCACTGGT
GUCACUG
CCACAUC







0144


AACCTTCCTGATTCT
CCUUCCUGAUUC
CAGAAGAGAAUC

225/226/227





CTTCTGTG
UCUUCUG
AGGAAGG







0145
ise2c.pk00
potassium
AACAGTGCTTGTGAT
CAGUGCUUGUGA
UCACUUAUCACA
+
228/229/230



3.f2
inwardly
AAGTGAAC
UAAGUGA
AGCACUG






rect-









ifier . . .










0146


AAGTTAATGGTGACT
GUUAAUGGUGAC
GAGGGCAGUCAC
+
231/232/233





GCCCTCGA
UGCCCUC
CAUUAAC







0147


AATAAAGCGATGACC
UAAAGCGAUGAC
CUAUGGGGUCAU
+
234/235/236





CCATAGGA
CCCAUAG
CGCUUUA







0148
ise2c.pk00
amino acid
AAACGGTACTGCAGC
ACGGUACUGCAG
CUUUUUGCUGCA
+
237/238/239



5.120
transporter
AAAAAGAC
CAAAAAG
GUACCGU







0149


AAGCTGCATACTTCT
GCUGCAUACUUC
GAGCCAAGAAGU
+
240/241/242





TGGCTCTC
UUGGCUC
AUGCAGC







0150


AAATGTTTACAGAGA
AUGUUUACAGAG
AUCGCGUCUCUG

243/244/245





CGCGATGA
ACGCGAU
UAAACAU







0151
ise2c.pk00
tubulin
AACGTCGATCTTACC
CGUCGAUCUUAC
GAACUCGGUAAG
+
246/247/248



1.d1

GAGTTCCA
CGAGUUC
AUCGACG







0152
ise2c.pk00
tubulin
AATTCAAAATGCGTG
UUCAAAAUGCGU
UGCACUCACGCA

249/250/251



1.k6

AGTGCATC
GAGUGCA
UUUUGAA







0153


AAATCGTAGACCTAG
AUCGUAGACCUA
CGAGGACUAGGU
+
252/253/254





TCCTCGAC
GUCCUCG
CUACGAU







0154
ise2c.pk00
tubulin
AAACTCAATTCAAAA
ACUCAAUUCAAA
CACGCAUUUUGA
+
255/256/257



1.12

TGCGTGAG
AUGCGUG
AUUGAGU







0155


AACTTATCACTGGTA
CUUAUCACUGGU
CUUCCUUACCAG

258/259/260





AGGAAGAT
AAGGAAG
UGAUAAG







0156
ise2c.pk00
ubiquitin
AAGAGTTACGAACCG
GAGUUACGAACC
UGGUGACCGGUU

261/262/263



2.b4

TCACCATA
GUCACCA
CGUAACUC







0157


AAACTTAGTCCGGAT
ACUUAGUCCGGA
UUCAUUAUCCGG
+
264/265/266





AATGAACC
UAAUGAA
ACUAAGU







0158


AAGGCGATGTACGAG
GGCGAUGUACGA
CAGGUUCUCGUA
+
267/268/269





AACCTGTT
GAACCUG
CAUCGCC







0159
ise2c.pk00
small
AACGACAAGATGCTG
CGACAAGAUGCU
CUCCUUCAGCAU
+
270/271/272



1.j16
nuclear
AAGGAGAC
GAAGGAG
CUUGUCG






ribonucleo-









protein










0160
ise2c.pk00
small
AAGATAAAGGTCGCG
GAUAAAGGUCGC
UCCACACGCGAC

273/274/275



6.h23
nuclear
TGTGGACC
GUGUGGA
CUUUAUC






ribonucleo-









protein










0161


AATGTCAAGACTGAT
UGUCAAGACUGA
GUUUGGAUCAGU

276/277/278





CCAAACAC
UCCAAAC
CUUGACA







0162


AACATTCGAGTCTGA
CAUUCGAGUCUG
ACCUGUUCAGAC
+
279/280/281





ACAGGTGG
AACAGGU
UCGAAUG







(Note: the sense RNA primer sequence and the antisense RNA primer sequences shown in table 7 were generated with 2


thymine residues at the 3′ end.)




















TABLE 8












SEQ ID NO








30
Target region/


Sample
seq id
gene id
Target sequence
forward
reverse
ppm
sense/antisense






















0075
ise1c.pk002.
Juvenile
AACATGGTATCCGAC
CAUGGUAUCCG
CCUGAAGUCGG

51/52/53



m13
hormone query
TTCAGGAA
ACUUCAGG
AUACCAUG







0076


AAGGTCGCTGACGAG
GGUCGCUGACG
CUUGUUCUCGU

54/55/56





AACAAGGA
AGAACAAG
CAGCGACC







0077


AAGTGTCCTGGGCTT
GUGUCCUGGGC
GAACUCAAGCC

57/58/59





GAGTTCCA
UUGAGUUC
CAGGACAC







0078
ise1c.pk003.
Juvenile
AAGAAGAAGCTCCTC
GAAGAAGCUCC
CACGUGGAGGA

60/61/62



f7
hormone query
CACGTGTT
UCCACGUG
GCUUCUUC







0079


AAGGTCGCTGACGAG
GGUCGCUGACG
CUUGUUCUCGU

63/64/65





AACAAGGA
AGAACAAG
CAGCGACC







0080


AATGTCCTGGGGCTG
UGUCCUGGGGC
GAAACUCAGCC
+
66/67/68





AGTTTCAA
UGAGUUUC
CCAGGACA







0081
ise1c.pk005.
Juvenile
AAGAATAAGCTCCTC
GAAUAAGCUCC
CACGUGGAGGA

69/70/71



a15
hormone query
CACGTGTT
UCCACGUG
GCUUAUUC







0082


AATTTGTCGAGGAGA
UUUGUCGAGGA
AUAGGGUCUCC

72/73/74





CCCTATTG
GACCCUAU
UCGACAAA







0083


AAGTTCGCGTTCACT
GUUCGCGUUCA
UUCAAGAGUGA
NT
75/76/77





CTTGAAGA
CUCUUGAA
ACGCGAAC







0084
ise1c.pk006.
Juvenile
AACTGCCCCTTAACC
CUGCCCCUUAA
AGAUGAGGUUA
+
78/79/80



d24
hormone query
TCATCTAT
CCUCAUCU
AGGGGCAG







0085


AATCACGCTGAAACC
UCACGCUGAAA
UACAGUGGUUU

81/82/83





ACTGTATA
CCACUGUA
CAGCGUGA







0086
ise2c.pk009.
Juvenile
AAAATATGGCGCGCC
AAUAUGGCGCG
ACAAUAGGCGC

84/85/86



i4
hormone query
TATTGTTT
CCUAUUGU
GCCAUAUU







0087


AACGTTCTCGGTCTT
CGUUCUCGGUC
CAGUGAAAGAC

87/88/89





TCACTGCT
UUUCACUG
CGAGAACG







0088


AAGTCATCGTTCCAA
GUCAUCGUUCC
GUAGACUUGGA

90/91/92





GTCTACCT
AAGUCUAC
CGAUGAC







0089
ise2c.pk001.
vacuolar
AACCCCTTGAATGTT
CCCCUUGAAUG
GACCUUAACAU
+
93/94/95



d19
query
AAGGTCGG
UUAAGGUC
UCAAGGGG







0090


AAGTACACCATGTTG
GUACACCAUGU
UACUUGCAACA

96/97/98





CAAGTATG
UGCAAGUA
UGGUGUAC







0091


AACGTGTCCATGATG
CGUGUCCAUGA
GUCAGCCAUCA
+
99/100/101





GCTGACTC
UGGCUGAC
UGGACACG







0092
ise2c.pk001.
vacuolar
AAACCTACAAAATGG
ACCUACAAAAU
UUUCGGCCAUU

102/103/104



e14
query
CCGAAAAC
GGCCGAAA
UUGUAGGU







0093


AATCTACGGACCCTT
UCUACGGACCC
CCAAAGAAGGG

105/106/107





CTTTGGAG
UUCUUUGG
UCCGUAGA







0094
ise2c.pk001.
vacuolar
AACTCTGACGTCATC
CUCUGACGUCA
GUAGAUGAUGA

108/109/110



f20
query
ATCTACGT
UCAUCUAC
CGUCAGAG







0095


AAGTGCTTGGGTAAC
GUGCUUGGGUA
GUCGGGGUUAC

111/112/113





CCCGACAG
ACCCCGAC
CCAAGCAC







0096


AACTGGCTCATCTCC
CUGGCUCAUCU
GCUGUAGGAGA

114/115/116





TACAGCAA
CCUACAGC
UGAGCCAG







0097
ise2c.pk010.
cadherin
AAACAGTGCGTCGTA
ACAGUGCGUCG
AUAUAUUACGA

117/118/119



h3
query
ATATATTC
UAAUAUAU
CGCACUGU







0098


AAGGCACATGGTCCT
GGCACAUGGUC
CAGUGAAGGAC

120/121/122





TCACTGAT
CUUCACUG
CAUGUGCC







0099


AACACCATGACCCTC
CACCAUGACCC
GUACACGAGGG

123/124/125





GTGTACAA
UCGUGUAC
UCAUGGUG







0100
ise2c.pk007.
cuticle
AACGAGGCCGGATCT
CGAGGCCGGAU
CUUAAGAGAUC

457/458/459



k24
protein
CTTAAGCA
CUCUUAAG
CGGCCUCG







0101


AACTTCACACATAAC
CUUCACACAUA
UGUCUAGUUAU

460/461/462





TAGACAAA
ACUAGACA
GUGUGAAG







0102


AATGCGTGGCGATTT
UUAGAAAUUAU
CUGGGCUUAUA

463/464/465





CAAACTTA
AAGCCCAG
AUUUCUAA







0103
ise2c.pk011.
cuticle
AAAAAACACAGACCA
AAAACACAGAC
UGAACGUGGUC

126/127/128



a10
protein
CGTTCACA
CACGUUCA
UGUGUUUU







0104


AATCGATGGTGGTGT
UCGAUGGUGGU
CGAAUAACACC
+
129/130/131





TATTCGCT
GUUAUUCG
ACCAUCGA







0105
ise2c.pk011.
cuticle
AAAGAAAATGCTACG
AGAAAAUGCUA
GUAACGCGUAG

132/133/134



h12
protein
CGTTACGA
CGCGUUAC
CAUUUUCU







0106


AACCCTTGGACACTA
CCCUUGGACAC
UUCCAGUAGUG

135/136/137





CTGGAAGA
UACUGGAA
UCCAAGGG







0107


AAGGATCCTATGTGT
GGAUCCUAUGU
CCUGGUACACA

138/139/140





ACCAGGTT
GUACCAGG
UAGGAUCC







0108
ise2c.pk001.
translation
AAACTCGGCACACAA
ACUCGGCACAC
AUUGUGUUGUG
+
141/142/143



d22
initiation
CACAATGG
AACACAAU
UGCCGAGU






factor










0109


AATACGAAGATATCT
UACGAAGAUAU
AAGGGCAGAUA
+
144/145/146





GCCCTTCC
CUGCCCUU
UCUUCGUA







0110


AATCAACAGCTCTTA
UCAACAGCUCU
UUUAUGUAAGA
+
147/148/149





CATAAATG
UACAUAAA
GCUGUUGA







0111
ise2c.pk001.
translation
AAAGAAGATCAGAAG
AGAAGAUCAGA
GCCAAUCUUCU

150/151/152



d9
initiation
ATTGGCCG
AGAUUGGC
GAUCUUCU






factor










0112


AAAAGCCGTCTGCTA
AAGCCGUCUGC
GUUGGAUAGCA

153/154/155





TCCAACAA
UAUCCAAC
GACGGCUU







0113


AATGCTAAATGCCAT
UGCUAAAUGCC
GCAAGCAUGGC
+
156/157/158





GCTTGCAT
AUGCUUGC
AUUUAGCA







0114
ise2c.pk001.
translation
AAGATCAGAAGATTG
GAUCAGAAGAU
UCCGGCCAAUC
+
159/160/161



i23
initiation
GCCGGAAG
UGGCCGGA
UUCUGAUC






factor










0115


AATTCTTCAGCAAAT
UUCUUCAGCAA
GUAUCGAUUUG
NT
162/163/164





CGATACCA
AUCGAUAC
CUGAAGAA







0116


AAATGCTGTCAAGAG
AUGCUGUCAAG
UAAAUCCUCUU

165/166/167





GATTTAAA
AGGAUUUA
GACAGCAU







0117
ise2c.pk001.
translation
AAGCTCGAGACTTGC
GCUCGAGACUU
UCAAGAGCAAG
+
168/169/170



l24
initiation
TCTTGATG
GCUCUUGA
UCUCGAGC






factor










0118


AACTGTTAGCTCAAG
CUGUUAGCUCA
GCAGACCUUGA
+
171/172/173





GTCTGCTA
AGGUCUGC
GCUAACAG







0119


AAGACTTTCTATCAG
GACUUUCUAUC
CAAAUUCUGAU

174/175/176





AATTTGCG
AGAAUUUG
AGAAAGUC







0120
ise2c.pk005.
translation
AAACTTAATCATGGA
ACUUAAUCAUG
UCGUCGUCCAU

177/178/179



b9
initiation
CGACGACA
GACGACGA
GAUUAAGU






factor










0121


AAAGAAGAAGAAGAA
AGAAGAAGAAG
CCUUCUUCUUC
+
180/181/182





GAAGGGAG
AAGAAGGG
UUCUUCU







0122


AAGATCAAGAGAATG
GAUCAAGAGAA
CCUCGACAUUC
+
183/184/185





TCGAGGAT
UGUCGAGG
UCUUGAUC







0123
ise2c.pk002.
SAR1
AAAATCGTCGGTTTT
AAUCGUCGGUU
GUCGCUAAAAC
+
186/187/188



m10

AGCGACGT
UUAGCGAC
CGACGAUU







0124


AACTGTCAATAGGCA
CUGUCAAUAGG
GCAUACUGCCU
+
189/190/191





GTATGCGT
CAGUAUGC
AUUGACAG







0125


AACCTGTACCAACAG
CCUGUACCAAC
AGUGGUCUGUU
+
192/193/194





ACCACTGG
AGACCACU
GGUACAGG







0126
ise2c.pk001.
Elongation
AACCAAAAATGGGCA
CCAAAAAUGGG
UUUCCUUGCCC
+
195/196/197



c14
factor
AGGAAAAG
CAAGGAAA
AUUUUUGG







0127


AACGTGGTATCACCA
CGUGGUAUCAC
UAUCGAUGGUG
+
198/199/200





TCGATATT
CAUCGAUA
AUACCACG







0128


AACAAAATGGACTCC
CAAAAUGGACU
CUCAGUGGAGU
+
201/202/203





ACTGAGCC
CCACUGAG
CCAUUUUG







0129
ise2c.pk001.
Elongation
AATCCGTGACTAACC
UCCGUGACUAA
AUUUUUGGUUA
+
204/205/206



d16
factor
AAAAATGG
CCAAAAAU
GUCACGGA







0130


AACATTGTCGTCATT
CAUUGUCGUCA
GUGUCCAAUGA
+
207/208/209





GGACACGT
UUGGACAC
CGACAAUG







0131
ise2c.pk005.
phospho-
AATTTGTGAGACTGG
UUUGUGAGACU
CGGCCACCAGU

421/422/423



h3
oligosacch-
TGGCCGAA
GGUGGCCG
CUCACAAA






aride . . .










0132


AATCTGATTGTATTC
UCUGAUUGUAU
GGGGGCGAAUA

424/425/426





GCCCCCTC
UCGCCCCC
CAAUCAGA







0133


AACACTCTAGTTCTG
CACUCUAGUUC
AAUAGGCAGAA

427/428/429





CCTATTCT
UGCCUAUU
CUAGAGUG







0134
ise2c.pk001.
myosin
AACACACATCACAAT
CACACAUCACA
UCCGCCAUUGU

430/431/432



d21

GGCGGATA
AUGGCGGA
GAUGUGUG







0135


AAGGATGGCATCATC
GGAUGGCAUCA
CUUGCCGAUGA

433/434/435





GGCAAGAA
UCGGCAAG
UGCCAUCC







0136


AAAGGCTTCATCGAC
AGGCUUCAUCG
CGCGGUGUCGA

436/437/438





ACCGCGAA
ACACCGCG
UGAAGCCU







0137
ise2c.pk001.
myosin
AAACTCCAATTATAA
ACUCCAAUUAU
AGUAGGUUAUA

210/211/212



j9

CCTACTAG
AACCUACU
AUUGGAGU







0138


AAGTACAAGGATCTG
GUACAAGGAUC
GCCGAUCAGAU

213/214/215





ATCGGCAA
UGAUCGGC
CCUUGUAC







0139


AAGACTTTCTTCATG
GACUUUCUUCA
GGGCCACAUGA

216/217/218





TGGCCCAT
UGUGGCCC
AGAAAGUC







0140
ise2c.pk002.
myosin
AAACAAAGTATCGCC
ACAAAGUAUCG
GGUGUAGGCGA

439/440/441



f12

TACACCGC
CCUACACC
UACUUUGU







0141


AATAGCGTCGATCTT
UAGCGUCGAUC
UCGUUGAAGAU

442/443/444





CAACGACT
UUCAACGA
CGACGCUA







0142
ise2c.pk001.
potassium
AACTCATAGAGCTTG
CUCAUAGAGCU
ACACAUCAAGC

210/220/221



b14
channel
ATGTGTGG
UGAUGUGU
UCUAUGAG






amino acid









transporter










0143


AAGATGTGGATGACG
GAUGUGGAUGA
CAGUGACGUCA
+
221/223/224





GTCACTGGT
CGUCACUG
UCCACAUC







0144


AACCTTCCTGATTCT
CCUUCCUGAUU
CAGAAGAGAAU
+
225/226/227





CTTCTGTG
CUCUUCUG
CAGGAAGG







0145
ise2c.pk003.
potassium
AACAGTGCTTGTGAT
CAGUGCUUGUG
UCACUUAUCAC
+
228/229/230



f2
inwardly
AAGTGAAC
AUAAGUGA
AAGCACUG






rectifier . . .










0146


AAGTTAATGGTGACT
GUUAAUGGUGA
GAGGGCAGUCA
+
231/232/233





GCCCTCGA
CUGCCCUC
CCAUUAAC







0147


AATAAAGCGATGACC
UAAAGCGAUGA
CUAUGGGGUCA
+
234/235/236





CCATAGGA
CCCCAUAG
UCGCUUUA







0148
ise2c.pk005.
amino acid
AAACGGTACTGCAGC
ACGGUACUGCA
CUUUUUGCUGC
+
237/238/239



l20
transporter
AAAAAGAC
GCAAAAAG
AGUACCGU







0149


AAGCTGCATACTTCT
GCUGCAUACUU
GAGCCAAGAAG
+
240/241/242





TGGCTCTC
CUUGGCUC
UAUGCAGC







0150


AAATGTTTACAGAGA
AUGUUUACAGA
AUCGCGUCUCU
+
243/244/245





CGCGATGA
GACGCGAU
GUAAACAU







0151
ise2c.pk001.
tubulin
AACGTCGATCTTACC
CGUCGAUCUUA
GAACUCGGUAA
+
246/247/248



d1

GAGTTCCA
CCGAGUUC
GAUCGACG







0152
ise2c.pk001.
tubulin
AATTCAAAATGCGTG
UUCAAAAUGCG
UGCACUCACGC
+
249/250/251



k6

AGTGCATC
UGAGUGCA
AUUUUGAA







0153


AAATCGTAGACCTAG
AUCGUAGACCU
CGAGGACUAGG
+
252/253/254





TCCTCGAC
AGUCCUCG
UCUACGAU







0154
ise2c.pk001.
tubulin
AAACTCAATTCAAAA
ACUCAAUUCAA
CACGCAUUUUG
+
255/256/257



l2

TGCGTGAG
AAUGCGUG
AAUUGAGU







0155


AACTTATCACTGGTA
CUUAUCACUGG
CUUCCUUACCA

258/259/260





AGGAAGAT
UAAGGAAG
GUGAUAAG







0156
ise2c.pk002.
ubiquitin
AAGAGTTACGAACCG
GAGUUACGAAC
UGGUGACGGUU
+
261/262/263



b4

TCACCATA
CGUCACCA
CGUAACUC







0157


AAACTTAGTCCGGAT
ACUUAGUCCGG
UUCAUUAUCCG
+
264/265/266





AATGAACC
AUAAUGAAt
GACUAAGU







0158


AAGGCGATGTACGAG
GGCGAUGUACG
CAGGUUCUCGU
+
267/268/269





AACCTGTT
AGAACCUG
ACAUCGGC







0159
ise2c.pk001.
small nuclear
AACGACAAGATGCTG
CGACAAGAUGC
CUCCUUCAGCA
+
270/271/272



j16
ribonucleo-
AAGGAGAC
UGAAGGAG
UCUUGUCG






protein










0160
ise2c.pk006.
small nuclear
AAGATAAAGGTCGCG
GAUAAAGGUCG
UCCACACGCGA
+
273/274/275



h23
ribonucleo-
TGTGGACC
CGUGUGGA
CCUUUAUC






protein










0161


AATGTCAAGACTGAT
UGUCAAGACUG
GUUUGGAUCAG
+
276/277/278





CCAAACAC
AUCCAAAC
UCUUGACA







0162


AACATTCGAGTCTGA
CAUUCGAGUCU
ACCUGUUCAGA
+
279/280/281





ACAGGTGG
GAAGGUt
CUCGAAUG





(Note: the sense RNA primer sequence and the antisense RNA primer sequences shown in table 8 were generated with 2


thymine residues at the 3′ end.)






















TABLE 9














SEQ ID NO





Target


30
15
8
Target region/


Sample
seq id
gene id
sequence
forward
reverse
ppm
ppm
ppm
sense/antisense
























0075


AAGGTCGCTGAC
GGUCGCUGAC
CUUGUUCUCG



51/52/53





GAGAACAAGGA
GAGAACAAG
UCAGCGACC









0076


AAGTGTCCTGGG
GUGUCCUGGG
GAACUCAAGC
+


54/55/56





CTTGAGTTCCA
CUUGAGUUC
CCAGGACAC









0077
ise1c.pk00
Juvenile
AAGAAGAAGCTC
GAAGAAGCUC
CACGUGGAGG



57/58/59



3.f7
hormone query
CTCCACGTGTT
CUCCACGUG
AGCUUCUUC









0078


AAGGTCGCTGAC
GGUCGCUGAC
CUUGUUCUCG



60/61/62





GAGAACAAGGA
GAGAACAAG
UCAGCGACC









0079


AATGTCCTGGGG
UGUCCUGGGG
GAAACUCAGC



63/64/65





CTGAGTTTCAA
CUGAGUUUC
CCCAGGACA









0080
ise1c.pk00
Juvenile
AAGAATAAGCTC
GAAUAAGCUC
CACGUGGAGG
+
+

66/67/68



5.a15
hormone query
CTCCACGTGTT
CUCCACGUG
AGCUUAUUC









0081


AATTTGTCGAGG
UUUGUCGAGG
AUAGGGUCUC



69/70/71





AGACCCTATTG
AGACCCUAU
CUCGACAAA









0082


AAGTTCGCGTTC
GUUCGCGUUC
UUCAAGAGUG
NT


72/73/74





ACTCTTGAAGA
ACUCUUGAA
AACGCGAAC









0083
ise1c.pk00
Juvenile
AACTGCCCCTTA
CUGCCCCUUA
AGAUGAGGUU



75/76/77



6.d24
hormone query
ACCTCATCTAT
ACCUCAUCUt
AAGGGGCAG










t










0084


AATCACGCTGAA
UCACGCUGAA
UACAGUGGUU
+


78/79/80





ACCACTGTATA
ACCACUGUAt
UCAGCGUGA










t










0085
ise2c.pk00
Juvenile
AAAATATGGCGC
AAUAUGGCGC
ACAAUAGGCG



81/82/83



9.i4
hormone query
GCCTATTGTTT
GCCUAUUGU
CGCCAUAUU









0086


AACGTTCTCGGT
CGUUCUCGGU
CAGUGAAAGA



84/85/86





CTTTCACTGCT
CUUUCACUG
CCGAGAACG









0087


AAGTCATCGTTC
GUCAUCGUUC
GUAGACUUGG
+


87/88/89





CAAGTCTACCT
CAAGUCUAC
AACGAUGAC









0088
ise2c.pk00
vacuolar query
AACCCCTTGAAT
CCCCUUGAAU
GACCUUAACA
+


90/91/92



1.d19

GTTAAGGTCGG
GUUAAGGUC
UUCAAGGGG









0089


AAGTACACCATG
GUACACCAUG
UACUUGCAAC



93/94/95





TTGCAAGTATG
UUGCAAGUA
AUGGUGUAC









0090


AACGTGTCCATG
CGUGUCCAUG
GUCAGCCAUC
NT


96/97/98





ATGGCTGACTC
AUGGCUGAC
AUGGACACG









0091
ise2c.pk00
vacuolarquery
AAACCTACAAAA
ACCUACAAAA
UUUCGGCCAU



99/100/101



1.e14

TGGCCGAAAAC
UGGCCGAAA
UUUGUAGGU









0092


AATCTACGGACC
UCUACGGACC
CCAAAGAAGG
+


102/103/104





CTTCTTTGGAG
CUUCUUUGG
GUCCGUAGA









0093
ise2c.pk00
vacuolar query
AACTCTGACGTC
CUCUGACGUC
GUAGAUGAUG



105/106/107



1.f20

ATCATCTACGT
AUCAUCUAC
ACGUCAGAG









0094


AAGTGCTTGGGT
GUGCUUGGGU
GUCGGGGUUA



108/109/110





AACCCCGACAG
AACCCCGAC
CCCAAGCAC









0095


AACTGGCTCATC
CUGGCUCAUC
GCUGUAGGAG



111/112/113





TCCTACAGCAA
UCCUACAGC
AUGAGCCAG









0096
ise2c.pk01
cadherin query
AAACAGTGCGTC
ACAGUGCGUC
AUAUAUUACG



114/115/116



0.h3

GTAATATATTC
GUAAUAUAU
ACGCACUGU









0097


AAGGCACATGGT
GGCACAUGGU
CAGUGAAGGA



117/118/119





CCTTCACTGAT
CCUUCACUG
CCAUGUGCC









0098


AACACCATGACC
CACCAUGACC
GUACACGAGG
NT


120/121/122





CTCGTGTACAA
CUCGUGUAC
GUCAUGGUG









0099
ise2c.pk00
cuticle protein
AACGAGGCCGGA
CGAGGCCGGA
CUUAAGAGAU



123/124/125



7.k24

TCTCTTAAGCA
UCUCUUAAG
CCGGCCUCG









0100


AACTTCACACAT
CUUCACACAU
UGUCUAGUUA



457/458/459





AACTAGACAAA
AACUAGACA
UGUGUGAAG









0101


AATGCGTGGCGA
UUAGAAAUUA
CUGGGCUUAU



460/461/462





TTTCAAACTTA
UAAGCCCAG
AAUUUCUAA









0102
ise2c.pk01
cuticle protein
AAAAAACACAGA
AAAACACAGA
UGAACGUGGU



463/464/465



1.a10

CCACGTTCACA
CCACGUUCA
CUGUGUUUU









0103


AATCGATGGTGG
UCGAUGGUGG
CGAAUAACAC
+


126/127/128





TGTTATTCGCT
UGUUAUUCG
CACCAUCGA









0104
ise2c.pk01
cuticle protein
AAAGAAAATGCT
AGAAAAUGCU
GUAACGCGUA



129/130/131



1.h12

ACGCGTTACGA
ACGCGUUAC
GCAUUUUCU









0105


AACCCTTGGACA
CCCUUGGACA
UUCCAGUAGU
+


132/133/134





CTACTGGAAGA
CUACUGGAA
GUCCAAGGG









0106


AAGGATCCTATG
GGAUCCUAUG
CCUGGUACAC
NT


135/136/137





TGTACCAGGTT
UGUACCAGG
AUAGGAUCC









0107
ise2c.pk00
translation
AAACTCGGCACA
ACUCGGCACA
AUUGUGUUGU



138/139/140



1.d22
initiation
CAACACAATGG
CAACACAAU
GUGCCGAGU








factor












0108


AATACGAAGATA
UACGAAGAUA
AAGGGCAGAU
+


141/142/143





TCTGCCCTTCC
UCUGCCCUU
AUCUUCGUA









0109


AATCAACAGCTC
UCAACAGCUC
UUUAUGUAAG
+


144/145/146





TTACATAAATG
UUACAUAAA
AGCUGUUGA









0110
ise2c.pk00
translation
AAAGAAGATCAG
AGAAGAUCAG
GCCAAUCUUC



147/148/149



1.d9
initiation
AAGATTGGCCG
AAGAUUGGC
UGAUCUUCU








factor












0111


AAAAGCCGTCTG
AAGCCGUCUG
GUUGGAUAGC



150/151/152





CTATCCAACAA
CUAUCCAAC
AGACGGCUU









0112


AATGCTAAATGC
UGCUAAAUGC
GCAAGCAUGG
+


153/154/155





CATGCTTGCAT
CAUGCUUGC
CAUUUAGCA









0113
ise2c.pk00
translation
AAGATCAGAAGA
GAUCAGAAGA
UCCGGCCAAU
+


156/157/158



1.i23
initiation
TTGGCCGGAAG
UUGGCCGGA
CUUCUGAUC








factor












0114


AATTCTTCAGCA
UUCUUCAGCA
GUAUCGAUUU
NT


159/160/161





AATCGATACCA
AAUCGAUAC
GCUGAAGAA









0115


AAATGCTGTCAA
AUGCUGUCAA
UAAAUCCUCU
+


162/163/164





GAGGATTTAAA
GAGGAUUUA
UGACAGCAU









0116
ise2c.pk00
translation
AAGCTCGAGACT
GCUCGAGACU
UCAAGAGCAA
+


165/166/167



1.l24
initiation
TGCTCTTGATG
UGCUCUUGA
GUCUCGAGC








factor












0117


AACTGTTAGCTC
CUGUUAGCUC
GCAGACCUUG
+


168/169/170





AAGGTCTGCTA
AAGGUCUGC
AGCUAACAG









0118


AAGACTTTCTAT
GACUUUCUAU
CAAAUUCUGA



171/172/173





CAGAATTTGCG
CAGAAUUUG
UAGAAAGUC









0119
ise2c.pk00
translation
AAACTTAATCAT
ACUUAAUCAU
UCGUCGUCCA



174/175/176



5.b9
initiation
GGACGACGACA
GGACGACGA
UGAUUAAGU








factor












0120


AAAGAAGAAGAA
AGAAGAAGAA
CCCUUCUUCU
+


177/178/179





GAAGAAGGGAG
GAAGAAGGG
UCUUCUUCU









0121


AAGATCAAGAGA
GAUCAAGAGA
CCUCGACAUU
+
+
+
180/181/182





ATGTCGAGGAT
AUGUCGAGG
CUCUUGAUC









0122
ise2c.pk00
SAR1
AAAATCGTCGGT
AAUCGUCGGU
GUCGCUAAAA
NT


183/184/185



2.m10

TTTAGCGACGT
UUUAGCGAC
CCGACGAUU









0123


AACTGTCAATAG
CUGUCAAUAG
GCAUACUGCC
+


186/187/188





GCAGTATGCGT
GCAGUAUGC
UAUUGACAG









0124


AACCTGTACCAA
CCUGUACCAA
AGUGGUCUGU
+


189/190/191





CAGACCACTGG
CAGACCACU
UGGUACAGG









0125
ise2c.pk00
Elongation
AACCAAAAATGG
CCAAAAAUGG
UUUCCUUGCC
+


192/193/194



1.c14
factor
GCAAGGAAAAG
GCAAGGAAA
CAUUUUUGG









0126


AACGTGGTATCA
CGUGGUAUCA
UAUCGAUGGU
+


195/196/197





CCATCGATATT
CCAUCGAUA
GAUACCACG









0127


AACAAAATGGAC
CAAAAUGGAC
CUCAGUGGAG
+


198/199/200





TCCACTGAGCC
UCCACUGAG
UCCAUUUUG









0128
ise2c.pk00
Elongation
AATCCGTGACTA
UCCGUGACUA
AUUUUUGGUU
+


201/202/203



1.d16
factor
ACCAAAAATGG
ACCAAAAAU
AGUCACGGA









0129


AACATTGTCGTC
CAUUGUCGUC
GUGUCCAAUG



204/205/206





ATTGGACACGT
AUUGGACAC
ACGACAAUG









0130
ise2c.pk00
phosphooligo-
AATTTGTGAGAC
UUUGUGAGAC
CGGCCACCAG
NT


207/208/209



5.h3
saccharide . . .
TGGTGGCCGAA
UGGUGGCCG
UCUCACAAA









0131


AATCTGATTGTA
UCUGAUUGUA
GGGGGCGAAU



421/422/423





TTCGCCCCCTC
UUCGCCCCC
ACAAUCAGA









0132


AACACTCTAGTT
CACUCUAGUU
AAUAGGCAGA



424/425/426





CTGCCTATTCT
CUGCCUAUU
ACUAGAGUG









0133
ise2c.pk00
myosin
AACACACATCAC
CACACAUCAC
UCCGCCAUUG



427/428/429



1.d21

AATGGCGGATA
AAUGGCGGA
UGAUGUGU









0134


AAGGATGGCATC
GGAUGGCAUC
CUUGCCGAUG



430/431/432





ATCGGCAAGAA
AUCGGCAAG
AUGCCAUCC









0135


AAAGGCTTCATC
AGGCUUCAUC
CGCGGUGUCG



433/434/435





GACACCGCGAA
GACACCGCG
AUGAAGCCU









0136
ise2c.pk00
myosin
AAACTCCAATTA
ACUCCAAUUA
AGUAGGUUAU



436/437/438



1.j9

TAACCTACTAG
UAACCUACU
AAUUGGAGU









0137


AAGTACAAGGAT
GUACAAGGAU
GCCGAUCAGA



210/211/212





CTGATCGGCAA
CUGAUCGGC
UCCUUGUAC









0138


AAGACTTTCTTC
GACUUUCUUC
GGGCCACAUG
NT


213/214/215





ATGTGGCCCAT
AUGUGGCCC
AAGAAAGUC









0139
ise2c.pk00
myosin
AAACAAAGTATC
ACAAAGUAUC
GGUGUAGGCG



216/217/218



2.f12

GCCTACACCGC
GCCUACACC
AUACUUUGU









0140


AATAGCGTCGAT
UAGCGUCGAU
UCGUUGAAGA



439/440/441





CTTCAACGACT
CUUCAACGA
UCGACGCUA









0141
ise2c.pk00
potassium
AACTCATAGAGC
CUCAUAGAGC
ACACAUCAAG



442/443/444



1.b14
channel amino
TTGATGTGTGG
UUGAUGUGU
CUCUAUGAG








acid transporter












0142


AAGATGTGGATG
GAUGUGGAUG
CAGUGACGUC



219/220/221





ACGTCACTGGT
ACGUCACUG
AUCCACAUC









0143


AACCTTCCTGAT
CCUUCCUGAU
CAGAAGAGAA
+


222/223/224





TCTCTTCTGTG
UCUCUUCUG
UCAGGAAGG









0144
ise2c.pk00
potassium
AACAGTGCTTGT
CAGUGCUUGU
UCACUUAUCA
+
+

225/226/227



3.f2
inwardly
GATAAGTGAAC
GAUAAGUGA
CAAGCACUG








rectifier . . .












0145


AAGTTAATGGTG
GUUAAUGGUG
GAGGGCAGUC
+


228/229/230





ACTGCCCTCGA
ACUGCCCUC
ACCAUUAAC









0146


AATAAAGCGATG
UAAAGCGAUG
CUAUGGGGUC
NT


231/232/233





ACCCCATAGGA
ACCCCAUAG
AUCGCUUUA









0147
ise2c.pk00
amino acid
AAACGGTACTGC
ACGGUACUGC
CUUUUUGCUG
+


234/235/236



5.l20
transporter
AGCAAAAAGAC
AGCAAAAAG
CAGUACCGU









0148


AAGCTGCATACT
GCUGCAUACU
GAGCCAAGAA



237/238/239





TCTTGGCTCTC
UCUUGGCUC
GUAUGCAGC









0149


AAATGTTTACAG
AUGUUUACAG
AUCGCGUCUC
+


240/241/242





AGACGCGATGA
AGACGCGAU
UGUAAACAU









0150
ise2c.pk00
tubulin
AACGTCGATCTT
CGUCGAUCUU
GAACUCGGUA
+
+

243/244/245



1.d1

ACCGAGTTCCA
ACCGAGUUC
AGAUCGACG









0151
ise2c.pk00
tubulin
AATTCAAAATGC
UUCAAAAUGC
UGCACUCACG
+


246/247/248



1.k6

GTGAGTGCATC
GUGAGUGCA
CAUUUUGAA









0152


AAATCGTAGACC
AUCGUAGACC
CGAGGACUAG
+
+

249/250/251





TAGTCCTCGAC
UAGUCCUCG
GUCUACGAU









0153
ise2c.pk00
tubulin
AAACTCAATTCA
ACUCAAUUCA
CACGCAUUUU
+
+

252/523/254



1.l2

AAATGCGTGAG
AAAUGCGUG
GAAUUGAGU









0154


AACTTATCACTG
CUUAUCACUG
CUUCCUUACC
NT


255/256/257





GTAAGGAAGAT
GUAAGGAAG
AGUGAUAAG









0155
ise2c.pk00
ubiquitin
AAGAGTTACGAA
GAGUUACGAA
UGGUGACGGU
+


258/259/260



2.b4

CCGTCACCATA
CCGUCACCA
UCGUAACUC









0156


AAACTTAGTCCG
ACUUAGUCCG
UUCAUUAUCC
+
+

261/262/263





GATAATGAACC
GAUAAUGAA
GGACUAAGU









0157


AAGGCGATGTAC
GGCGAUGUAC
CAGGUUCUCG
+


264/265/266





GAGAACCTGTT
GAGAACCUG
UACAUCGCC









0158
ise2c.pk00
small nuclear
AACGACAAGATG
CGACAAGAUG
CUCCUUCAGC
+


267/268/269



1.j16
ribonucleoprotein
CTGAAGGAGAC
CUGAAGGAG
AUCUUGUCG









0159
ise2c.pk00
small nuclear
AAGATAAAGGTC
GAUAAAGGUC
UCCACACGCG
+


270/271/272



6.h23
ribonucleoprotein
GCGTGTGGACC
GCGUGUGGA
ACCUUUAUC









0160


AATGTCAAGACT
UGUCAAGACU
GUUUGGAUCA
+


273/274/275





GATCCAAACAC
GAUCCAAAC
GUCUUGACA









0161


AACATTCGAGTC
CAUUCGAGUC
ACCUGUUCAG
+
+

276/277/278





TGAACAGGTGG
UGAACAGGU
ACUCGAAUG









(Note: the sense RNA primer sequence and the antisense RNA primer sequences shown in table 9 were generated with 2


thymine residues at the 3′ end.)


























TABLE 10









Injection
Droplet
Topical
Topical
Topical
Topical
Topical
Topical








Mortality
Feeding
assay 1
Assay 2
Assay 3
Assay 4
Assay 4
Assay 4
Top. 5
Top. 5


well
seq i.d.
midgut
gene id
(%)
Result
30 ppm
30 ppm
30 ppm
30 ppm
15 ppm
8 ppm
15 ppm
8 ppm




























77
ise1c.pk002.m13
no
Juvenile
NT
NT
NT


+


+






hormone





query


81
ise1c.pk005.a15
no
Juvenile
NT
NT
NT


+
+

+





hormone





query


114
ise2c.pk001.i23
no
translation
NT
NT
NT
+
+
+


+





initiation





factor


122
ise2c.pk005.b9
Yes
translation
NT
NT
NT
+
+
+
+
+
+
+





initiation





factor


143
ise2c.pk001.b14
no
potassium
NT
NT
NT

+



+





channel ami-





acid





transporter


145
ise2c.pk003.f2
Yes
potassium
NT
NT
NT
+
+
+
+

+





inwardly





rectifier . . .


146
ise2c.pk003.f2
Yes
potassium
NT
NT
NT
+
+
+


+





inwardly





rectifier . . .


149
ise2c.pk005.l20
Yes
hypothetical
NT
NT
NT
+
+



+





sodium





dependent





transport


151
ise2c.pk001.d1
No
alpha tubulin
NT
NT
NT
+
+
+
+

+


154
ise2c.pk001.l2
No
alpha tubulin
NT
NT
NT
+
+
+
+

+


157
ise2c.pk002.b4
Yes
Probable
NT
NT
NT
+
+
+
+

+





ubiquitin--





protein





ligase


158
ise2c.pk002.b4
Yes
Probable
NT
NT
NT
+
+



+





ubiquitin--





protein





ligase


162
ise2c.pk006.h23
Yes
RNA-
NT
NT
NT
+
+
+
+

+





binding





protein squid






















TABLE 11





DsRNA #
gene id
seqID
Comment
8 ppm
4 ppm
2 ppm







0163
pre-mRNA-binding protein
ise2c.pk006.m8
Plate 2 A1





0164
pre-mRNA-binding protein
ise2c.pk006.m8
Plate 2 B1


0165
pre-mRNA-binding protein
ise2c.pk006.m8
Plate 2 C1


0166
pre-mRNA-binding protein
ise2c.pk006.m8
Plate 2 D1
S


0167
pre-mRNA-binding protein
ise2c.pk006.m8
Plate 2 E1
S


0168
chymotrypsin-like; protease
ise2c.pk001.a23
Plate 2 F1
S


0169
chymotrypsin-like; protease
ise2c.pk001.a23
Plate 2 G1


0170
chymotrypsin-like; protease
ise2c.pk001.a23
Plate 2 H1


0171
chymotrypsin-like; protease
ise2c.pk001.a23
Plate 2 A2
S


0172
chymotrypsin-like; protease
ise2c.pk001.a23
Plate 2 B2
S


0173
chymotrypsinogen; protease
ise2c.pk001.a7
Plate 2 C2
S


0174
chymotrypsinogen; protease
ise2c.pk001.a7
Plate 2 D2


0175
chymotrypsinogen; protease
ise2c.pk001.a7
Plate 2 E2


0176
chymotrypsinogen; protease
ise2c.pk001.a7
Plate 2 F2


0177
chymotrypsinogen; protease
ise2c.pk001.a7
Plate 2 G2


0178
actin-depolymerizing
ise2c.pk004.c4
Plate 2 H2


0179
actin-depolymerizing
ise2c.pk004.c4
Plate 2 A3


0180
actin-depolymerizing
ise2c.pk004.c4
Plate 2 B3


0181
actin-depolymerizing
ise2c.pk004.c4
Plate 2 C3


0182
actin-depolymerizing
ise2c.pk004.c4
Plate 2 D3


0183
actin depolymerizing factor
ise2c.pk004.l4
Plate 2 E3


0184
actin depolymerizing factor
ise2c.pk004.l4
Plate 2 F3


0185
actin depolymerizing factor
ise2c.pk004.l4
Plate 2 G3


0186
actin depolymerizing factor
ise2c.pk004.l4
Plate 2 H3


0187
actin depolymerizing factor
ise2c.pk004.l4
Plate 2 A4


0188
dismutase; superoxide
ise2c.pk004.n19
Plate 2 B4


0189
dismutase; superoxide
ise2c.pk004.n19
Plate 2 C4


0190
dismutase; superoxide
ise2c.pk004.n19
Plate 2 D4


0191
dismutase; superoxide
ise2c.pk004.n19
Plate 2 E4


0192
dismutase; superoxide
ise2c.pk004.n19
Plate 2 F4


0193
superoxide dismutase
ise2c.pk005.f21
Plate 2 G4


0194
superoxide dismutase
ise2c.pk005.f21
Plate 2 H4


0195
superoxide dismutase
ise2c.pk005.f21
Plate 2 A5


0196
adenylate kinase isozyme 3
ise2c.pk010.h5
Plate 2 B5


0197
adenylate kinase isozyme 3
ise2c.pk010.h5
Plate 2 C5


0198
adenylate kinase isozyme 3
ise2c.pk010.h5
Plate 2 D5


0199
adenylate kinase isozyme 3
ise2c.pk010.h5
Plate 2 E5


0200
adenylate kinase isozyme 3
ise2c.pk010.h5
Plate 2 F5


0201
ecdysone oxidase
ise2c.pk001.c18
Plate 2 G5


0202
ecdysone oxidase
ise2c.pk001.c18
Plate 2 H5


0203
ecdysone oxidase
ise2c.pk001.c18
Plate 2 A6


0204
innexin-2
ise2c.pk004.p1
Plate 2 B6


0205
innexin-2
ise2c.pk004.p1
Plate 2 C6


0206
innexin-2
ise2c.pk004.p1
Plate 2 D6


0207
innexin-2
ise2c.pk004.p1
Plate 2 E6


0208
innexin-2
ise2c.pk004.p1
Plate 2 F6






















TABLE 12





DsRNA#
gene id
seqID
Comment
16 ppm
8 ppm
4 ppm







0163
pre-mRNA-binding protein
ise2c.pk006.m8
Plate 2 A1
S




0164
pre-mRNA-binding protein
ise2c.pk006.m8
Plate 2 B1
S


0165
pre-mRNA-binding protein
ise2c.pk006.m8
Plate 2 C1
S


0166
pre-mRNA-binding protein
ise2c.pk006.m8
Plate 2 D1
S


0167
pre-mRNA-binding protein
ise2c.pk006.m8
Plate 2 E1
S


0168
chymotrypsin-like; protease
ise2c.pk001.a23
Plate 2 F1
ss
S


0169
chymotrypsin-like; protease
ise2c.pk001.a23
Plate 2 G1
ss


0170
chymotrypsin-like; protease
ise2c.pk001.a23
Plate 2 H1


0171
chymotrypsin-like; protease
ise2c.pk001.a23
Plate 2 A2


0172
chymotrypsin-like; protease
ise2c.pk001.a23
Plate 2 B2


0173
chymotrypsinogen; protease
ise2c.pk001.a7
Plate 2 C2
ss


0174
chymotrypsinogen; protease
ise2c.pk001.a7
Plate 2 D2
S


0175
chymotrypsinogen; protease
ise2c.pk001.a7
Plate 2 E2
S


0176
chymotrypsinogen; protease
ise2c.pk001.a7
Plate 2 F2
S


0177
chymotrypsinogen; protease
ise2c.pk001.a7
Plate 2 G2
S


0178
actin-depolymerizing
ise2c.pk004.c4
Plate 2 H2


0179
actin-depolymerizing
ise2c.pk004.c4
Plate 2 A3
ss


0180
actin-depolymerizing
ise2c.pk004.c4
Plate 2 B3
s


0181
actin-depolymerizing
ise2c.pk004.c4
Plate 2 C3


0182
actin-depolymerizing
ise2c.pk004.c4
Plate 2 D3


0183
actin depolymerizing factor
ise2c.pk004.l4
Plate 2 E3


0184
actin depolymerizing factor
ise2c.pk004.l4
Plate 2 F3


0185
actin depolymerizing factor
ise2c.pk004.l4
Plate 2 G3


0186
actin depolymerizing factor
ise2c.pk004.l4
Plate 2 H3


0187
actin depolymerizing factor
ise2c.pk004.l4
Plate 2 A4


0188
dismutase; superoxide
ise2c.pk004.n19
Plate 2 B4


0189
dismutase; superoxide
ise2c.pk004.n19
Plate 2 C4
s


0190
dismutase; superoxide
ise2c.pk004.n19
Plate 2 D4


0191
dismutase; superoxide
ise2c.pk004.n19
Plate 2 E4


0192
dismutase; superoxide
ise2c.pk004.n19
Plate 2 F4
s


0193
superoxide dismutase
ise2c.pk005.f21
Plate 2 G4


0194
superoxide dismutase
ise2c.pk005.f21
Plate 2 H4


0195
superoxide dismutase
ise2c.pk005.f21
Plate 2 A5


0196
adenylate kinase isozyme 3
ise2c.pk010.h5
Plate 2 B5


0197
adenylate kinase isozyme 3
ise2c.pk010.h5
Plate 2 C5


0198
adenylate kinase isozyme 3
ise2c.pk010.h5
Plate 2 D5


0199
adenylate kinase isozyme 3
ise2c.pk010.h5
Plate 2 E5


0200
adenylate kinase isozyme 3
ise2c.pk010.h5
Plate 2 F5


0201
ecdysone oxidase
ise2c.pk001.c18
Plate 2 G5


0202
ecdysone oxidase
ise2c.pk001.c18
Plate 2 H5


0203
ecdysone oxidase
ise2c.pk001.c18
Plate 2 A6


0204
innexin-2
ise2c.pk004.p1
Plate 2 B6


0205
innexin-2
ise2c.pk004.p1
Plate 2 C6


0206
innexin-2
ise2c.pk004.p1
Plate 2 D6


0207
innexin-2
ise2c.pk004.p1
Plate 2 E6


0208
innexin-2
ise2c.pk004.p1
Plate 2 F6
















TABLE 13







Summary of FAW droplet feeding data for the first set of synthetic dsRNA primers












Assay #1
Assay #2
Assay #3
Assay #4



(table 6)
(table 7)
(table 8)
(table 8)


















30 ppm
30 ppm
30 ppm
30 ppm
15 ppm
8 ppm





0075
ise1c.pk002.m13
Juvenile hormone query



NT




0076


NT







0077


NT


+




0078
ise1c.pk003.f7
Juvenile hormone query
NT







0079


NT







0080


NT

+





0081
ise1c.pk005.a15
Juvenile hormone query
NT


+
+



0082


NT







0083


+
+
NT
NT




0084
ise1c.pk006.d24
Juvenile hormone query
NT

+





0085


+


+




0086
ise2c.pk009.i4
Juvenile hormone query








0087


NT







0088


+


+




0089
ise2c.pk001.d19
vacuolar query
+

+
+




0090


NT







0091


+

+
NT




0092
ise2c.pk001.e14
vacuolar query
NT







0093


NT


+




0094
ise2c.pk001.f20
vacuolar query
+







0095


+







0096


NT







0097
ise2c.pk010.h3
cadherin query
NT







0098


NT
+






0099


NT


NT




0100
ise2c.pk007.k24
cuticle protein
NT







0101


NT







0102


NT







0103
ise2c.pk011.a10
cuticle protein
NT
+






0104


NT
+
+
+




0105
ise2c.pk011.h12
cuticle protein
NT







0106


NT
+

+




0107


+


NT




0108
ise2c.pk001.d22
translation initiation factor
NT

+





0109


NT
+
+
+




0110


NT

+
+




0111
ise2c.pk001.d9
translation initiation factor
NT







0112


NT
+






0113


NT

+
+




0114
ise2c.pk001.i23
translation initiation factor
NT
+
+
+




0115




NT
NT




0116


NT


+




0117
ise2c.pk001.l24
translation initiation factor
NT

+
+




0118


NT

+
+




0119


NT
+






0120
ise2c.pk005.b9
translation initiation factor
NT







0121


NT
+
+
+




0122


NT
+
+
+
+
+


0123
ise2c.pk002.m10
SAR1


+
NT




0124


NT

+
+




0125


NT
+
+
+




0126
ise2c.pk001.c14
Elongation factor
NT
+
+
+




0127


NT
+
+
+




0128


NT

+
+




0129
ise2c.pk001.d16
Elongation factor
NT
+
+
+




0130


NT

+





0131
ise2c.pk005.h3
phosphooligosaccharide . . .



NT




0132


NT







0133


NT







0134
ise2c.pk001.d21
myosin
NT







0135


NT







0136


NT







0137
ise2c.pk001.j9
myosin
NT







0138


NT
+






0139





NT




0140
ise2c.pk002.f12
myosin
NT







0141


NT







0142
ise2c.pk001.b14
potassium channel amino acid
NT









transporter


0143


NT

+





0144


NT

+
+




0145
ise2c.pk003.f2
potassium inwardly rectifier . . .
NT
+
+
+
+



0146


NT
+
+
+




0147


+
+
+
NT




0148
ise2c.pk005.120
amino acid transporter
NT
+
+
+




0149


NT
+
+





0150


NT

+
+




0151
ise2c.pk001.d1
tubulin
NT
+
+
+
+



0152
ise2c.pk001.k6
tubulin
NT


+




0153


NT
+
+
+
+



0154
ise2c.pk001.l2
tubulin
NT
+
+
+
+



0155





NT




0156
ise2c.pk002.b4
ubiquitin
NT

+
+




0157


NT
+
+
+
+



0158


NT
+
+
+




0159
ise2c.pk001.j16
small nuclear ribonucleoprotein
NT
+
+
+




0160
ise2c.pk006.h23
small nuclear ribonucleoprotein
NT

+
+




0161


NT

+
+




0162


NT
+
+
+
+










Example 2. Transformation of Maize

Immature maize embryos from greenhouse donor plants are bombarded with a plasmid containing the silencing element of the invention operably linked to either a tissue specific, tissue selective, or constitutive promoter and the selectable marker gene PAT (Wohlleben et al. (1988) Gene 70:25-37), which confers resistance to the herbicide Bialaphos. In one embodiment, the constructs will have 2 identical 2-300 bp segments of the target gene in opposite orientations with an “intron” segment between them acting as a hairpin loop. Such a construct can be linked to the dMMB promoter. Alternatively, the selectable marker gene is provided on a separate plasmid. Transformation is performed as follows. Media recipes follow below.


Preparation of Target Tissue

The ears are husked and surface sterilized in 30% Clorox bleach plus 0.5% Micro detergent for 20 minutes, and rinsed two times with sterile water. The immature embryos are excised and placed embryo axis side down (scutellum side up), 25 embryos per plate, on 560Y medium for 4 hours and then aligned within the 2.5 cm target zone in preparation for bombardment.


A plasmid vector comprising the silencing element of interest operably linked to either the tissue specific, tissue selective, or constitutive promoter is made. This plasmid DNA plus plasmid DNA containing a PAT selectable marker is precipitated onto 1.1 μm (average diameter) tungsten pellets using a CaCl2 precipitation procedure as follows: 100 μl prepared tungsten particles in water; 10 μl (1 μg) DNA in Tris EDTA buffer (1 μg total DNA); 100 μl 2.5 M CaCl2; and, 10 μl 0.1 M spermidine.


Each reagent is added sequentially to the tungsten particle suspension, while maintained on the multitube vortexer. The final mixture is sonicated briefly and allowed to incubate under constant vortexing for 10 minutes. After the precipitation period, the tubes are centrifuged briefly, liquid removed, washed with 500 ml 100% ethanol, and centrifuged for 30 seconds. Again the liquid is removed, and 105 μl 100% ethanol is added to the final tungsten particle pellet. For particle gun bombardment, the tungsten/DNA particles are briefly sonicated and 10 μl spotted onto the center of each macrocarrier and allowed to dry about 2 minutes before bombardment.


The sample plates are bombarded at level #4 in a particle gun. All samples receive a single shot at 650 PSI, with a total of ten aliquots taken from each tube of prepared particles/DNA.


Following bombardment, the embryos are kept on 560Y medium for 2 days, then transferred to 560R selection medium containing 3 mg/liter Bialaphos, and subcultured every 2 weeks. After approximately 10 weeks of selection, selection-resistant callus clones are transferred to 288J medium to initiate plant regeneration. Following somatic embryo maturation (2-4 weeks), well-developed somatic embryos are transferred to medium for germination and transferred to the lighted culture room. Approximately 7-10 days later, developing plantlets are transferred to 272V hormone-free medium in tubes for 7-10 days until plantlets are well established. Plants are then transferred to inserts in flats (equivalent to 2.5″ pot) containing potting soil and grown for 1 week in a growth chamber, subsequently grown an additional 1-2 weeks in the greenhouse, then transferred to classic 600 pots (1.6 gallon) and grown to maturity.


Plants are monitored and scored for the appropriate marker, such as the control of Lepidoptera and have insecticidal activity. For example, a FAW feeding assay could be preformed. In such assays, leaf discs from the transgenic plant are excised using a 1 cm cork borer or leaf punch. Six leaf discs are prepared for each plant. The leaves are placed in a 24 well microtiter plate on top of 500 ul of 0.8% agar. Each leaf disc is infested with 2 neonate Fall armyworm and the plate is then sealed with mylar. A small ventilation hole is made for each well and the plates are then stored in a 28C growth chamber. The assay is scored for mortality, stunting, and leaf consumption at 96 hours.


Bombardment medium (560Y) comprises 4.0 g/l N6 basal salts (SIGMA C-1416), 1.0 ml/1 Eriksson's Vitamin Mix (1000× SIGMA-1511), 0.5 mg/l thiamine HCl, 120.0 g/l sucrose, 1.0 mg/12,4-D, and 2.88 g/l L-proline (brought to volume with D-I H2O following adjustment to pH 5.8 with KOH); 2.0 g/l Gelrite (added after bringing to volume with D-I H2O); and 8.5 mg/l silver nitrate (added after sterilizing the medium and cooling to room temperature). Selection medium (560R) comprises 4.0 g/l N6 basal salts (SIGMA C-1416), 1.0 ml/l Eriksson's Vitamin Mix (1000× SIGMA-1511), 0.5 mg/l thiamine HCl, 30.0 g/l sucrose, and 2.0 mg/l 2,4-D (brought to volume with D-I H2O following adjustment to pH 5.8 with KOH); 3.0 g/l Gelrite (added after bringing to volume with D-I H2O); and 0.85 mg/l silver nitrate and 3.0 mg/l bialaphos (both added after sterilizing the medium and cooling to room temperature).


Plant regeneration medium (288J) comprises 4.3 g/l MS salts (GIBCO 11117-074), 5.0 ml/l MS vitamins stock solution (0.100 g nicotinic acid, 0.02 g/l thiamine HCl, 0.10 g/l pyridoxine HCl, and 0.40 g/l glycine brought to volume with polished D-I H2O) (Murashige and Skoog (1962) Physiol. Plant. 15:473), 100 mg/l myo-inositol, 0.5 mg/l zeatin, 60 g/l sucrose, and 1.0 ml/l of 0.1 mM abscisic acid (brought to volume with polished D-I H2O after adjusting to pH 5.6); 3.0 g/l Gelrite (added after bringing to volume with D-I H2O); and 1.0 mg/l indoleacetic acid and 3.0 mg/l bialaphos (added after sterilizing the medium and cooling to 60° C.). Hormone-free medium (272V) comprises 4.3 g/l MS salts (GIBCO 11117-074), 5.0 ml/l MS vitamins stock solution (0.100 g/l nicotinic acid, 0.02 g/l thiamine HCl, 0.10 g/l pyridoxine HCl, and 0.40 g/l glycine brought to volume with polished D-I H2O), 0.1 g/l myo-inositol, and 40.0 g/l sucrose (brought to volume with polished D-I H2O after adjusting pH to 5.6); and 6 g/l bacto-agar (added after bringing to volume with polished D-I H2O), sterilized and cooled to 60° C.


Example 3. Agrobacterium-mediated Transformation of Maize

For Agrobacterium-mediated transformation of maize with a silencing element of the invention, the method of Zhao is employed (U.S. Pat. No. 5,981,840, and PCT patent publication WO98/32326; the contents of which are hereby incorporated by reference). Such as a construct can comprise 2 identical 2-300 bp segments of the target gene in opposite orientations with an “intron” segment between them acting as a hairpin loop. Such a construct can be linked to the dMMB promoter. Briefly, immature embryos are isolated from maize and the embryos contacted with a suspension of Agrobacterium, where the bacteria are capable of transferring the polynucleotide comprising the silencing element to at least one cell of at least one of the immature embryos (step 1: the infection step). In this step the immature embryos are immersed in an Agrobacterium suspension for the initiation of inoculation. The embryos are co-cultured for a time with the Agrobacterium (step 2: the co-cultivation step). The immature embryos are cultured on solid medium following the infection step. Following this co-cultivation period an optional “resting” step is contemplated. In this resting step, the embryos are incubated in the presence of at least one antibiotic known to inhibit the growth of Agrobacterium without the addition of a selective agent for plant transformants (step 3: resting step). The immature embryos are cultured on solid medium with antibiotic, but without a selecting agent, for elimination of Agrobacterium and for a resting phase for the infected cells. Next, inoculated embryos are cultured on medium containing a selective agent and growing transformed callus is recovered (step 4: the selection step). The immature embryos are cultured on solid medium with a selective agent resulting in the selective growth of transformed cells. The callus is then regenerated into plants (step 5: the regeneration step), and calli grown on selective medium are cultured on solid medium to regenerate the plants.


Example 4: Soybean Embryo Transformation
Culture Conditions

Soybean embryogenic suspension cultures (cv. Jack) are maintained in 35 ml liquid medium SB196 (see recipes below) on rotary shaker, 150 rpm, 26° C. with cool white fluorescent lights on 16:8 hr day/night photoperiod at light intensity of 60-85 μE/m2/s. Cultures are subcultured every 7 days to two weeks by inoculating approximately 35 mg of tissue into 35 ml of fresh liquid SB196 (the preferred subculture interval is every 7 days).


Soybean embryogenic suspension cultures are transformed with the plasmids and DNA fragments described in the examples above by the method of particle gun bombardment (Klein et al. (1987) Nature, 327:70).


Soybean Embryogenic Suspension Culture Initiation

Soybean cultures are initiated twice each month with 5-7 days between each initiation.


Pods with immature seeds from available soybean plants 45-55 days after planting are picked, removed from their shells and placed into a sterilized magenta box. The soybean seeds are sterilized by shaking them for 15 minutes in a 5% Clorox solution with 1 drop of ivory soap (95 ml of autoclaved distilled water plus 5 ml Clorox and 1 drop of soap). Mix well. Seeds are rinsed using 2 1-liter bottles of sterile distilled water and those less than 4 mm are placed on individual microscope slides. The small end of the seed are cut and the cotyledons pressed out of the seed coat. Cotyledons are transferred to plates containing SB1 medium (25-30 cotyledons per plate). Plates are wrapped with fiber tape and stored for 8 weeks. After this time secondary embryos are cut and placed into SB196 liquid media for 7 days.


Preparation of DNA for Bombardment

Either an intact plasmid or a DNA plasmid fragment containing the genes of interest and the selectable marker gene are used for bombardment. Plasmid DNA for bombardment are routinely prepared and purified using the method described in the Promega™ Protocols and Applications Guide, Second Edition (page 106). Fragments of the plasmids carrying the silencing element of interest are obtained by gel isolation of double digested plasmids. In each case, 100 ug of plasmid DNA is digested in 0.5 ml of the specific enzyme mix that is appropriate for the plasmid of interest. The resulting DNA fragments are separated by gel electrophoresis on 1% SeaPlaque GTG agarose (BioWhitaker Molecular Applications) and the DNA fragments containing silencing element of interest are cut from the agarose gel. DNA is purified from the agarose using the GELase digesting enzyme following the manufacturer's protocol.


A 50 μl aliquot of sterile distilled water containing 3 mg of gold particles (3 mg gold) is added to 5 μl of a 1 μg/μl DNA solution (either intact plasmid or DNA fragment prepared as described above), 50 μl 2.5M CaCl2 and 20 μl of 0.1 M spermidine. The mixture is shaken 3 min on level 3 of a vortex shaker and spun for 10 sec in a bench microfuge. After a wash with 400 μl 100% ethanol the pellet is suspended by sonication in 40 μl of 100% ethanol. Five μl of DNA suspension is dispensed to each flying disk of the Biolistic PDS1000/HE instrument disk. Each 5 μl aliquot contains approximately 0.375 mg gold per bombardment (i.e. per disk).


Tissue Preparation and Bombardment with DNA


Approximately 150-200 mg of 7 day old embryonic suspension cultures are placed in an empty, sterile 60×15 mm petri dish and the dish covered with plastic mesh. Tissue is bombarded 1 or 2 shots per plate with membrane rupture pressure set at 1100 PSI and the chamber evacuated to a vacuum of 27-28 inches of mercury. Tissue is placed approximately 3.5 inches from the retaining/stopping screen.


Selection of Transformed Embryos

Transformed embryos were selected either using hygromycin (when the hygromycin phosphotransferase, HPT, gene was used as the selectable marker) or chlorsulfuron (when the acetolactate synthase, ALS, gene was used as the selectable marker).


Hygromycin (HPT) Selection

Following bombardment, the tissue is placed into fresh SB196 media and cultured as described above. Six days post-bombardment, the SB196 is exchanged with fresh SB196 containing a selection agent of 30 mg/L hygromycin. The selection media is refreshed weekly. Four to six weeks post selection, green, transformed tissue may be observed growing from untransformed, necrotic embryogenic clusters. Isolated, green tissue is removed and inoculated into multiwell plates to generate new, clonally propagated, transformed embryogenic suspension cultures.


Chlorsulfuron (ALS) Selection

Following bombardment, the tissue is divided between 2 flasks with fresh SB196 media and cultured as described above. Six to seven days post-bombardment, the SB196 is exchanged with fresh SB196 containing selection agent of 100 ng/ml Chlorsulfuron. The selection media is refreshed weekly. Four to six weeks post selection, green, transformed tissue may be observed growing from untransformed, necrotic embryogenic clusters. Isolated, green tissue is removed and inoculated into multiwell plates containing SB196 to generate new, clonally propagated, transformed embryogenic suspension cultures.


Regeneration of Soybean Somatic Embryos into Plants


In order to obtain whole plants from embryogenic suspension cultures, the tissue must be regenerated.


Embryo Maturation

Embryos are cultured for 4-6 weeks at 26° C. in SB196 under cool white fluorescent (Phillips cool white Econowatt F40/CW/RS/EW) and Agro (Phillips F40 Agro) bulbs (40 watt) on a 16:8 hr photoperiod with light intensity of 90-120 uE/m2s. After this time embryo clusters are removed to a solid agar media, SB166, for 1-2 weeks. Clusters are then subcultured to medium SB103 for 3 weeks. During this period, individual embryos can be removed from the clusters and screened for the appropriate marker or the ability of the plant, when injected with the silencing elements, to contol the Lepidoptera.


Embryo Desiccation and Germination

Matured individual embryos are desiccated by placing them into an empty, small petri dish (35×10 mm) for approximately 4-7 days. The plates are sealed with fiber tape (creating a small humidity chamber). Desiccated embryos are planted into SB71-4 medium where they were left to germinate under the same culture conditions described above. Germinated plantlets are removed from germination medium and rinsed thoroughly with water and then planted in Redi-Earth in 24-cell pack tray, covered with clear plastic dome. After 2 weeks the dome is removed and plants hardened off for a further week. If plantlets looked hardy they are transplanted to 10″ pot of Redi-Earth with up to 3 plantlets per pot.


Media Recipes

SB 196—FN Lite liquid proliferation medium (per liter)—



















MS FeEDTA - 100x Stock 1
10
ml



MS Sulfate - 100x Stock 2
10
ml



FN Lite Halides - 100x Stock 3
10
ml



FN Lite P, B, Mo - 100x Stock 4
10
ml



B5 vitamins (1 ml/L)
1.0
ml



2,4-D (10 mg/L final concentration)
1.0
ml



KNO3
2.83
gm



(NH4)2SO4
0.463
gm



Asparagine
1.0
gm



Sucrose (1%)
10
gm



pH 5.8










FN Lite Stock Solutions















Stock #

1000 ml
500 ml







1
MS Fe EDTA 100x Stock





Na2 EDTA*
3.724 g 
1.862 g 



FeSO4—7H2O
2.784 g 
1.392 g 


2
MS Sulfate 100x stock



MgSO4—7H2O
37.0 g
18.5 g



MnSO4—H2O
1.69 g
0.845 g



ZnSO4—7H2O
0.86 g
0.43 g



CuSO4—5H2O
0.0025 g 
0.00125 g  


3
FN Lite Halides 100x Stock



CaCl2—2H2O
30.0 g
15.0 g



KI
0.083 g 
0.0715 g 



CoCl2—6H2O
0.0025 g 
0.00125 g  


4
FN Lite P, B, Mo 100x Stock



KH2PO4
18.5 g
9.25 g



H3BO3
0.62 g
0.31 g



Na2MoO4—2H2O
0.025 g 
0.0125 g 





*Add first, dissolve in dark bottle while stirring






SB1 solid medium (per liter) comprises: 1 pkg. MS salts (Gibco/BRL—Cat#11117-066); 1 ml B5 vitamins 1000× stock; 31.5 g sucrose; 2 ml 2,4-D (20 mg/L final concentration); pH 5.7; and, 8 g TC agar.


SB 166 solid medium (per liter) comprises: 1 pkg. MS salts (Gibco/BRL—Cat#11117-066); 1 ml B5 vitamins 1000× stock; 60 g maltose; 750 mg MgCl2 hexahydrate; 5 g activated charcoal; pH 5.7; and, 2 g gelrite.


SB 103 solid medium (per liter) comprises: 1 pkg. MS salts (Gibco/BRL—Cat#11117-066); 1 ml B5 vitamins 1000× stock; 60 g maltose; 750 mg MgCl2 hexahydrate; pH 5.7; and, 2 g gelrite.


SB 71-4 solid medium (per liter) comprises: 1 bottle Gamborg's B5 salts w/sucrose (Gibco/BRL—Cat#21153-036); pH 5.7; and, 5 g TC agar.


2,4-D stock is obtained premade from Phytotech cat# D 295—concentration is 1 mg/ml.


B5 Vitamins Stock (per 100 ml) which is stored in aliquots at −20 C comprises: 10 g myo-inositol; 100 mg nicotinic acid; 100 mg pyridoxine HCl; and, 1 g thiamine. If the solution does not dissolve quickly enough, apply a low level of heat via the hot stir plate. Chlorsulfuron Stock comprises 1 mg/ml in 0.01 N Ammonium Hydroxide


The article “a” and “an” are used herein to refer to one or more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one or more element.


All publications and patent applications mentioned in the specification are indicative of the level of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.


Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

Claims
  • 1. A plant cell having stably incorporated into its genome a heterologous polynucleotide comprising a silencing, wherein said silencing element comprises a fragment of at least 20 consecutive nucleotides of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50, wherein said silencing element, when ingested by a pest from the Lepidoptera order, reduces the level of a target sequence in said pest and thereby controls the pest from the Lepidoptera order.
  • 2. The plant cell of claim 1, wherein said pest comprises Spodoptera frugiperda.
  • 3. The plant cell of claim 1, wherein said silencing element comprises a) a polynucleotide comprising the sense or antisense sequence of the sequence set forth in SEQ ID NO: 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 102, 105, 108, 111, 114, 117, 120, 123, 126, 129, 132, 135, 138, 141, 144, 147, 150, 153, 156, 159, 162, 165, 168, 171, 174, 177, 180, 183, 186, 189, 192, 195, 198, 201, 204, 207, 210, 213, 216, 219, 222, 225, 228, 231, 234, 237, 240, 243, 246, 249, 252, 255, 258, 261, 264, 267, 270, 273, 276, 279, 282, 285, 288, 291, 294, 297, 300, 303, 306, 309, 312, 315, 318, 321, 324, 327, 330, 333, 336, 339, 342, 345, 348, 351, 354, 357, 360, 363, 366, 369, 372, 375, 378, 381, 384, 387, 390, 393, 396, 399, 402, 405, 408, 411, 415, or 418;b) a polynucleotide comprising the sense or antisense sequence of a sequence having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 102, 105, 108, 111, 114, 117, 120, 123, 126, 129, 132, 135, 138, 141, 144, 147, 150, 153, 156, 159, 162, 165, 168, 171, 174, 177, 180, 183, 186, 189, 192, 195, 198, 201, 204, 207, 210, 213, 216, 219, 222, 225, 228, 231, 234, 237, 240, 243, 246, 249, 252, 255, 258, 261, 264, 267, 270, 273, 276, 279, 282, 285, 288, 291, 294, 297, 300, 303, 306, 309, 312, 315, 318, 321, 324, 327, 330, 333, 336, 339, 342, 345, 348, 351, 354, 357, 360, 363, 366, 369, 372, 375, 378, 381, 384, 387, 390, 393, 396, 399, 402, 405, 408, 411, 415, or 418;c) a polynucleotide comprising the sequence set forth in SEQ ID NO: 52, 53, 55, 56, 58, 59, 61, 62, 64, 65, 67, 68, 70, 71, 73, 74, 76, 77, 79, 80, 82, 83, 85, 86, 88, 89, 91, 92, 94, 95, 97, 98, 100, 101, 103, 104, 106, 107, 109, 110, 112, 113, 115, 116, 118, 119, 121, 122, 124, 125, 127, 128, 130, 131, 133, 134, 136, 137, 139, 140, 142, 143, 145, 146, 148, 149, 151, 152, 154, 155, 157, 158, 160, 161, 163, 164, 166, 167, 169, 170, 172, 173, 175, 176, 178, 179, 181, 182, 184, 185, 187, 188, 190, 191, 193, 194, 196, 197, 199, 200, 202, 203, 205, 206, 208, 209, 211, 212, 214, 215, 217, 218, 220, 221, 223, 224, 226, 227, 229, 230, 232, 233, 235, 236, 238, 239, 241, 242, 244, 245, 247, 248, 250, 251, 253, 254, 256, 257, 259, 260, 262, 263, 265, 266, 268, 269, 271, 272, 274, 275, 277, 278, 280, 281, 283, 284, 286, 287, 289, 290, 292, 293, 295, 296, 298, 299, 301, 302, 304, 305, 307, 308, 310, 311, 313, 314, 316, 317, 319, 320, 322, 323, 325, 326, 328, 329, 331, 332, 334, 335, 337, 338, 340, 341, 343, 344, 346, 347, 349, 350, 352, 353, 355, 356, 358, 359, 361, 362, 364, 365, 367, 368, 370, 371, 373, 374, 376, 377, 379, 380, 382, 383, 385, 386, 388, 389, 391, 392, 394, 395, 397, 398, 400, 401, 403, 404, 406, 407, 409, 410, 412, 413, 416, 417, 419, or 420d) a polynucleotide comprising a nucleotide sequence having at least 95% sequence identity to SEQ ID NO: 52, 53, 55, 56, 58, 59, 61, 62, 64, 65, 67, 68, 70, 71, 73, 74, 76, 77, 79, 80, 82, 83, 85, 86, 88, 89, 91, 92, 94, 95, 97, 98, 100, 101, 103, 104, 106, 107, 109, 110, 112, 113, 115, 116, 118, 119, 121, 122, 124, 125, 127, 128, 130, 131, 133, 134, 136, 137, 139, 140, 142, 143, 145, 146, 148, 149, 151, 152, 154, 155, 157, 158, 160, 161, 163, 164, 166, 167, 169, 170, 172, 173, 175, 176, 178, 179, 181, 182, 184, 185, 187, 188, 190, 191, 193, 194, 196, 197, 199, 200, 202, 203, 205, 206, 208, 209, 211, 212, 214, 215, 217, 218, 220, 221, 223, 224, 226, 227, 229, 230, 232, 233, 235, 236, 238, 239, 241, 242, 244, 245, 247, 248, 250, 251, 253, 254, 256, 257, 259, 260, 262, 263, 265, 266, 268, 269, 271, 272, 274, 275, 277, 278, 280, 281, 283, 284, 286, 287, 289, 290, 292, 293, 295, 296, 298, 299, 301, 302, 304, 305, 307, 308, 310, 311, 313, 314, 316, 317, 319, 320, 322, 323, 325, 326, 328, 329, 331, 332, 334, 335, 337, 338, 340, 341, 343, 344, 346, 347, 349, 350, 352, 353, 355, 356, 358, 359, 361, 362, 364, 365, 367, 368, 370, 371, 373, 374, 376, 377, 379, 380, 382, 383, 385, 386, 388, 389, 391, 392, 394, 395, 397, 398, 400, 401, 403, 404, 406, 407, 409, 410, 412, 413, 416, 417, 419, or 420.
  • 4. The plant cell of claim 1, wherein said silencing element comprises a hairpin RNA.
  • 5. The plant cell of claim 4, wherein said polynucleotide comprising the silencing element comprises, in the following order, a first segment, a second segment, and a third segment, wherein a) said first segment comprises at least about 20 nucleotides having at least 90% sequence complementarity to a target sequence set forth in SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50;b) said second segment comprises a loop of sufficient length to allow the silencing element to be transcribed as a hairpin RNA; and,c) said third segment comprises at least about 20 nucleotides having at least 85% complementarity to the first segment.
  • 6. The plant cell of claim 1, wherein said silencing element is operably linked to a heterologous promoter.
  • 7. The plant cell of claim 1, wherein said plant cell has stably incorporated into its genome a second polynucleotide comprising a suppressor enhancer element comprising the target pest sequence or an active variant or fragment thereof, wherein the combined expression of the silencing element and the suppressor enhancer element increases the concentration of an inhibitory RNAi specific for the pest target sequence in said plant cell.
  • 8. The plant cell of claim 1, wherein said plant cell is from a monocot.
  • 9. The plant cell of claim 8, wherein said monocot is maize, barley, millet, wheat or rice.
  • 10. The plant cell of claim 1, wherein said plant cell is from a dicot.
  • 11. The plant cell of claim 10, wherein said dicot is soybean, canola, alfalfa, sunflower, safflower, tobacco, Arabidopsis, or cotton.
  • 12. A plant or plant part comprising a plant cell of claim 1.
  • 13. The plant or plant part of claim 7, wherein the combined expression of said silencing element and the suppressor enhancer element increases the concentration of an inhibitory RNA specific for the pest target sequence in the phloem of said plant or plant part.
  • 14. A transgenic seed from the plant of claim 12.
  • 15. A method for controlling Lepidoptera comprising feeding to a Lepidoptera a composition comprising a silencing element, wherein said silencing element, when ingested by said Lepidoptera, reduces the level of a target Lepidoptera sequence and thereby controls the Lepidoptera and said silencing element comprises a fragment of at least 20 consecutive nucleotides of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50.
  • 16. The method of claim 15, wherein said composition comprises a plant or plant part having stably incorporated into its genome a polynucleotide comprising said silencing element.
  • 17. The method of claim 15, wherein said pest comprises Spodoptera frugiperda.
  • 18. The method of claim 15, wherein said silencing element comprises a) a polynucleotide comprising the sense or antisense sequence of the sequence set forth in SEQ ID NO: 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 102, 105, 108, 111, 114, 117, 120, 123, 126, 129, 132, 135, 138, 141, 144, 147, 150, 153, 156, 159, 162, 165, 168, 171, 174, 177, 180, 183, 186, 189, 192, 195, 198, 201, 204, 207, 210, 213, 216, 219, 222, 225, 228, 231, 234, 237, 240, 243, 246, 249, 252, 255, 258, 261, 264, 267, 270, 273, 276, 279, 282, 285, 288, 291, 294, 297, 300, 303, 306, 309, 312, 315, 318, 321, 324, 327, 330, 333, 336, 339, 342, 345, 348, 351, 354, 357, 360, 363, 366, 369, 372, 375, 378, 381, 384, 387, 390, 393, 396, 399, 402, 405, 408, 411, 415, or 418;b) a polynucleotide comprising the sense or antisense sequence of a sequence having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 102, 105, 108, 111, 114, 117, 120, 123, 126, 129, 132, 135, 138, 141, 144, 147, 150, 153, 156, 159, 162, 165, 168, 171, 174, 177, 180, 183, 186, 189, 192, 195, 198, 201, 204, 207, 210, 213, 216, 219, 222, 225, 228, 231, 234, 237, 240, 243, 246, 249, 252, 255, 258, 261, 264, 267, 270, 273, 276, 279, 282, 285, 288, 291, 294, 297, 300, 303, 306, 309, 312, 315, 318, 321, 324, 327, 330, 333, 336, 339, 342, 345, 348, 351, 354, 357, 360, 363, 366, 369, 372, 375, 378, 381, 384, 387, 390, 393, 396, 399, 402, 405, 408, 411, 415, or 418;c) a polynucleotide comprising the sequence set forth in SEQ ID NO: 52, 53, 55, 56, 58, 59, 61, 62, 64, 65, 67, 68, 70, 71, 73, 74, 76, 77, 79, 80, 82, 83, 85, 86, 88, 89, 91, 92, 94, 95, 97, 98, 100, 101, 103, 104, 106, 107, 109, 110, 112, 113, 115, 116, 118, 119, 121, 122, 124, 125, 127, 128, 130, 131, 133, 134, 136, 137, 139, 140, 142, 143, 145, 146, 148, 149, 151, 152, 154, 155, 157, 158, 160, 161, 163, 164, 166, 167, 169, 170, 172, 173, 175, 176, 178, 179, 181, 182, 184, 185, 187, 188, 190, 191, 193, 194, 196, 197, 199, 200, 202, 203, 205, 206, 208, 209, 211, 212, 214, 215, 217, 218, 220, 221, 223, 224, 226, 227, 229, 230, 232, 233, 235, 236, 238, 239, 241, 242, 244, 245, 247, 248, 250, 251, 253, 254, 256, 257, 259, 260, 262, 263, 265, 266, 268, 269, 271, 272, 274, 275, 277, 278, 280, 281, 283, 284, 286, 287, 289, 290, 292, 293, 295, 296, 298, 299, 301, 302, 304, 305, 307, 308, 310, 311, 313, 314, 316, 317, 319, 320, 322, 323, 325, 326, 328, 329, 331, 332, 334, 335, 337, 338, 340, 341, 343, 344, 346, 347, 349, 350, 352, 353, 355, 356, 358, 359, 361, 362, 364, 365, 367, 368, 370, 371, 373, 374, 376, 377, 379, 380, 382, 383, 385, 386, 388, 389, 391, 392, 394, 395, 397, 398, 400, 401, 403, 404, 406, 407, 409, 410, 412, 413, 416, 417, 419, or 420;d) a polynucleotide comprising the sequence set forth in SEQ ID NO: 52, 53, 55, 56, 58, 59, 61, 62, 64, 65, 67, 68, 70, 71, 73, 74, 76, 77, 79, 80, 82, 83, 85, 86, 88, 89, 91, 92, 94, 95, 97, 98, 100, 101, 103, 104, 106, 107, 109, 110, 112, 113, 115, 116, 118, 119, 121, 122, 124, 125, 127, 128, 130, 131, 133, 134, 136, 137, 139, 140, 142, 143, 145, 146, 148, 149, 151, 152, 154, 155, 157, 158, 160, 161, 163, 164, 166, 167, 169, 170, 172, 173, 175, 176, 178, 179, 181, 182, 184, 185, 187, 188, 190, 191, 193, 194, 196, 197, 199, 200, 202, 203, 205, 206, 208, 209, 211, 212, 214, 215, 217, 218, 220, 221, 223, 224, 226, 227, 229, 230, 232, 233, 235, 236, 238, 239, 241, 242, 244, 245, 247, 248, 250, 251, 253, 254, 256, 257, 259, 260, 262, 263, 265, 266, 268, 269, 271, 272, 274, 275, 277, 278, 280, 281, 283, 284, 286, 287, 289, 290, 292, 293, 295, 296, 298, 299, 301, 302, 304, 305, 307, 308, 310, 311, 313, 314, 316, 317, 319, 320, 322, 323, 325, 326, 328, 329, 331, 332, 334, 335, 337, 338, 340, 341, 343, 344, 346, 347, 349, 350, 352, 353, 355, 356, 358, 359, 361, 362, 364, 365, 367, 368, 370, 371, 373, 374, 376, 377, 379, 380, 382, 383, 385, 386, 388, 389, 391, 392, 394, 395, 397, 398, 400, 401, 403, 404, 406, 407, 409, 410, 412, 413, 416, 417, 419, or 420.
  • 19. The method of claim 15, wherein said silencing element comprises a hairpin RNA.
  • 20. The method of claim 19 wherein said polynucleotide comprising the silencing element comprises, in the following order, a first segment, a second segment, and a third segment, wherein a) said first segment comprises at least about 20 nucleotides having at least 90% sequence complementarity to the target polynucleotide;b) said second segment comprises a loop of sufficient length to allow the silencing element to be transcribed as a hairpin RNA; and,c) said third segment comprises at least about 20 nucleotides having at least 85% complementarity to the first segment.
  • 21. The method of claim 15, wherein said silencing element is operably linked to a heterologous promoter.
  • 22. The method of claim 16, wherein said plant or plant part has stably incorporated into its genome a second polynucleotide comprising a suppressor enhancer element comprising the target pest sequence or an active variant or fragment thereof, wherein the combined expression of the silencing element and the suppressor enhancer element increases the concentration of an inhibitory RNAi specific for the pest target sequence in said plant cell.
  • 23. The method of claim 15, wherein said plant is a monocot.
  • 24. The method of claim 23, wherein said monocot is maize, barley, millet, wheat or rice.
  • 25. The method of claim 15, wherein said plant is a dicot.
  • 26. The method of claim 25, wherein said plant is soybean, canola, alfalfa, sunflower, safflower, tobacco, Arabidopsis, or cotton.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to, U.S. Provisional Application No. 61/021,699, filed Jan. 17, 2008, and U.S. Provisional Application No. 61/021,676, filed Jan. 17, 2008; and of U.S. Non Provisional application Ser. No. 12/351,267 filed Jan. 9, 2009, now granted as U.S. Pat. No. 8,847,013, and is a divisional of U.S. Non Provisional application Ser. No. 14/501,240 Sep. 30, 2014, which are herein incorporated by reference in their entirety.

Provisional Applications (2)
Number Date Country
61021699 Jan 2008 US
61021676 Jan 2008 US
Divisions (1)
Number Date Country
Parent 14501240 Sep 2014 US
Child 15446107 US
Continuations (1)
Number Date Country
Parent 12351267 Jan 2009 US
Child 14501240 US